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ABSTRACT 
Stroke is a complex pathophysiological process and the role of inflammation in its initiation 
and resolution has been much debated. Inflammation is now emerging as a contributor in the 
development of ischaemic brain damage. The use of anti -inflammatory strategies to reduce 
damage and improve functional outcome of stroke patients may be valuable in the treatment 
for a condition that currently has no effective treatment. The exact contribution of the 
inflammatory response and the involvement of the various components of the immune 
system are still under investigation. 
In this thesis, focal cerebral ischaemia was induced in three animal models in an attempt to 
investigate the contribution of the inflammatory response. The rat monofilament model of 
middle cerebral artery (MCA) occlusion, considered by some to be a pro- inflammatory 
model, was set up for the first time in Edinburgh and validated as suitable model for further 
investigation. Permanent and transient models were established to allow the evaluation of 
possible reperfusion injury. Both monofilament models were compared with the 
Endothelin -1 model already established and routinely in use in the laboratory. Analysis of 
the volume of damage and distribution of the lesion revealed no differences between the 
three models. However, this observation did not in itself rule out the possibility of different 
pathophysiological mechanisms in the three models that ultimately resulted in apparently 
similar sized lesions. 
FK506, a potent neuroprotectant widely used experimentally, exhibited different 
neuroprotective efficacies. In all models, FK506 significantly reduced the overall volume of 
both damage and oedema. The majority of the neuroprotection was observed in the cortex 
although striatal protection was seen in the transient rat monofilament model. The 
neuroprotection observed in the transient monofilament model was approximately twice that 
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seen in the permanent model and similar to that in the Endothelin -1 model suggesting 
distinct pathways that lead to cell death. Data for FK506 administration in the mouse 
monofilament model demonstrated neuroprotection for the first time in this species was 
included as an interesting comparison with the rat data. 
In keeping with the investigation of inflammation in cerebral ischaemia, it was proposed that 
FK506 neuroprotection was in part mediated through modulation of the inflammatory 
response. The response of the microglia, the resident immune cells of the central nervous 
system was examined following FK506 administration. Although the drug appeared to have 
a noticeable effect the activation state of the microglia, the response was not consistent and 
difficult to quantify by histological methods. Microglial cultures were established to 
investigate the effect of FK506 in a less complex system. Ramified microglial cultures were 
established but the analysis of microglia in vitro by morphology also proved difficult and 
another method of assessing activation of the cells was pursued. The microglia are known to 
secrete noxious stimuli when activated amongst which are the pro- inflammatory cytokines. 
IL-1P, IL -6 and TNFa gene expression was investigated to assess microglial activation. 
Lipopolysaccharide treated animals and treated microglial preparations were used initially to 
refine the use of multiplex polymerase chain reaction (MPCR) analysis of gene products. 
This was extended to tissue from both monofilament models. IL -1(3, IL -6 and TNFa were 
detected in the cortex and striatum when measured at 3 and 24 hrs post occlusion and 
showed an earlier cytokine response where reperfusion occurred. It is suggested that the 
early cytokine response is associated with the endogenous inflammatory cells. Western 
analysis experiments were performed to verify the presence of the corresponding cytokine 
proteins with little success. The recent availability of improved cytokine antibodies enabled 
the examination of cytokines (IL -1f3 and TNFa) in ischaemic by enzyme linked 
immunosorbant assay (ELISA). No TNFa response was detected despite the presence of 
mRNA. IL -lß was detected at 3 and 24 hrs post -insult with greater expression at 24 hrs. It 
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may be speculated that this increased expression at the later time is related to the peripheral 
inflammatory cell infiltration. There was no difference in expression levels between models 
and FK506 had no affect on the cytokine expression. 
In summary, the re- introduction of blood to ischaemic tissue appears to alter the response of 
the individual cells although this does not change their ultimate fate. In instances where 
reperfusion is established, the tissue appears to be more amenable to neuroprotection by 
FK506. It is suggested that this is associated with the blockade of the endogenous 
inflammatory mechanisms that respond acutely to an ischaemic insult. 
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INCIDENCE & EPIDEMIOLOGY OF STROKE 
Stroke is defined by the World Health Organisation as "rapidly developing signs of focal (or 
global) disturbance of cerebral function lasting longer than 24 hours with no apparent 
non -vascular cause" (Thorvaldsen et al., 1995). Thus defined, it is the most common 
disabling and lethal neurological disease of adult life (Dyken et al., 1984) and is still the 
third leading cause of death among adults after cancer and myocardial infarction (Gorelick, 
1995; Office for National Statistics Mid -year estimates 1994). Worldwide there are 
approximately 4.6 million deaths attributed to stroke each year (Bonita & Beaglehole, 1995). 
The most comprehensive data on stroke comes from the United States (US) where the 
incidence is approximately 250 -400 in 100 000 (750 000 per year) with a mortality rate of 
30 %. Recent figures from the American Heart Association show that someone suffers a 
stroke every 53 seconds with a stroke related death occurring every 3.3 minutes (min) 
(American Heart Association, 2000). Over 4 million survivors live with debilitating 
consequences of the disease. By the year 2050 it is expected that there will be over a million 
strokes per year in the US (Barone & Feuerstein, 1999; Dirnagl et al., 1999). 
In comparison, epidemiological studies in the United Kingdom (UK) indicate that there are 
approximately 60 000 deaths from stroke each year with 100 000 people experiencing a first 
time stroke, 10 000 of these are under retirement age (Office for National Statistics Mortality 
Statistics, 1997). In England and Wales, as with the rest of the world, stroke is the single 
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largest cause of severe disability with over 300 000 people being affected at any one time 
(Office for National Statistics Mid -year Estimates 1994; Prevelance from Geddes, 1996). 
Stroke patients occupy around 20 % of all acute hospital beds and 25 % of long -term beds 
(Wade, 1994), costing the National Health Service an estimated £2.3 billion that is forecast 
to rise around 30 % by the year 2023 (Department of Health, Burdens of Disease 1996). In 
England, 1 in every 500 deaths is stroke related and these deaths account for 8 % of all 
deaths in men and 13 % of deaths in women (Health Survey for England 1995). In Scotland, 
the statistics from the Clinical Outcome Indicators Report 1999 for the period 1995 -1998 
show that 29 439 patients presenting with a stroke were admitted and 22 328 patients (76 %) 
survived for 30 days following emergency admission (Scottish Executive Health Department 
Clinical Outcomes Indicators Report 1999). 
The term stroke, or cerebral ischaemia, is generally used to describe the cessation of oxygen 
and glucose (substrates) supplied to a brain region as a consequence of transient or 
permanent interruption of blood supply causing neuronal cell death (Edvinsson et al., 1993). 
The concept of ischaemia is not particularly useful as the condition is better described by the 
term oligaemia, which by definition implies an organ or some portion receives a reduced 
blood supply and therefore insufficient oxygen and suitable substrates (Graham, 1985). 
Cerebral ischaemia is commonly divided into two major categories. The first and most 
common, accounting for 80 % of cerebrovascular accidents (CVA) is termed ischaemic 
stroke (Ringelstein & Nabavi, 2000). This classification can be further sub -divided into 
global ischaemia, seen in conditions such as cardiac arrest where there is cessation of blood 
flow from the heart and focal ischaemia, which is observed following a localised disruption 
of the blood supply to the brain via the occlusion of a branch or stem of an intracranial vessel 
(Ter Horst & Korf, 1997). The occlusion of a cerebral vessel that results in the disruption of 
the blood supply can be caused either by a thrombosis (clot formation within the vessel), 
embolism (movement of a clot from elsewhere in the body) or stenosis (a severe narrowing 
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of an artery in or leading to the brain (National Institute of Neurological Disorders and 
Stroke 2000). In humans, occlusion of the middle cerebral artery (MCA) is the most 
common underlying cause of ischaemic stroke (Nedergaard, 1988). Ischaemic incidents that 
are resolved within 24 hours are termed transient ischaemic attacks and may be indicative of 
a major impending (Moncayo et al., 2000; Ter Horst & Korf, 1997). Haemorrhagic stroke is 
the second classification of ischaemic stroke and accounts for approximately 20 % of CVAs 
and is the consequence of a ruptured intracranial vessel ( Ringelstein & Nabavi, 2000). 
Bleeding from a ruptured vessel can occur intracerebrally into the brain parenchyma or into 
the subdural or subarachnoid spaces surrounding the brain. In the UK, 80 % of initial 
strokes suffered are ischaemic in nature, 10 % are due to primary intracerebral haemorrhage 
and 5 % are caused by subarachnoid haemorrhage. In 5 % of stroke cases, the type of stroke 
is not clear. Among patients who suffer an ischaemic stroke, 3 -4 % experience another 
ischaemic episode shortly after the initial insult and 10 % of these patients die within the first 
2 -4 weeks. Approximately 10 % have a recurrence of stroke within a year. Among patients 
who have an intracerebral haemorrhage, 50 % die within 30 days and 60 % within one year 
(The Stroke Association 2000). 
BRAIN STRUCTURE & CEREBRAL CIRCULATION 
Brain parenchyma consists of two types of cells, neurones and neuroglia (glia). In the human 
brain, there are approximately 101° neurones and 101' supporting glial cells that are supplied 
by a cerebrovascular network consisting of endothelial cells and smooth muscle. Both 
morphology (e.g. pyramidal neurones) and neurochemistry (e.g. serotonergic neurones) are 
used to classify neurones whereas the glia are divided into three classes. Oligodendrocytes 
are responsible for formation and maintenance of myelin, the astrocytes provide metabolic 
support for the neurones and modulate the extracellular environment and the microglia are 
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considered to be the resident inflammatory cells of the central nervous system (CNS) (Moller 
et al., 2000; Perry et al., 1993; Raivich et al., 1999; Streit, 1993). One unique aspect of the 
cerebral circulation is the absence of a lymphatic system that is found in most other organs. 
Substances of brain origin that are deposited in the lymph nodes are believed to have been 
transferred from the cerebrospinal fluid to the extracranial fluid through the cribiform plate 
and the spaces around the trunks of emerging cranial and spinal nerves (Scremin, 1995). 
The anatomy of the arterial supply of the cerebral hemispheres in the rat is similar to that in 
humans (Yamori et al., 1976). Each species has an anterior, middle and posterior cerebral 
artery supplying each hemisphere. These vessels are all derived mainly from the internal 
carotid arteries (ICA) but connected via an azygous anterior cerebral and posterior 
communicating artery to form a modified Circle of Willis (Figure 1). The vertebral arteries 
fuse to form the basilar artery that supplies posterior structures of the brain via the posterior 
cerebral artery. The middle cerebral artery of the rat runs laterally over the surface of the 
olfactory tract before branching to supply the cerebral cortex where distally the branching is 
more variable. The medial lenticulostriate arteries branch from the MCA and supply the 
posterior caudate putamen (striatum) and olfactory tract (Yamori et al., 1976). The baseline 
blood flow through the striatum is substantially lower than that the cortical flow and 
consequently flow disturbances are more likely to produce injury (del Zoppo & Hallenbeck, 
2000). In the rat however, the local cerebral blood flow of the striatum is similar to the 
overlying cortex (Sakurada et al., 1978). The anterior striatum is supplied by the lateral 
striate branches and receives a medial supply from Hubner's arteries from the anterior 


















AAA anterior amygdaloid IOA internal ophthalmic 
ACA anterior cerebral MCA middle cerebral artery 
ASA anterior striates OA olfactory 
CAA cortico -amygdaloid PA posterior communicating 
CCA common carotid PCA posterior cerebral 
CSA cortico -striates PSA posterior striates (lenticulate) 
ECA external carotid SA stapedial (pteriopalatine) 
ICA internal carotid TA trigeminal 
Figure 1. Simplified diagram showing the cerebral circulation of the rat. Diagram additionally shows 
the placement of a nylon monofilament to occlude the middle cerebral artery. 
The anterior choroidal arteries supply the choroid plexus and the hippocampus and the 
posterior choroidal arteries supply caudal structures such as the cerebellum. In the rat brain, 
as in many other species, there are numerous arterial /venous anastomoses that make it almost 
impossible to produce complete localised ischaemia by occlusion of a blood vessel (Scremin, 
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1995) and the redundancy of the arterial supply to the brain serves a protective role (del 
Zoppo & Hallenbeck, 2000). 
One crucial component of the brain intimately linked with the cerebral blood supply is the 
blood brain barrier (BBB). The morphological characteristics of the BBB are tight junctions 
between the endothelial cells, minimal transport by pinocytotic vesicles and a close 
interaction between the endothelial cells and astrocytes (Dermietzel & Krause, 1991). The 
cerebrovascular endothelium functions as a regulator of haemostasis and a sentinel of the 
microcirculation (del Zoppo & Hallenbeck, 2000). The existence of the BBB effectively 
prevents the transport of proteins and polar substances from the extracellular fluid and 
protects the brain for alterations in systemic fluctuations of hormones (Dalton Dietrich, 
1999). There are however several areas of the brain such as the area postrema and some 
parts of the hypothalamus where the BBB is incomplete. These areas are associated with the 
functioning and feedback mechanisms of the neuroendocrine system. In these areas, the 
capillaries have fenestrations and the endothelial cells contain a large number of pinocytotic 
vesicles (Heistad & Kontas, 1983). In addition to the physical barrier that exists, there is also 
a chemical or enzymatic barrier (e.g. monoamine oxidase in the endothelial cells) that 
contributes to the maintenance of brain homeostasis. Small hydrophobic molecules are able 
to cross the BBB because of the lipophilic nature of the membranes. Hydrophilic substances 
such as proteins and saccharides cannot readily diffuse through the membrane and therefore 
require specific transport mechanisms (Dermietzel & Krause, 1991) such as the multi -drug 
resistance receptor 1, which is the transporter for drugs such as FK506 (Yokogawa et al., 
1999). Following an ischaemic insult the integrity of the BBB may become disrupted 
allowing exposure of brain tissue to unregulated levels of blood borne substances. 
Additionally, BBB disruption contributes to damage and the formation of oedema within the 
ischaemic tissue (Edvinsson et al., 1993; Heistad & Kontas, 1983). 
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CONTROL OF THE CEREBRAL CIRCULATION 
Two notable characteristics of the cerebral circulation are the ability of the brain to maintain 
relatively constant cerebral blood flow (CBF) over a wide range of perfusion pressures, 
termed autoregulation (Harper, 1966) and the ability to dynamically alter local blood flow to 
accommadate for dynamic changes in metabolic activity of the brain, termed flow 
metabolism coupling. 
Autoregulation, first described in the brain by Fog in the 1930s, protects the brain against 
changes in systemic blood pressure (Fog, 1939). In man, cerebral blood pressure remains 
constant within the mean arterial blood pressure (MABP) range of 65 -140 mm Hg 
(Strandgaard & Paulson, 1984). Beyond these limits, autoregulatory mechanisms of the brain 
fail. At MABP above 140 mm Hg there is a forced dilation of the cerebral blood vessels, 
cerebral blood flow (CBF) rises and oedema eventually results (hypertensive 
encephalopathy). Beyond the lower limit, CBF falls and signs on hypoxia becomes evident 
(Harper, 1990; Heistad & Kontas, 1983) (Figure 2). It is important to note that in ischaemic 






Figure 2. Autoregulation curve (Harper, 1990). 
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The concept of flow metabolism coupling predates autoregulation by some 40 years. Roy & 
Sherrington, as far back as 1890, suggested a link between vascular and functional activity in 
the brain and related it to the chemical products of cerebral metabolism (Roy & Sherrington, 
1890). Although the precise mechanisms that drive flow metabolism coupling have not been 
definitively established and number of potential molecules have been proposed including 02, 
H+, NO and adenosine (Harper, 1990; Matsuyama, 1997; Sokoloff & Kety, 1960). The 
functional activity of any brain region is intrinsically linked with energy consumption in that 
region imposed by normal physiological activity. In man, the normal flow rate is 
approximately 1.5 ml.µmol glucose consumption'.min'. Under ischaemic conditions, as 
with the autoregulatory response of the brain, flow metabolism coupling is compromised. 
PATHOPHYSIOLOGY OF CEREBRAL ISCHAEMIA 
The brain, although it only comprises 2 -3 % of total body weight, receives 15 % of total 
cardiac output and consumes 20 % of oxygen and 25 % of glucose circulating in the blood 
(Graham, 1985). In humans, it accounts for 25 % of basal metabolism with a metabolic rate 
3.5 times higher than that of other primate species (Lee et al., 2000). Calculation of the 
respiratory quotient of the brain gives a value of one implying that oxidative catabolism of 
glucose is the most likely single source of energy. Glucose extracted from the blood is 
metabolised to carbon dioxide and water by glycolysis with one glucose molecule yielding 
42 adenosine triphosphate (ATP) molecules. Like other tissues of the body, the brain is able 
to metabolise glucose anaerobically forming lactic acid but the energy yield from this 
process is small (Siesjo, 1984). Under normal circumstances, no substance found in the 
circulation can replace glucose. However, in conditions such as starvation, the brain may 
oxidise ketone bodies when blood concentrations of these molecules is increased above 
normal (Siesjo, 1978). 
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One third of the energy generated by oxidative metabolism of glucose is used for the 
maintenance of synaptic transmission, one third for cell homeostasis and the remaining third 
for the maintenance of structural integrity (Back, 1998). Due to the large metabolic 
requirement of the brain (60 W) and its very limited capacity for substrate storage, the 
survival of cells in the organ is dependent on the continuous and adequate supply of oxygen 
and nutrients. The interruption of the blood supply that occurs in conditions such as cerebral 
ischaemia which causes an energy crisis within the tissue can lead to neuronal cell death 
within minutes (Astrup et al., 1981). 
VIABILITY THRESHOLDS 
CBF in man has been calculated to be 50 m1.100 g'.min' which remains constant although 
there are continuous alterations in local blood flow that adjust in response to the metabolic 
needs of different brain regions (Harper, 1990). In the rat, CBF is approximately 
150 m1.100 g'.min' (McCulloch et al., 1982) where the higher CBF value in the rat 
compared with the human value reflects the difference in neuronal density between the 
species (Hossmann, 1994). 
Astrup et al. (1977) recognised the concept of viability thresholds in cerebral ischaemia and 
differentiation in critical blood flow rates required for electrical failure versus membrane 
failure (Astrup et al., 1977). Although the determination of thresholds has been conducted in 
a number of different species making it difficult to directly compare absolute values, there is 
a distinct hierarchy of susceptibility of energy dependent cellular functions (Hossmann, 
1994) (Figure 3). The threshold for depression of protein synthesis, oedema formation and 
acidosis occurs before the threshold of electrical failure. Protein synthesis is most sensitive 
to a decline in CBF. Glucose utilisation transiently increases as flow rates decrease and then 
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decline sharply corresponding to lactate accumulation and acidosis. Below this level, ATP 
and phosphocreatine (PCr) levels begin to decline (Hossmann, 1994). When CBF rates drop 
to one third of normal levels, there is loss of electrical excitability. Membrane failure and ion 
homeostasis is lost when CBF falls below one quarter of normal values (Siesjo, 1992a). At 
this level of CBF, ion fluxes result in the death of neurones in minutes (Sweeney et al., 
1995). In the rat, CBF rates below 25 m1.100 mg'.min' produces well- demarcated tissue 
damage. This threshold value is higher than that of larger species that is again most likely 
explained by the higher neuronal density in the rat brain (Back, 1998). 
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Figure 3. Viability thresholds of cerebral ischaemia (Hossmann, 1994; Siesjo, 1984; Siesjo 1992a). 
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CORE, PENUMBRA & REPERFUSION INJURY 
In discussions regarding focal cerebral ischaemia there are a number of terms that are used to 
describe the damage that follows the occlusion of a blood vessel and are best clarified. The 
term lesion is defined in the Oxford English Dictionary as damage, injury or morbid change 
in the functioning or texture of an organ. Infarct is defined as a small area of dead tissue 
caused by an inadequate blood supply and thus the process of infarction is the events that 
lead to the dead tissue or area of coagulation necrosis that develops (Garcia & Liu, 1996). 
It has long been widely believed that an ischaemic lesion consists of a densely ischaemic 
core and perifocal areas that may become recruited in the infarction process (Garcia et al., 
1995; Memezawa et al., 1992). The core (or focus) of an insult is the brain area where 
irreversible damage occurs. Following MCA occlusion, the core is thought to lie within the 
striatum as it shows the most pronounced decreases in blood flow during ischaemia, has 
limited collateral flow (often called an end artery territory) and is the first tissue to be 
damaged (Dewar et al., 1999; Garcia et al., 1995; Siesjo, 1992a). Damage is seen in the 
lateral striatum following only 30 min of vessel occlusion (Memezawa et al., 1992). 
The original concept of core and penumbra was based on the electrophysiological data where 
the term penumbra was used to describe the observation of electrically silent but structurally 
intact neurones found between the necrotic core and normal brain tissue (Symon et al., 
1977). The area of compromised tissue resembled the partly illuminated area around the 
complete shadow of the moon in full eclipse, hence the name penumbra (Hossmann, 1994). 
The peri- infarct zone contains cells that are at risk and survival is dependent on severity and 
duration of vessel occlusion (Hallenbeck & Dutka, 1990). Astrup et al. (1981) defined the 
penumbra as brain tissue perfused at a level between thresholds of functional impairment and 
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loss of morphological integrity that would have the capacity to recover if perfusion was 
re- established (Astrup et al., 1981). Although the majority of the tissue damage occurs 
within the first few hours following cerebral ischaemia, it is well established that penumbral 
tissue may continue to deteriorate at a later time (Garcia & Kamijyo, 1974; Heiss et al., 
1999). The concept of core and penumbral tissue has led to the view that the tissue of the 
penumbra can be salvaged by administration of pharmacological agents or by relatively 
prompt reperfusion (Figure 4) (Memezawa et al., 1992). This concept, in principle provides a 
so- called `therapeutic window of opportunity' for intervention but does require knowledge of 
the temporal development of the lesion and suitable target identification (Bartus et al., 1995). 
There are physiological (blood flow) and biochemical differences between core and 
penumbra tissues and also different responses to neuroprotectant compounds (Ginsberg et 
al., 1996; Zhang et al., 1995). The ischaemic penumbra is a dynamic tissue structure (Back, 
1998) which Ginsberg & Pulsinelli (1994) called `an evolving zone of bioenergetic 
upheaval' (Ginsberg & Pulsinelli, 1994). Siesjö (1992) suggested that recruitment of tissue in 
the penumbra may occur as cell death continues until well -perfused tissue is encountered or 
alternatively small islands of necrotic cells develop affecting neighbouring cells to ultimately 
coalesce and produce a large infarct (Siesjo, 1992a). Data from both cats and monkeys 
suggest that there is a gradual development of the lesion during the first 4 -8 hours (hrs) 
although there is a large amount of variability. This variability in experimental animals may 
reflect differences in collateral blood supply of individual animals and differences in species. 
Slow evolution of the penumbra in the cortex may be a consequence of collateral blood flow 
(Memezawa et al., 1992). It should be noted that the anatomical and temporal extent of 
ischaemic penumbra is not as consistent in man as the penumbra in animals, even when 
using the same technology (Akins et al., 1996; Baird & Warach, 1998; Heiss & Graf, 1994). 
The peri- infarct region of the lesion in rats is larger than that seen in human and 
sub -human primates and may explain the moderate results obtained with potential therapies 
when administered in the clinical setting (Siesjo, 1992a). In addition, human strokes tend to 
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be more variable, both in infarct size and neurological deficit (Lutsep & Clark, 1999). A 
further point to consider when discussing the development of ischaemic damage is the effect 
of physiological variables such as CO2 levels, blood pressure and temperature on outcome 
following an insult. These variables can only be controlled under experimental conditions. 
An ideology that is closely allied to the concept of the core and penumbra of an ischaemic 
lesion is concept of reperfusion injury. Reperfusion injury is well recognised in the heart and 
in other organs that are susceptible to ischaemic damage (Grech et al., 1995; Werns & 
Lucchesi, 1990; Zwacka et al., 1998) and thus potentially it may occur in the ischaemic 
brain. Del Zoppo et al. (2000) recently recognised that reperfusion injury in the brain is a 
widely held concept but commented that there is little data to support this claim. They did 
however acknowledge that under some circumstances an increase in ischaemic damage may 
seen (del Zoppo et al., 2000). Experimental data, clinical observations and data available 
from other organs suggest that reperfusion results in a smaller infarct volume (del Zoppo et 
al., 2000). The restoration of the blood to the ischaemic tissue, on one hand, halts the 
processes leading to cell death but may alternatively lead to further damage in compromised 
tissue, depending on both the duration of ischaemia and efficiency of reperfusion (Marchal et 
al., 1999; Park & Lucchesi, 1999). The return of blood to ischaemic tissue signals both the 
return of substrates vital for cellular metabolism and the removal of accumulated metabolic 
waste that is conducive to the restoration of normal metabolism. However, following 
transient occlusion of the MCA, the initial period of ischaemia leads to slowly maturing cell 
death despite the resumption of basic biochemical functions within the cell due to the return 
of blood to the ischaemic zone (Figure 4) (Kuroda & Siesjo, 1997). It is plausible that the 
development of lesion occurs because of depression of protein synthesis resulting from 
deranged cellular functioning, gradual accumulation of calcium (Ca2 +) intracellularly that 
contributes to mitochondrial dysfunction, generation of damaging free radicals and altered 
signalling within the cell. In addition to intracellular events, the return of blood to ischaemic 
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tissue may initiate an inflammatory response that may in itself cause the release of damaging 
molecules such as free radicals and pro- inflammatory cytokines and the infiltration of 
peripheral cells such as leukocytes and monocytes (Kuroda & Siesjo, 1997). 
Recanalisation is a complex issue and does not necessarily equate with adequate tissue 
perfusion despite the return of blood to the area. Intricate phenomena (haemorrhage, oedema, 
vascular plugging) may lead to a 'no-reflow' situation (Marchai et al., 1999). On the other 
hand, reperfusion may occur as a result of perfusion pressure though collateral vessels. The 
concept of no -reflow following an ischaemic insult is a debated topic with some authors 
questioning it occurrence (Kuroda & Siesjo, 1997; Li et al., 1998). Positron emission 
tomography (PET) studies in humans suggest that early reperfusion is not detrimental and 
contradicts the experimental concept of reperfusion injury and supports the use of early 
thrombolysis (Marchai et al., 1999). Impairment of microvascular reperfusion could occur 
due to narrowing of the blood vessels as a result of perivascular swelling and oedema 
causing raised intracranial pressure, a change in blood dynamics caused by fluid shifts in the 
damaged tissue or capillary plugging by cells such as leukocytes (Gartshore et al., 1997; 
Hallenbeck & Dutka, 1990). Reperfusion may also affect the function of the arteries whose 
role is critical to maintaining cerebrovascular resistance. Cipolla et al. (1997) showed 
abnormal structure and function of the MCA with diminished myogenic reactivity and tone 
associated with longer reperfusion (Cipolla et al., 1997). 
In rats, Kaplan et al. (1991) reported that the maximal reperfusion window was 3 hrs 
following 30 or 60 min occlusion (Kaplan et al., 1991). Memezawa et al. (1992) showed that 
30 min occlusion caused infarction in the lateral striatum although some experimental 
animals did have cortical damage. A 60 min MCA occlusion produced extensive damage 
with both striatal damage and extensive cortical damage that was however smaller than a 120 
or 180 min occlusion. They showed that reperfusion following occlusion was beneficial if 
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instituted between 90 and 120 post -occlusion but after 120 min, return of blood flow failed 
to salvage tissue. For optimal tissue salvage reperfusion needed to be established within 
60 min of occlusion. Additional observations from this study proved tissue damage 
following 1 hour (hr) occlusion in a rat monofilament model was smaller that 24 hrs 
permanent occlusion, again supporting the notion that reperfusion following ischaemia is 
beneficial (Memezawa et al., 1992). Data from studies in this laboratory using the 
Endothelin -1 (Et -1) model (considered to be a permanent occlusion) and the Endothelin -3 
(Et -3) model (developed as a model of MCA occlusion with controlled reperfusion) showed 
no significant difference in the volume of damage between the two models implying no 
beneficial effect of reperfusion (Henshall, 1997). A study using PET to evaluate reperfusion 
injury in monkeys showed significantly greater damage following transient occlusion of the 
MCA compared with a permanent occlusion model with the increase damage observed in the 
cortex (Takamatsu et al., 2000). In a series of experiments, Du et al. (1996) demonstrated 
that a mild focal insult (30 min) caused infarction after 3 days and led to a lesion that was 
indistinguishable from that induced by a severe (90 min) occlusion after 14 days. The 
authors suggested that the delayed development of the lesion was due to apoptotic cell death 
in the peri- infarct zone of the lesion (Du et al., 1996). However, in a study that repeated 
these experiments using the Endothelin models, no difference in the volume of ischaemic 
damage was seen following a 30 min occlusion when assessed at 3 or 14 days suggesting 
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Figure 4. Levels of residual blood flow and duration of ischaemia (a) showing that lower levels of 
blood flow are tolerated for shorter than higher residual flow. The green curve (b) shows theoretically 
optimal reperfusion. The red curve denotes reperfusion injury (Halestrap et al., 2000). 
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BIOCHEMICAL SEQUELAE OF ISCHAEMIA 
Damage to brain tissue following an ischaemic insult is a consequence of a number of 
inter -related process including acidosis, lipid peroxidation, altered protein synthesis and 
phosphorylation, impaired perfusion, Ca'+ overload and glutamate mediated excitotoxic 
mechanisms (Obrenovitch & Richards, 1995). 
A precipitous fall of ATP occurs rapidly following vessel occlusion with ATP levels falling 
to below 25 % of basal values in under 5 min (Eklof & Siesjo, 1972; Lipton, 1999). 
Reduction in the level of ATP following an ischaemic insult is fundamental to the initiation 
the pathological sequealae that ultimately lead to cell death (Siesjo, 1984; Siesjo, 1992a). 
The inability of the cells of the brain to synthesise ATP and other nucleoside triphosphates 
because of a lack of suitable substrates directly threatens the integrity of the cells. The 
degradation of molecules required for normal metabolic functioning and the maintenance of 
cell structure is no longer matched by resynthesis. Oxidative phosphorylation ceases under 
ischaemic conditions although energy dependent functions within the cell continue. Initially 
there is a shift to glycogen and phosphocreatine hydrolysis by creatine kinase (CK) in order 
to maintain ATP levels (Katsura et al., 1994). Following this, the absence of glucose results 
in anaerobic glycolysis leading to intracellular and extracellular acidosis. The fall of 
intracellular pH is explained by the mismatch between ATP synthesis and hydrolysis as the 
metabolism changes. The drop in extracellular pH is a consequence of the generation of 
hydrogen (H +) ions and their extrusion from the cells by membrane transporters (Martin et 
al., 1994). The further reduction in ATP levels causes the failure of ion pumps that maintain 
membrane potential, disruption of homeostasis and leads to loss of function (Lipton, 1999). 
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Although discussed in sections in this thesis for clarity, the biochemical sequealae are a 
series of inter- related events that occur following the reduction of cerebral blood flow. The 
events in the cascade are complex and it is sometimes difficult to view the events 
individually and at all times one must be aware of the implications that a pathological change 
in one cellular function potentially has deleterious effects on a number of other functions. An 
overall schematic representation of the ischaemic cascade (Figure 5) gives a simplified flow 
diagram of the events following an ischaemic insult. 
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Figure 5. The ischaemic cascade. 
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ION PERTURBATIONS 
The dissipation of ion gradients and the consequent loss of ion homeostasis in ischaemia is 
caused the failure of membrane pumps (ATPases) that normally maintain intracellular and 
extracellular ion concentrations. The loss of ion homeostasis is also caused by increased 
`leakiness' of the cell membranes because of the disruption of the BBB (Heistad & Kontas, 
1983; Siesjo, 1992a). As ATP levels drop, membrane potential falls causing an increase in 
intracellular sodium (Na +) and the release of potassium ions (K +). This depolarisation results 
in the release of neurotransmitters and excitatory amino acids (EEAs) such as glutamate. An 
increase in extracellular K+ causes depolarisation of adjacent cells, which in turn activates 
Na +/K+ ATPases. Activation of these pumps increases ATP utilisation. Release of glutamate 
and activation of N- methyl -D- aspartate (NMDA) glutamate receptors causes Caz+ influx and 
subsequent activation of ATP -requiring Caz+ pumps (Sweeney et al., 1995). It is also 
possible that under ischaemic conditions the ion transporters in the membranes are actually 
reversed and so contribute to the worsening ionic imbalances (Phillis et al., 2000). The 
observation that Na+ ions accumulate gradually and incessantly during experimental focal 
ischaemia (but only in the severely damaged brain regions) has lead to the novel suggestion 
that Na +concentration in these regions, together with assessment of local cerebral blood flow 
and the apparent diffusion coefficient of water, can be used to estimate the time of onset of 
ischaemia. This knowledge is important regarding choice of pharmacological treatment of a 
stroke such as thrombolytic therapy (Wang et al., 2000). 
ACIDOSIS & OEDEMA FORMATION 
Oedema has been shown to develope in the first 6 hrs following MCA occlusion in the rat 
and remained constant between 12 hrs and 3 days (Menzies et al., 1993) whilst in stroke 
patients maximum oedema is seen at 72 hrs (Rosenberg, 1999). Intracellular pH begins to 
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fall by 0.5 -1 units shortly after insult. This can be explained by the mismatch of ATP 
metabolism as the cells switch from aerobic to anaerobic metabolism, as the cells are unable 
to continue oxidative phosphorylation. The fall in extracellular pH is caused by the extrusion 
of H+ ions and lactate (Martin et al., 1994). The accumulation of lactate within the cells also 
contributes to the lowered pH intracellularly (Plum, 1983; Siesjo, 1992b; Rehncrona et al., 
1981). Energy failure and acidotic activation of transporters in the membranes causing an 
accumulation of Na+ and Cl ions in the cell and with them osmotically obligated water. 
Tissue swelling can cause massive secondary damage by compression of the contralateral 
brain and other remote regions. This is one of the primary causes of mortality in both 
experimental models and human stroke sufferers (Witte et al., 2000). 
Betz et al. (1994) demonstrated that Na+ ions were principally involved in oedema formation 
in the first 3 -6 hrs following MCA occlusion (Betz et al., 1994). The cells attempt to rectify 
the intracellular pH at the expense of their own volume regulation (Siesjo, 1992b). The 
increase in water causes cell swelling and leads to necrosis of the cells, so called cytotoxic 
oedema. Cytotoxic oedema occurs rapidly as a result of disturbances in cell metabolism and 
ion homeostasis, without disruption of the BBB. Cytotoxic oedema is principally caused by 
the reduction in Na +/K +- ATPase activity. Such oedema occurs following both 60 and 120 min 
of transient occlusion and also following permanent MCA occlusion but is not seen after 
only 30 min occlusion (Yang et al., 1992). Vasogenic oedema occurs at later time points 
following occlusion and results from the breakdown of the BBB with a net gain of interstitial 
fluid (Betz et al., 1994; Samdani et al., 1999). Swelling of the brain with no apparent 
disruption of the BBB suggests that cytotoxic oedema is primarily responsible, whereas at 
later time points, vasogenic oedema is the main contributor to damage. 
Changes in BBB permeability have been demonstrated following an ischaemic insult 
(Belayev et al., 1996a) and are likely to induce oedema formation that further exacerbates 
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tissue damage as BBB breakdown occurs faster than oedema formation (Hatashita & Hoff, 
1990). In a global ischaemia experiment, Schwab et al. (1997) demonstrated that the regions 
that were most vulnerable to ischaemic damage corresponded to those areas with increased 
water content (Schwab et al., 1997). BBB breakdown is accompanied by extravasion of 
blood borne agents that contribute to damage. If reperfusion occurs, the brain tissue is 
exposed to further potential mediators of damage (Kastrup et al., 1999). 
Biphasic opening of the BBB has been demonstrated following transient MCA occlusion 
(1 hr), occurring at 15 min after recirculation and again at 5 and 72 hrs (Kuroiwa et al., 
1985). Belayev et al. (1996) showed an initial acute disruption of the BBB using Evans Blue 
extravasion between 3 and 5 hrs again following transient MCA occlusion with a later more 
widespread increase in permeability at 48 hrs. Most prominent leakage of serum protein was 
observed in the striatum with leakage in the cortex at later time points (Belayev et al., 
1996a). In permanent MCA occlusion, there is no early disruption of the BBB as occurs in a 
transient occlusion (Betz et al., 1994) suggesting the secondary disruption is a reperfusion 
related event. In the photothrombic model of MCA occlusion, BBB breakdown occurs more 
rapidly (Forsting et al., 1994) perhaps reflecting damage to the endothelium by free radicals 
produced by the dye breakdown and thrombus formation (Dalton Dietrich, 1999). The 
comparison of two models of MCA occlusion (photothrombic and electrocoagulation) 
showed that oedema formation was greater in the photothrombic model despite similar 
damage in both (Takamatsu et al., 1998). 
Suggested mechanisms of passage of macromolecular substances across the BBB in 
pathological situations include acute destruction of the endothelium and opening of 
endothelial tight junctions as a consequence of disturbed autoregulation although it is a 
subject of much debate (Belayev et al., 1996a). It is also possible that BBB damage occurs 
when a surge of blood returns to the ischaemic tissue. This may be an artefact of the 
22 
experimental model used. In the monofilament model, the introduction and withdrawal of the 
nylon suture may cause endothelial damage, at least in the internal carotid artery and 
therefore the method of occlusion may influence BBB patency (Gartshore et al., 1997). 
As with the extent of damage, the disruption of the BBB is believed to depend on the level of 
blood flow reduction and duration of the insult (Hallenbeck & Dutka, 1990). In global 
ischaemia, the insult is less severe and BBB integrity is maintained (Schwab et al., 1997). 
Instantaneous massive breakdown of the BBB is seen following 3 hrs of MCA occlusion 
with 3 hrs of reperfusion also suggesting that late reperfusion causes more severe BBB 
disruption (Kastrup et al., 1999). In patients fatal oedema formation has been reported 
following thrombolysis with tissue plasminogen activator (tPA) (Koudstaal et al., 1995). 
Recently, Pfefferkorn et al. (2000) investigated plasminogen activation in focal cerebral 
ischaemia and reperfusion. They showed increases in plasminogen in the ipsilateral 
hemisphere and suggested that microvascular injury may be a consequence of the proteolytic 
functions of the plasminogen -plasmin system as plasmin directly degrades components of 
the extracellular matrix. Administration of tPA therefore would increase oedema formation 
and also haemorrhage as a result of compromised microvascular patency ( Pfefferkorn et al., 
2000). Reperfusion therefore carries an inherent risk of vasogenic oedema and the integrity 
of the BBB may play an important role in during post -ischaemic reperfusion (Kastrup et al., 
1999). Experimentally, reperfusion exacerbates the swelling of the brain following 
ischaemia. Reperfusion provides hydrostatic pressure for water movement across the vessels 
within the ischaemic territory and additionally provides energy for the ATPases on the vessel 
walls that maintain the influx of Na+ into the brain parenchyma (Gartshore et al., 1997). 
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GLUTAMATE 
Despite being principle excitatory neurotransmitter in the mammalian brain, glutamate is 
toxic to neurones (Obrenovitch et al., 1996). Neurotoxicity caused by the application of 
exogenous glutamate, termed excitotoxicity, has been demonstrated and studied both in vitro 
systems (Choi et al., 1988; Choi, 1990a) and in in vivo (Murata et al., 2000; Wahl et al., 
1994). Increases in concentrations of EEAs, including glutamate, have been correlated with 
histopathological damage following an ischaemic insult (Butcher et al., 1990). Additionally, 
compounds that antagonise NMDA (MK -801) and AMPA (NBQX, YM90K) glutamate 
receptors have been shown to be neuroprotective in a number of animal models of focal 
cerebral ischaemia indicating a central role for the neurotransmitter in the pathophysiology 
of the disease (Lipton, 1999). 
Glutamate in neurones and glia of the brain is present principally in metabolic or 
neurotransmitter pools and its intracellular concentration is 4 times greater in than that in the 
extracellular environment (Obrenovitch & Richards, 1995). Normal extracellular glutamate 
levels measured by microdialysis are 1 -5 µM (Lipton, 1999) with brief increases (1 -2 mM) 
associated with synaptic transmission (Obrenovitch et al., 2000). Under mild ischaemic 
conditions and in vitro, the concentration of EEAs can increase 2 -5 fold and under severe 
ischaemic conditions between 10 -60 fold (Martin et al., 1994). Wahl et al. (1994) suggested 
that the majority of glutamate released into the extracellular space during severe ischaemia is 
of metabolic origin and from both neurones and glia (Wahl et al., 1994). In both focal and 
global ischaemia, extracellular glutamate begins to increase rapidly, within 1 -2 mins, of an 
insult (Lipton, 1999). A biphasic change in glutamate release following an insult confirms 
that there are several mechanisms of release and multiple sub -cellular origins (Obrenovitch 
& Richards, 1995; Szatkowski & Attwell, 1994). 
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The excessive release of intracellular glutamate from its stores following an ischaemic insult 
can occur through a number of pathways, either individually or in concert and can directly 
and indirectly regulate the downstream mechanisms of cell death (Figure 5) (Krupinski et al., 
2000). Initially, neuronal depolarisation causes the release of synaptic glutamate as would 
occur under normal conditions. Thereafter, the imbalance of ATP driven glutamate uptake 
and leakage of the transmitter from the cells, CaZ+ dependent exocytotic release for 
neurotransmitter pools, reversal of the glutamate transporters of neurones and/or glia and 
ultimately cell lysis causes a huge increase in extracellular glutamate concentration affecting 
neighbouring cells and creating a vicious circle of depolarisation and further 
neurotransmitter release (Kenner et al., 1999; Rossi et al., 2000). Ischaemic glutamate 
release is thought to be modulated by Na+ fluxes, free radicals/NO, temperature and some 
kinase pathways (Lipton, 1999). Released glutamate is rapidly cleared during reperfusion 
suggesting uptake mechanisms affected by ischaemia recover once membrane gradients are 
restored. The consequences of such an efflux of the transmitter has down stream effects that 
challenge cell viability. Obrenovitch & colleagues (2000) suggest that the glutamate alone is 
not the principle mediator of the cell damage following ischaemia but is one of the 
contributors (Obrenovitch et al., 2000). The neurotransmitter activates both ion channel 
coupled receptors (NMDA, AMPA and kainate) and metabotropic receptors that are linked to 
second messenger cascades. Excessive activation of the ionotropic receptors leads to 
perturbations in ion homeostasis and massive CaZ+ influx principally through the NMDA 
receptor. A large increase in intracellular CaZ+ through ion channels leads to CaZ+ induced 
CaZ+ release from major intracellular stores such as the endoplasmic reticulum (ER) and 
mitochondria (Siesjo et al., 1999). 
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CALCIUM 
Intracellular and extracellular Caz+ levels are approximately 0.1 and 1000 tmo1.1-I, 
respectively. Caz+ fluxes, integral to signal transduction, are tightly regulated and Ca-'+ 
homeostasis is maintained by ATP driven ion exchangers. The majority of the intracellular 
Caz+ in the cytoplasm is bound to proteins or phospholipids or sequestered into the ER, 
mitochondria and calciosomes (Kristian & Siesjo, 1998; Siesjo et al., 1999). Voltage -gated 
Caz+ channels are located both pre- and post synaptically at excitatory synapses in the CNS 
where transmission is mediated by glutamate (Morley et al., 1994). 
The Caz+ hypothesis was originally embraced to explain the link between excessive Cat+ 
influx and myocardial damage (Dhalla et al., 1999; Jennings et al., 1960; Kristian & Siesjo, 
1998) and was then implicated in neuronal death in a variety of neurodegenerative disorders 
(Kristian & Siesjo, 1998). The Caz+ overload in the cytosol of ischaemic tissues occurs 
because of failure of ATP -dependent extrusion, influx of Caz+ ions through 
voltage- dependent channels activated by membrane depolarisation and activation of 
glutamate receptors, principally NMDA receptors. Intracellular Caz+ binding and 
sequestration is also affected and Caz+ is displaced and released from intracellular locations 
such as the mitochondria and the ER (Mattson et al., 2000b; Siesjo et al., 1999). Lee et al. 
(1999) proposed that the survival of neuronal cells is critically dependent upon an optimal 
intracellular Caz+ `set point'. Inadequate Caz+ places the cells at risk of apoptosis, 
intermediate Caz+ levels where survival is favoured and elevated Caz+ levels is toxic and 
leads to necrosis (Lee et al., 1999). Following 2 hrs of MCA occlusion, Kristián et al. 
(1998) demonstrated that in the focal areas of the ischaemic brain virtually all the 
extracellular Caz+ was translocated to the intracellular fluids. With recirculation, the 
extracellular Caz+ concentration only returned to 50 % of the pre -ischaemia value for 6 hrs 
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and then decreased again. In the penumbral areas, there was a decrease in extracellular Cat+ 
that returned to near normal levels upon recirculation proving that ischaemia has a profound 
effect on cell Cat+ metabolism (Kristian et al., 1998). 
The massive increase of intracellular Ca-+ has a number of consequences. In addition to 
increasing the rate of ATP depletion as the cells attempt to maintain normal homeostasis, 
Caz+ activates enzymes (protein kinase C, phospholipases, proteases, nitric oxide synthase) 
that cause intracellular damage, activate second messenger pathways that culminate in 
altered gene expression and increase the production of free radicals (Kermer et al., 1999; 
Siesjo, 1993; Sweeney et al., 1995). Many of these are energy consuming processes and so 
lead to further reductions in already critically compromised ATP levels. 
ZINC 
There is evidence to suggest that Caz+ is not the only divalent cation that is toxic under 
ischaemic conditions (Lee et al., 1999). Zinc (Znz +) is present in all cells as a component of 
metalloenzymes and transcription factors but also acts as a neurotransmitter or 
neuromodulator. Elevated levels of extracellular ZnZ+ are known to be toxic to cultured 
neurones (Choi et al., 1988). It has been suggested that excessive Znz+ release and entry into 
cells via voltage gated channels (in a similar manner to Cat +) reaches levels that may alter 
the function of cellular macromolecules. Studies with chemical chelators of Znz+ ions have 
been shown to reduce damage in global models of ischaemia. The protection afforded in 
these studies was not permanent suggesting that ZnZ+ was involved in the rate of cell death 
but did not affect final outcome (Lee et al., 1999). Studies in permanent focal ischaemia also 
suggest a link between Znz+ release, translocation and brain injury (Sorensen et al., 1998). It 
has also been suggested, from experiments in vitro, that ZnZ+ may be neuroprotective by 
blocking the NMDA receptor (Choi, 1990b). 
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FREE RADICALS & NITRIC OXIDE 
Under normal physiological conditions, potentially damaging free radicals (classified by 
virtue of their unpaired electrons) such as superoxide anions (Of) and hydroxyradicals 
(OH) together with hydrogen peroxide (H202) and NO are generated by mitochondrial 
respiration in complex I and III of the electron transport chain (Chan, 1999; Wems & 
Lucchesi, 1990; Kuroda & Siesjo, 1997). The generation of toxic free radicals and reactive 
oxygen species (ROS) by all aerobic cells is normally kept in check by both enzymatic and 
non -enzymatic defence systems. Cells contain vitamins such as ascorbic acid and 
a- tocopherol that act as free radical scavengers. They also contain enzymes such as 
superoxide dismutase, glutathione peroxidase and catalase that metabolise free radicals and 
their precursors (Siesjo, 1992b). Under ischaemic conditions, free radical production may 
outstrip the capabilities of the endogenous defence mechanisms and the activity of protective 
enzymes may be compromised by energy depletion. When reperfusion is established 
following an ischaemic insult, the return of blood to the compromised tissue leads second 
burst of free radicals as substrates for oxidation are provided and partial recovery of the 
bioenergetic state of the tissue occurs (Chan, 1996; Kuroda & Siesjo, 1997). 
The cellular source of free radicals is difficult to establish because of their short life span in 
vivo. Both neurones and glia can generate free radicals and it is thought that the endothelium 
and activated leukocytes, particularly during reperfusion, are candidates for free radical 
production (Matsuyama, 1997). The link between free radicals and cell damage in ischaemia 
is strengthened by observations that free radical scavengers such as allopurinol and 
methylthiourea reduce infarct size following permanent MCA occlusion (Siesjo, 1992b). The 
radical spin trap a- phenyl -N -tert -butyl nitrone (PBN) also ameliorated damage following 
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2 hrs of MCA occlusion (Kristian & Siesjo, 1997). Superoxide dismutase over -expressing 
and knockout mice show protection against and exacerbation of damage, respectively, after 
an ischaemic insult (Chan, 1999). The formation of superoxide, hydrogen peroxide, 
peroxynitrite and hydroxyl radicals leads to peroxidation of lipid membranes, causes damage 
to proteins and DNA and thereby compromising the structure and functioning integrity of the 
cells (Dawson, 1994). 
NO is an important physiological regulator of functions such as vasodilation, 
neurotransmission and under physiological conditions is found at low levels in the body 
(Dawson, 1994; Dawson et al., 1999). Levels of nitric oxide are controlled by constitutively 
expressed neuronal and endothelial isoforms of nitric oxide synthase (nNOS/NOS -I and 
eNOS/NOS -III, respectively). During ischaemia -reperfusion and other neurodegenerative 
processes in the CNS, the concentration of NO is rapidly increased by hyperactivation of 
nNOS. An unnaturally high level of NO in the brain is detrimental as its reaction with 
superoxide anions produces toxic compounds such as peroxynitrite and hydroxyl radicals. 
High levels of NO are produced under pathological conditions such as inflammation by an 
inducible form of NO synthase (iNOS/NOS -II) supporting a beneficial role of NO 
production where its expression leads to the elimination of the inflammatory agents 
(Colasanti & Suzuki, 2000). 
The role of NO is cerebral ischaemia is complex and unclear as it has been suggested to be 
both cytotoxic and cytoprotective (Lipton & Wang, 1996; Anderson & Meyer, 2000; Kermer 
et al., 1999; Mason et al., 2000). NOS inhibitors have been shown to be both protective 
against cerebral infarction (Buisson et al., 1992) and also to increase post -ischaemic damage 
(Dawson, 1994). NO precursors such as L- arginine and nitrovasodilators have been shown to 
have no effect on lesion size (Anderson & Meyer, 2000) but have also been shown to reduce 
damage (Zhang et al., 1997). NO donor compounds have been shown to be protective in 
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vitro and in vivo (Mason et al., 2000). Additionally, ischaemic damage has been shown to be 
significantly reduced in neuronal NOS knockout mice (Chan, 1996). Possible explanations 
for the ambiguous nature of NO may be attributed to its vasodilatory properties (causing 
improvement of blood flow) or its inhibitory actions on the NMDA receptor (attenuating of 
Cat+ influx) that may be a consequence of its redox state (Lipton & Wang, 1996) and the 
complexity of the regulatory mechanisms of the nitric oxide synthases that control NO 
production (Colasanti & Suzuki, 2000). Anderson et al. (2000) have proposed that the 
severity of the ischaemia may explain the relative importance of NO in the ischaemic tissue. 
More severe ischaemic insults are linked with greater tissue acidosis related to the anaerobic 
metabolism that inhibits the NOS activity (Anderson & Meyer, 2000) . 
The point at which NO is produced following an insult may be of great importance and 
explain the disparate findings regarding its role in cerebral ischaemia. In the early stages of 
local blood flow reduction, eNOS activity may be beneficial producing NO that causes 
vasodilation. Later, when the vascular effects are no longer protective, nNOS activity 
produces NO that is damaging to the tissue. At an even later time point the long lasting 
production of NO by iNOS contributes to the progression of cell damage (Kermer et al., 
1999). These ideas regarding the temporal production of NO are supported by a series of in 
vitro studies with NOS inhibitors where early inhibition produced increased damage whereas 
delayed inhibition had either no effect or only a slightly beneficial impact on infarct volume 
(Mason et al., 2000). Disappointing neuroprotection achieved with NOS inhibitors may be 
due to the fact that inhibition of NO formation only leaves other free radicals that cause cell 
damage (Dawson, 1999). This idea is supported by the observation that rats treated with a 
combination of NOS inhibitor and free radical scavenger have a greater reduction in infarct 
volume (Spinnewyn et al., 1999). 
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MITOCHONDRIAL DYSFUNCTION 
Stroke can be described essentially as a disease of mitochondrial dysfunction. Mitochondria 
play a central role in both apoptosis and necrosis and are therefore key players in the 
evolution of ischaemic damage (Halestrap et al., 2000). The mitochondria are strongly linked 
to glutamate excitotoxicity, which is central to the pathophysiology of ischaemic cell death 
(Stout et al., 1998). Oxidative phosphorylation in the mitochondria requires an intact inner 
membrane that is impermeable to all but a few selective metabolites and ions. If the 
membrane potential and integrity is compromised or lost, the organelles become uncoupled 
and hydrolyse ATP rather than synthesising it (Halestrap et al., 2000). 
There are at least three general mechanisms (with inter -related effects) that are known by 
which the mitochondria participate in cell death: disruption of oxidative phosphorylation and 
ATP production, release of proteins that trigger caspase activation and the alteration of the 
redox potential of the cell (Green & Reed, 1998). Following transient ischaemia, there 
appear to be two components to mitochondrial dysfunction. The first component is an initial 
decline in respiratory function at the onset of ischaemia. Secondary deterioration in 
mitochondrial function is associated with reperfusion when there is partial recovery in ATP 
levels (Nakai et al., 1997). During ischaemia, the accumulation of CaZ+ in the mitochondria 
can trigger the assembly and opening of a high conductance pore, the mitochondrial 
permeability transition pore (MPT), in the inner membrane of the mitochondria. The pore is 
thought to be formed by a cyclophilin -D mediated conformational change in the adenine 
nucleotide translocase proteins in the membrane (Halestrap et al., 2000). The formation of 
this pore leads to the collapse of the electrical potential, increased acidosis, cessation of ATP 
production and generation of free radicals. The pore also allows the release of CaZ+ and 
Mgt +, as well as low and high molecular weight compounds (Kristian & Siesjo, 1998). 
Transient opening of the MTP causes halting of ATP synthesis, swelling of the organelle, 
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rupture of the outer membrane and release of cytochrome c (an essential component of the 
respiratory electron transport chain) and subsequent activation of caspases that can set the 
apoptotic cascade in motion. The closure of the pore allows restoration of ATP production 
and thus leads to cell death by apoptosis as opposed to by necrosis (Halestrap et al., 2000). 
Cyclosporin A (CsA), which has been shown to neuroprotective in a number of models and 
species of cerebral ischaemia, is thought in part to be neuroprotective as it blocks the 
formation of the MTP (Sharkey et al., 2000). CsA prevents MPT formation by blocking the 
translocation of the mitochondrial matrix specific cyclophilin -D (small intracellular 
regulatory protein of the immunophilin family) to the inner membrane of the mitochondria 
and thereby decreasing sensitivity to Calf ions (Friberg et al., 1998). 
As mentioned previously, the mitochondria are thought to be involved in glutamate toxicity 
(Ankarcrona et al., 1995). The mitochondria have a large capacity for Cat+ and may be 
neuroprotective by removing the Cat+ ions from the cytoplasm. However, the uptake of Cat+ 
may be detrimental to the mitochondria as the excessive glutamate stimulation and activation 
of intracellular enzymes can cause the generation of free radicals. Free radicals can 
potentially damage structures of the cells including the mitochondria and thus confound the 
energetic crisis of the cells (Stout et al., 1998). 
GENE EXPRESSION & PROTEIN SYNTHESIS 
Focal ischaemia causes changes in gene expression within minutes of the onset of ischaemia, 
particularly in the ischaemic hemisphere (Johansson et al., 2000). Most of the genes that 
respond rapidly are members of the immediate early gene (IEG) family such as c-fos and 
c-jun those products are transcription factors and regulate the expression of other genes (An 
et al., 1993; Soriano et al., 2000). Under normal conditions in the brain, the expression of the 
32 
IEGs is low. The stimulation of cells that causes changes in the cytoplasm such as elevated 
Caz+ levels or the activation of kinases (in particular, protein kinase A or C) results in 
phosphorylation of deoxyribonucleic acid (DNA) binding proteins that bind to response 
elements that regulate gene transcription. The products of the IEGs regulate the expression 
of downstream effector genes that affect the functional status and viability of the cells (Akins 
et al., 1996). Evidence is accumulating that suggests that signalling pathways leading to gene 
expression can intersect and can alter the cell's response to a given stimulus. IEGs dimerise 
with different transcription factors with different outcomes (Kermer et al., 1999). 
The genes induced following a transient and permanent MCA occlusion may differ because 
of the differences in biochemical events and every gene may vary spatially and temporally 
with varying degrees of ischaemia. Following a mild focal ischaemic insult, IEG expression 
is limited to the ischaemic zone whereas more severe insults tend to induce expression in 
regions beyond this (An et al., 1993; Collaco -Moraes et al., 1994). Gene expression may 
also differ in different models of occlusion. For example, genes induced after transient 
ischaemia may reflect the prominent role of free radicals and oxidative stress associated with 
reperfusion whereas the same genes may play a less important role in permanent arterial 
occlusion (O'Neill & Kaltschmidt, 1997; Sharp et al., 2000). Other genes that are induced 
following ischaemia including heat shock proteins (Sharp & Sagar, 1994), neurotransmitters 
and corresponding receptors (Kogure & Kato, 1993), transcription regulators such as nuclear 
factor of kappa light chain gene enhancer in B cells (NF -KB) (Salminen et al., 1995) and 
neurotrophic factors including nerve growth factor (NGF) (Mattson, 1997). 
The expression of the transcription regulator NF -KB has also been of much interest in the 
stroke research field in the past few years (Carroll et al., 1998; Carroll et al., 2000; 
Christman et al., 2000; Gabrielet aí.1999; Schneider et al., 1999; Stephenson et al., 2000) 
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and is of particular interest in the context of an inflammatory response as it is an immediate 
early transcriptional activator of the genes encoding inflammatory cytokines (Zwacka et al., 
1998). NF -KB is a pre -formed factor that is usually sequestered in the cytoplasm of cells by 
inhibitor of kappa light chain gene enhancer in B cells (IKB), which when phosphorylated 
and/or cleaved frees the bound NF -K allowing translocation to the nucleus. In the nucleus, 
NF -KB influences the expression of a wide variety of genes including many stress activated 
genes (MacManus & Linnik, 1997). Again, as with other members of the pathophysiological 
cascade of ischaemia such as NO, NF -KB can be either detrimental or beneficial to cell 
survival and may be highly context dependent (Kristian & Siesjo, 1997; Sharp et al., 2000). 
The induction of heat shock proteins occurs within the same time frame as the expression of 
the IEGs and may be neuroprotective (Akins et al., 1996). These proteins along with other 
chaperone proteins aid the restoration of structure and function of denatured proteins. 
Following ischaemia, heat shock protein gene expression is seen in glial cells and in cells in 
the penumbra (Sharp et al., 1999). There is also an alteration in expression of genes involved 
in the apoptotic death cascade such as bc1-2, Bax and the caspases (see Neuronal Death: 
Necrosis & Apoptosis). An increase in nitric oxide synthase mRNAs is seen in the initial 
hours following cerebral ischaemia and is different depending on occlusion type (MacManus 
& Linnik, 1997). Another area that has been intensively investigated is the expression of 
genes of the inflammatory cascade such as cell adhesion molecule as and cytokines 
(discussed later in this chapter and in Chapter 6). 
Although mRNA is frequently studied, it is critical to study protein function. If a gene is 
involved in ischaemic pathology, the associated protein must be present (Sharp et al., 2000). 
Genes such as the IEGs are detected in both core and penumbral regions following focal 
ischaemia but expression of proteins may differ as protein synthesis may be affected in 
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regions of dense ischaemia (Akins et al., 1996). Protein synthesis is a prerequisite for 
ong -term survival of cells and is extremely sensitive to cell energy charge and ionic content 
(Lipton, 1999). Prolonged inhibition of protein synthesis, if uncompensated, will ultimately 
lead to cell death. Protein synthesis is an energy requiring process and thus depletion of ATP 
during ischaemia is responsible for its cessation. During reperfusion synthesis may still be 
compromised despite the return of energy yielding compounds (Krause & Tiffany, 1993). In 
a study in mice, Hara et al. (2000) showed that 1 hr of reperfusion led to full recovery of 
energy metabolism but not protein synthesis (Hara et al., 2000). Protein synthesis is 
dependent not only on intact DNA and intact transcription machinery but also intact 
transport machinery for transcription factors and messenger RNA (mRNA) and intact 
translation machinery (Krause & Tiffany, 1993). Soriano et al. (2000) propose that the 
inhibition of protein synthesis after focal ischaemia is not caused by inhibition of 
transcription but by inhibition at the translation step (Soriano et al., 2000). Free radicals and 
increased Cat+ levels following interruption of cerebral blood flow can potentially damage 
all the components of the protein synthesis cascade. There is little or no protein synthesis in 
the core of an ischaemic lesion as this region is ATP depleted but synthesis does continue in 
the cells in the penumbral zones that will survive the insult (Sharp et al., 2000). 
NEURONAL DEATH: NECROSIS & APOPTOSIS 
There are two principal death pathways, necrosis or a mechanism resembling apoptosis that 
occur following an ischaemic insult in any organ or tissue. Apoptosis was defined by Kerr et 
al. in 1972 and was originally based on morphological differences in thymocytes that 
appeared to die by two processes (Kerr et al., 1972). Necrosis appears to be a passive 
mechanism of cell death. This cell death is associated with derangement of ion homeostasis 
related to membrane failure and is characterised by early cell and organelle (mitochondrial) 
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swelling. This is followed by loss of cytoplasmic membrane integrity and cellular 
disintegration, often accompanied by an inflammatory response (Snider et al., 1999) and 
usually affecting a large group of adjacent cells (Banasiak et al., 2000). Apoptosis or 
apoptosis -like cell death is viewed as an energy requiring `programmed' physiological 
response that is most apparent during development where more cells than are ultimately 
required die. In this respect, apoptotic cell death sculpts, shape and optimises function 
(Golstein, 1998). During development apoptosis is heavily influenced by the availability of 
growth factors and is not confined to neurones as it also occurs in glial cells ( Kuschinsky & 
Gillardon, 2000). Apoptosis also plays a role in rapidly dividing tissue such as intestinal villi 
and dysfunction of the death pathways may be linked to tumour growth (Kinloch et al., 
1999). Apoptotic cell death plays an important role in the removal of compromised cells 
without the induction of a major inflammatory response (Linnik & Ringer, 1999). 
It has been recently suggested that the `classical' concept of cell death following ischaemia 
may not be completely accurate (Kuschinsky & Gillardon, 2000; Lee et al., 2000). Although 
there are distinct morphological characteristics associated with the different pathways it is 
likely that necrosis and apoptosis are part of a continuum of cell death and that similar 
mechanisms may be operative in both processes (Roy & Sapolsky, 1999). There is also a 
third potential form of cell death, autophagocytotic cell death that has been described and 
may occur in ischaemia although it has not been well investigated. Autophagocytosis is the 
mechanism by which protein turnover occurs in normally functioning cells and which if 
activated under pathological conditions, may lead to destruction of cells (Lipton, 1999). The 
execution of cell death following an insult may be the sum total of a number of complex 
pathways that interact that may be dictated by the metabolic status of the cells (Nicotera et 
al., 1999b). 
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Necrotic cells exhibit pyknosis (shrinkage) and eosinophila and as stated before, are grossly 
distinguished by loss of plasma membrane integrity. Ultrastructural changes include 
clumping of heterochromatin and swelling of endoplasmic reticulum cisternae (Garcia et al., 
1995). The DNA in necrosising cells also undergoes random fragmentation following histone 
proteolysis (Banasiak et al., 2000). Apoptosing cells exhibit shrinkage of cytoplasm, 
condensation of nuclear material into `clumps', nuclear condensation and fusion of the ER 
with the plasma membrane. It is this formation of membrane bound apoptotic bodies that 
contain cytoplasmic organelles and nuclear fragments which gives the cells a `blebbed' 
appearance (Banasiak et al., 2000). Analysis of the DNA fragments from ischaemic tissue 
reveal that staggered ends as opposed to the blunt DNA ends of cells undergoing 
developmental apoptosis supporting the notion of an non -classical apoptotic cell death 
following ischaemia (Kuschinsky & Gillardon, 2000). Nuclear DNA damage following 
cerebral ischaemia may involve two distinct mechanisms: oxidative injury and 
endonuclease- mediated DNA fragmentation (Charriaut -Marlangue et al., 1995; Chopp, et 
al., 1996). In a permanent occlusion model, Nagayama et al. (2000) demonstrated that in the 
penumbral zone of a cerebral insult that oxidative injury to nuclear DNA (direct damage 
from reactive oxygen species) may be a significant and contributory cause to the expansion 
of a brain damage and could perhaps be an early, potentially reversible event. 
Endonuclease- mediated fragmentation is a hallmark of apoptosis and occurs relatively late 
following ischaemia (Nagayama et al., 2000). 
The contribution of apoptosis in ischaemia is a controversial subject although there is 
evidence to suggest that key components of the cell death programmes contribute cell death 
in experimental animals (Banasiak et al., 2000; Du, et al, 1996; MacManus & Linnik, 1997; 
Nicotera et al., 1999b; Rabuffetti et al., 2000; van Lookeren & Gill, 1996). A few studies 
suggest that apoptosis occurs in stroke patients however such studies are limited by the 
difficulty in obtaining post -mortem tissue at time points that correspond to the time window 
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when cell death is occurring (Mattson et al., 2000a). Observations from animal stroke 
models, suggest that apoptosis occurs in the in penumbral regions of the infarct and while 
necrosis predominates in the more severely stressed ischaemic core (Akins et al., 1996; 
Charriaut- Marlangue et al., 1996; Linnik & Ringer, 1999). Apoptosis in the penumbra may 
be the consequence of milder stresses than those experienced in the core but may also be due 
to secondary mediators such as free radicals, glutamate, cytokines and lipid peroxidation 
products resulting from damage to the tissue in the core (Nicotera et al., 2000). Li et al. 
(1995) reported that, following transient MCA occlusion, apoptotic cells (terminal 
deoxynucleotidyl transferase nick end labelling (TUNEL) stained) were primarily localised 
to the boundary zones of the infarct and also concluded that apoptosis accompanies necrosis 
(Li et al., 1995a). Du et al. (1996) suggested that neuronal apoptosis was present after mild 
focal ischaemia and that the lesion developed at a later time point (14 days) although this has 
been difficult to replicate. Following a severe insult, there was only limited evidence of 
apoptosis (Du et al., 1996). 
The two main forms of cell death may therefore not be mutually exclusive and overlap both 
spatially and temporarily but it is thought that necrotic mechanisms occur earlier than 
apoptotic ones (Roy & Sapolsky, 1999; Velier et al., 1999). It is also thought that moderately 
damaged cells die in the suicidal apoptotic manner once their repair capacity is exhausted 
and cells subjected to more severe insults die rapidly by necrosis (Kuschinsky & Gillardon, 
2000). Residual mitochondrial function (ATP synthesis) is required for apoptosis and it is 
important to remember that ATP depletion is central to the pathology of cerebral ischaemia 
(Siesjo, 1984; Siesjo, 1992a). This is highlighted by experiments where the reduction of ATP 
levels in cells that have received an apoptotic stimulus causes necrosis instead of the 
expected apoptosis (Nicotera et al., 1999b). The relative contributions of each type of cell 
death in ischaemia is difficult to assess as both electrophoresis laddering patterns of genomic 
DNA and TUNEL staining can be inconclusive and are best supported by 
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electronmicroscopy and discrimination of morphological features (Banasiak et al., 2000; 
Bortner et al., 1995). 
The fundamental principles of the apoptotic cascade have been established by studies on the 
nematode Caenorhabditis elegans (C. elegans) because of the homology in structure and 
function of its death genes compared with vertebrates (Kuschinsky & Gillardon, 2000). It is 
the interplay of pro- and anti -apoptotic genes that determines cell survival. From mutant 
studies in C. elegans, ced -3 and ced -4 have been identified as essential for death (Ashkenazi 
& Dixit, 1998; Ellis et al., 1991) whilst ced -9 functions to protect cells from dying 
(Hengartner & Horvitz, 1994). In mammals, the homologous genes to ced -3 and ced -9 have 
been identified as interleukin 113-converting enzyme (ICE) and bc1-2 respectively. ICE 
belongs to a family of death related genes termed çysteine aspartases (caspases) and is also 
known as caspase 1. The human homologue of ced -4 has been identified as APAF -1, an 
activator of the caspase enzyme family ( Hengartner, 1998). 
The bc1-2 family consists of proteins with pro- and anti -apoptotic activity that are essential 
components of the death machinery in neurones (Adams & Cory, 1998; Antonsson & 
Martinou, 2000; Bergeron & Yuan, 1998; Chen et al., 1995). Bc1-2 has been shown to inhibit 
apoptosis and has the capacity to promote neuronal survival in a number of experimental 
settings (Chen et al., 2000). In ischaemia, bc1-2 appears to prevent cell death. This has been 
demonstrated using both transgenic and viral vector technology where infarct volume was 
decreased (Linnik & Ringer, 1999). Bc1-2 and other closely related genes (Bcl -x) interact 
with each other to regulate their function. Bc1-2 associated protein X (Bax) is a potent 
accelerator of apoptosis, which like bc1-2 is activated following ischaemia (MacManus & 
Linnik, 1997). Bc1-2 is found on the membranes of the ER, the nuclear envelope and the 
outer mitochondrial membrane and may play a role in the mitochondria] transition pore. 
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Other mechanisms that have been proposed for bc1-2, which may be important in ischaemia 
include the prevention of free radical production, modulation of intracellular Ca'+ or 
prevention of intracellular acidification (Banasiak et al., 2000). 
Caspases are proteases that are the main effectors in apoptotic cell death and to date more 
than 14 mammalian members of the family have been identified (Nicotera et al., 2000b). 
They are expressed as inactive pro- enzymes (30 -50 lc Da) and are activated by proteolytic 
cleavage (Thornbeny & Lazebnik, 1998, Nicholson & Thomberry, 1997). All caspases 
contain a conserved pentapeptide QACXG and are divided into three groups based on their 
tetrapeptide recognition sequences. The DexDases and (IVL)ExDases participate in the 
signalling and execution of apoptosis whereas the WEHDases are involved in inflammatory 
processes (Nicotera et al., 2000). The cleavage of caspase pro- enzymes at specific sites is 
the trigger for cellular destruction cascade and can be initiated by activation of death ligand 
receptors (Fas /CD95) or by activated upstream caspases (Hengartner, 1998). The caspases 
appear to contribute to apoptosis through the direct disassembly of cell structures 
(Thornberry & Lazebnik, 1998). It has recently been proposed that the degree of caspase 
activation may be of importance suggesting that a moderate degree of caspase activation may 
not always result in cellular demise (Nicotera et al., 2000). The degree of caspase activation 
may reflect the severity of the ischaemic insult (Matsushita et al., 1998). In an ischaemic 
insult necrosis and apoptosis are present in adjacent cells suggesting a common extracellular 
environment and that the pathways leading to the different endpoints may overlap (Li et al., 
1997). 
Caspase 1 expression is increased following ischaemia although in a delayed fashion and has 
been localised to the microglia (Bhat et al., 1996). Studies with transgenic animals revealed 
that inhibition of caspase 1 decreased infarct size and improved neurological outcome 
(Friedlander et al., 1996). The beneficial effects of caspase 1 inhibition are thought to be 
40 
mediated by the reduction in production of interleukin -1 ß (IL-43) and although not 
obligatory during apoptosis it may be a contributing factor to cell death in ischaemia (Linnik 
& Ringer, 1999). The protective effects seen may be due to anti -inflammatory effects of 
reduction of IL -113 production, rather than inhibition of apoptosis or a combination of both 
(Loddick et al., 1996; Schulz et al., 1999). The inhibition of caspase 1 like enzymes 
pharmacologically using fluoromethyl ketone inhibitors (e.g. z- VAD.fmk) also causes a 
reduction in ischaemic damage (Wiessner et al., 2000). Again it is difficult to distinguish 
anti -apoptotic and anti -inflammatory actions of these agents (Dalkara & Moskowitz, 1996; 
Rabuffetti et al., 2000). In addition, inhibition of a specific member of the caspase family 
pharmacologically is questionable as the compounds may not be truly selective and may 
have other non -specific effects within cells (Nicotera et al., 2000a). 
Cerebral ischaemia & inflammation 
In the past, the CNS was thought to be an immune privileged site because of the lack of 
expression of molecules involved in a classical immune response (Becher et al., 2000). The 
brain has no lymphatic drainage, was previously assumed to have no classical antigen 
presenting cells and additionally because of the BBB, access of blood -borne immune cells is 
highly restricted (Perry et al., 1993). Compared with other organs of the body, the immune 
reactions in the brain are markedly reduced (Becher et al., 2000; Gebicke -Haerter et al., 
1996; Perry et al., 1993). In recent years, the idea of immune privilege status of the brain has 
been re- examined and reviewed (Barone & Feuerstein, 1999; Hallenbeck, 1997; Jean et al., 
1998). The inflammatory processes of the brain are thought to be more subtle and differ from 
those in non -CNS tissue (Matyszak, 1998). 
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Inflammation following an ischaemic insult is believed to develop as a consequence of two 
sequential but closely linked processes: activation of the resident inflammatory cells of the 
brain and the mobilisation and infiltration of peripheral inflammatory cells (Stanimirovic & 
Satoh, 2000). In effect, the inflammatory response can be divided into endogenous and 
exogenous components. The development of a post -ischaemic inflammatory response is 
co- ordinated by the activation, expression and secretion of numerous pro -inflammatory 
genes and mediators by both parenchymal and endothelial cells. The initiation of the 
exogenous inflammatory response following an ischaemic insult takes place in the 
microvasculature as it provides an interface for circulating inflammatory cells such as the 
polymorphonuclear leukocytes (PMNLs) to adhere to before passing into the underlying 
parenchyma (del Zoppo et al., 2000). 
Inflammation in the brain following injury has been termed `a dual edge sword' (Barone & 
Feuerstein, 1999). Classically, inflammation is the body's response to damage and is 
beneficial in terms of removal of compromised tissue and elimination of invading pathogens 
(Andersson et al., 1992). However, in functioning to eliminate foreign entities, the response 
may in turn cause more damage to surrounding tissue and therefore have a detrimental 
outcome. There is also a regenerative component to inflammation, particularly in the CNS, 
were signalling molecules originating from cells associated with the inflammatory response 
promote cell survival and repair (Andersson et al., 1992). The inflammatory response can 
therefore be viewed to be finely balanced with the potential to have devastating 
consequences under certain conditions (Becher et al., 2000). 
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LEUKOCYTES & CELL ADHESION MOLECULES IN ISCHAEMIA 
The role of white blood cells, particularly PMNLs and monocytes, in the pathophysiology of 
ischaemic disease has been studies for over 3 decades in organs such as the heart, intestine 
and skeletal muscle and have been implicated in the evolution of ischaemia -reperfusion 
injury (Hartl et al., 1996; Vasthare et al., 1990). The term PMNL refers to three of 
leukocytes types (eosinophils, basophils and neutrophils) found in the blood that have 
multi -lobed nuclei and abundant membrane -bound granules. The neutrophils are the most 
abundant type of leukocyte. The fourth type of leukocyte is the monocyte which is larger 
than the other types and has an oval or horseshoe -shaped nucleus and few cytoplasmic 
granules (Vander et al., 1994). The leukocytes, as fundamental participants in an immune 
response of the body, are there as a defence to protect tissues but may also have deleterious 
effects in ischaemic brain tissue (Dallegri & Ottonello, 1997; Kubes & Ward, 2000). The 
accumulation of leukocytes and monocytes following both clinical and experimental cerebral 
ischaemia was first identified in the 1970s by Sörnäs et al. (1972) and Garcia et al. (1974) 
(Garcia & Kamijyo, 1974; Somas et al., 1972). These studies were followed by 
epidemiological studies in the 1980s, that suggested leukocytes contributed to the initiation 
of stroke by affecting blood dynamics or by participation in clot formation (Prentice et al., 
1982). In the late 1980s, the contribution of leukocytes in the pathogenesis of brain injury 
was intensively investigated by many groups and has been followed by a large number of 
studies that have assessed the role of these cells in cerebral ischaemia (Rothlein, 1997). 
Accumulated evidence indicates that leukocytes play a key role leading to secondary brain 
damage particularly during reperfusion (Jean et al., 1998). 
Leukocyte presence at the site of inflammation is dependent on the co- ordinated expression 
of cell adhesion molecules, both ligands and receptors on the invading cells and the vascular 
endothelium, respectively. These molecules orchestrate and facilitate the adherence of the 
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immune cells that is followed by the migration into the target tissue. There are three families 
of cell adhesion molecules including the integrins, the selectins and the immunoglobulin 
super family (Arvin et al., 1996; Kochanek & Hallenbeck, 1992). Integrins are essential 
determinants in the adhesion of leukocytes to the endothelium and consist of a CD11 and a 
CD18 subunit. The most important integrins are LFA -1 and Mac -1 that both contain a 
common CD18 subunit (Kochanek & Hallenbeck, 1992). The integrins bind to members of 
the largest family of the cell adhesion molecules the immunoglobulin superfamily or the 
intercellular cell adhesion molecules (ICAMs) that includes intercellular cell adhesion 
molecule -1 (ICAM -1) and vascular cell adhesion molecule (VCAM -1). These molecules are 
expressed on the endothelium and are modulated by inflammatory mediators such as the 
cytokines (Stanimirovic & Satoh, 2000; del Zoppo et al., 2000). The third class of cell 
adhesion molecules is the selectins including E- and P- selectin that are expressed on 
activated endothelium and L- selectin that is constitutively expressed on leukocytes (Ley, 
1996). 
There is multistep recruitment (rolling- activation -adhesion) of leukocytes as they enter the 
site of inflammation. The initial interactions rely on the selectins that facilitate the transient 
and reversible adhesion known as rolling. P- selectin (pre -formed in the cell) is rapidly 
secreted from storage granules called Wiebel -Palade bodies (within the first 90 min 
following insult (del Zoppo et al., 2000)) followed by transcription induction of E- selectin 
(4 -6 hrs), cell adhesion molecules and integrins (Hallenbeck, 1996; Stanimirovic & Satoh, 
2000). Firm adhesion occurs when inflammatory mediators released by the endothelial cells 
activate PMNLs and cause expression of integrins (LFA -1 and Mac -1) that bind to the ICAM 
receptors expressed on the endothelium. Transmigration then follows mediated by adhesion 
molecule interaction with the extracellular matrix (ECM) and the PMNLs enter the tissue 
(Ley, 1996). 
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In stroke patients, neutrophils have been detected within the first 18 his after an acute 
ischaemic stroke (Bednar et al., 1991). Subsequent studies observed an upregulation in cell 
adhesion molecules indicating neutrophil activation in stroke patients as early as 4 hrs 
(Fassbender et al., 1995). Patients who have suffered an acute ischaemic insult have a 
functional alteration in their systemic PMNLs where the cells are more susceptibly to 
activation and which could indicate a trend towards increased accumulation in infarcted 
tissue (Caimi et al., 2000). An increased number of PMNLs have been found in the 
microvessels and ischaemic parenchyma of various species following cerebral ischaemia 
(Barone et al., 1991; Barone et al., 1992; Clark et al., 1993; del Zoppo et al., 1991; Garcia & 
Kamijyo, 1974; Hallenbeck et al., 1986; Kochanek & Hallenbeck, 1992). In the first studies 
of leukocyte accumulation using a myeloperoxidase assay, PMNL accumulation was seen in 
the brain tissue at the periphery of the lesion with maximum infiltration at 48 -72 hrs 
following permanent occlusion of the MCA. PMNLS were seen in the core of the infarct at 
7 days (Garcia & Kamijyo, 1974). More recent studies have shown that the PMNLs are the 
first of the exogenous inflammatory cells to reach the cerebral parenchyma accumulating in 
the vasculature 1 -4 hrs post recirculation and peak in the parenchyma between 24 and 72 hrs 
(Garcia et al., 1994; Hallenbeck, 1996). In rats subjected to permanent MCA occlusion, 
leukocytes are detected in the vessels of as early as 30 min post- occlusion (Garcia et al., 
1994). Again in a rat model of focal cerebral ischaemia it has been shown that neutrophil 
infiltration occurs earlier and to a greater extent in reperfused tissue (Clark et al., 1994a). 
Zhang et al. (1994) correlated maximum infarct expansion with the time of neutrophil 
infiltration (6 -24 hrs) following transient MCA occlusion (Zhang et al., 1994). 
It has been proposed that PMNLs obstruct the cerebral vessels and contribute to the 
`no- reflow' phenomenon (Mori et al., 1992). The no -reflow phenomenon has been 
demonstrated in the baboon (del Zoppo et al., 1991) although as a phenomenon it has been 
questioned (Aspey et al., 1989). Leukocytes may have other detrimental effects such as the 
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release of vasoactive mediators, cause alteration of the vasoreactivity of the cerebral vessels 
and release of cytotoxic enzymes and free radicals that can threaten the brain tissue (Pantoni 
et al., 1998). Data that implicates leukocytes and other white blood cells such as monocytes 
in the pathology of cerebral ischaemia comes from studies that block or alter the function of 
these cells. Animals that have been rendered neutropenic by anti- neutrophil serum or by 
chemical means (vinblastine) have smaller infarcts than non -treated animals. These results 
are interpreted cautiously as the rheological effect of the treatments may influence outcome 
and in some cases development of damage was only delayed and had no effect on final lesion 
size (Bednar et al., 1991). More convincing results have been obtained in experiments where 
antibodies that reduced circulating leukocytes were administered prior to occlusion and 
caused reduction in lesion volume (Matsuo et al., 1994; Shiga et al., 1991). Experimental 
strategies using antibodies directed at the cell adhesion molecules (anti -ICAM -1 or 
anti -CDllb antibodies) have proved successful in experimental models in terms of damage 
reduction although there is somewhat confusing data regarding this therapeutic approach 
from both pre -clinical investigations and clinical trials. Takeshima et al. (1992) demonstrated 
that an anti -CD 1 lb /CD 18 antibody did not afford protection from severe focal cerebral 
ischaemia in the cat although neuroprotection was assessed only 4.5 hrs post ischaemia using 
2,3,5- triphenyltetrazolium chloride (ITC) staining. It is questionable if the damage or any 
neuroprotection would be clearly evident at this time point (Takeshima et al., 1992). Zhang 
et al. (1995) reported no reduction in lesion volume with either anti -ICAM -1 or anti -CD11b 
antibodies in a permanent model of MCA occlusion in the rat (Zhang et al., 1995). However, 
in the transient model, PMNL infiltration and lesion volume were reduced even if treatment 
was administered 2 hrs post -occlusion (Zhang et al., 1995). Chen et al. (1994) showed 
similar results and correlated the reduction in PMNL accumulation with the reduction in 
damage (Chen et al., 1994). Treatment with the anti -CD11b antibodies did not delay the 
maturation of the lesion, as the reduction in ischaemic damage was still evident at 7 days 
post -treatment (Zhang et al., 1995). In contrast to the anti -ischaemic effectiveness of the 
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anti -adhesion molecule strategies in animal models, the trial for the murine anti -ICAM 
antibody for stroke (Enlimomab trial) failed, demonstrating the difficulties of extrapolation 
of animal data to the clinic (del Zoppo et al., 2000). However, this apparent failure maybe 
due to the lack of reperfusion in the patients and perhaps positive results would have been 
seen had tPA been included in the treatment regime. 
Studies in baboons and in rats subjected to MCA occlusion have shown the upregulation of 
selectin molecules on the microvascular endothelium (Okada et al., 1994; Wang et al., 
1994b). ICAM -1 mRNA and protein levels are increased in focal cerebral ischaemia and 
have been correlated with the infiltration of neutrophils in a variety of studies (Winquist & 
Kerr, 1997; Matsuo et al., 1994; Shiga et al., 1991; Wang et al., 1994b; Wang & Feuerstein, 
1995). ICAM -1 expression is strongly expressed on ipsilateral cerebral vessels when 
compared with the contralateral cortex (Schroeter et al., 1994). Selectins are expressed 
within the first few hours following an embolic stroke in the rat, peaking between 6 and 12 
hrs. In contrast, the ICAMs are maximal at 48 hrs (Zhang et al., 1999b). In a study using 
spontaneously hypertensive rats subjected to permanent or transient MCA occlusion, 
Morikawa et al. (1996) showed differences in blocking selectin binding in the two occlusions 
similar to that observed with the anti -CD1lb antibodies i.e. effective in the transient model 
of occlusion but not the permanent model ( Morikawa et al., 1996). Transgenic mice deficient 
in ICAM -1 support the involvement of the adhesion molecules in the development of 
ischaemic damage. The homozygous knockout mice showed a reduction in infarct size and 
neurological deficit, had an increased survival and elevated blood flow in the infarcted 
hemisphere (Winquist & Kerr, 1997). 
A potential cavaet of studies that investigate cell adhesion molecules and leukocytes 
particularly in focal cerebral ischaemia is that many of the studies employ the intraluminal 
monofilament model. This model has been criticised because the insertion and removal of 
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the occluding device can cause damage to the endothelium of the cerebral vessels which 
could lead to spurious results (Jean et al., 1998). These criticisms have been somewhat 
answered by the fact that using another model of occlusion (autologous emboli in rabbits) 
where less damage may be caused to the endothelium (Bowes et al., 1995). It should be 
appreciated that whilst observations regarding leukocyte infiltration may be an 
epiphenomenon of the model, other evidence regarding the inflammatory response (cytokine 
expression, microglial activation) do still indicate a potential role for inflammation in the 
pathophysiology of the disease. 
GLIAL CELLS - MICROGLIA & ASTROCYTES 
The term `reactive gliosis' is used to describe the response of the endogenous glial cells to 
damage of neuronal tissues and is a topic of much discussion regarding its beneficial or 
detrimental role following brain injury (Kreutzberg, 1996; Giulian et al., 1993). Glial cells 
respond to neuronal damage by under -going a number of characteristic changes and although 
may vary generally respond stereotypically and reproducibly although not necessarily at the 
same time (Streit et al., 1999). 
Microglia 
Microglia often classed as the resident immune cells of the CNS and are the first non -neural 
cells to respond to CNS injury. They synthesise and secrete molecules such as cytokines and 
free radicals. These cells may be viewed as the co- ordinators of the inflammatory response in 
the brain as their activation is often followed by the infiltration of peripheral immune cells 
(Brint et al., 1988; Kato & Walz, 2000; Kuge et al., 1995). The role of microglia in the 
pathophysiology of cerebral ischaemia is discussed in detail in Chapter S. 
48 
Astrocytes 
Astrocytes are the predominant neuroglial cell type of the CNS and exist in two typical 
forms. Stellar -fibrillary astrocytes are normally located in the white mater whilst 
protoplasmatic astrocytes are located in the grey matter (Raivich et al., 1999). As a cell 
type, they perform a variety of protective functions in the adult brain among which is 
protection against excitotoxic death by the removal of glutamate from the synaptic cleft. 
These cells buffer extracellular K+ concentrations, process nutrients, regulate extracellular 
volume and release a host of neurotrophic factors (Nawashiro et al., 2000). The astrocytes 
also provide physical support to the neighbouring neurones, meninges and vasculature and 
induce the formation of tight junctions on endothelial cells (Raivich et al., 1999; Kato, et al., 
1994). 
The astrocytes, like the microglial cells, respond to brain injury and their response depends 
on the extent of the trauma. Following injury the astrocytes rapidly synthesise glial fibrillary 
acidic protein (GFAP) and the protoplasmatic cells transform into fully stellarised, fibrillary 
astrocytes. This morphological change is controlled by cytokines expressed following injury 
(Raivich et al., 1999). The characteristic hyperplasia and hypertrophy with increased GFAP 
staining that accompanies astrocyte activation has been reported in following cerebral 
ischaemic in the rat (Kindy et al., 1992; Petito & Halaby, 1993) although others have 
reported a decline in GFAP reactivity (Chen et al., 1993; Li et al., 1995b). GFAP mRNA has 
been shown to be increased at 3 hrs post -occlusion, spread throughout the affected 
hemisphere within 3 days and have declined by 7 days (Yamashita et al., 1996). Conversely, 
Liu et al. (1999) examined the astrocytic response following permanent MCA occlusion by 
measuring GFAP mRNA and protein expression and showed loss of GFAP mRNA as early 
as 3 hrs in the core of the infarct with an increase in expression in the peri- infarct area. 
Elevated expression remained for 25 days and was associated with gliotic scar formation 
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(Liu et al., 1999). The astroglial activation has been associated with enhanced astroglial 
function and following insult these cells are thought to have an increased capacity for 
glutamate uptake, maintain water and ionic homeostasis and therefore may facilitate 
recovery following an ischaemic insult (Kato et al., 1994). Another role suggested for the 
reactive fibrillary astrocytes is that they act as a physical barrier between healthy and 
damaged tissues (Raivich et al., 1999). These suggestions are supported by the observation 
that GFAP null transgenic mice were more sensitive to permanent MCA occlusion with 
transient common carotid occlusion implying the astrocytes have a beneficial role in the 
ischaemic brain (Nawashiro et al., 2000). 
CYTOKINE EXPRESSION 
Cytokines are expressed in the normal brain at levels that are hardly detectable. After injury 
however, various cytokines (interleukin -1 ß, interleukin-6 and tumour necrosis factor alpha) 
collectively called the pro -inflammatory cytokines, are known to be synthesised and released 
(Sharma & Kumar, 1998). The cytokines that are expressed in ischaemic tissue may play a 
significant role in the outcome of the compromised tissue. Cytokine expression in focal 
cerebral ischaemia is discussed in detail in Chapter 6. 
iNOS 
As discussed previously, NO has a notable role in the pathology of focal cerebral ischaemia. 
Of particular interest in a discussion centring on the inflammatory response to the reduction 
of blood flow to the brain is inducible or immunological nitric oxide synthase (iNOS). iNOS 
is not normally present in most cells but its expression is induced in pathological states, 
particularly those with associated inflammation (Nathan, 1997). Intracellular Calf does not 
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regulate the enzyme unlike the other isoforms which are expressed in the post -ischaemic 
rodent brain, peaking at 12-48 hrs and is localised to the inflammatory cells and the cerebral 
blood vessels (del Zoppo et al., 2000). iNOS has also bee observed in the brains of stroke 
victims supporting it role in the pathology of ischaemia (del Zoppo et al., 2000). 
MODELS OF CEREBRAL ISCHAEMIA 
Stroke is a highly variable clinical condition and it is therefore difficult, despite advances in 
neuroimaging systems, to evaluate the dynamic biochemical events that follow ischaemia, 
determine the outcome of an insult or assess potential neuroprotective compounds in stroke 
patients. The cause, location, severity of an insult and the contribution of pre- existing 
systemic diseases are all uncontrolled variables in the patients that present with a stroke 
(Hsu, 1993). Therefore, studies to understand the pathology of the disease conducted in 
human patients would require large sample sizes to account for the variations (Macrae, 1992; 
McAuley, 1995). The use of animal models to study cerebral ischaemia has given enormous 
insight, into the pathological biochemical events that follow an ischaemic insult and also 
provides a means of investigating and assessing possible therapeutic neuroprotective 
strategies (Hunter et al., 1995). 
One advantage of using in vivo models to study cerebral ischaemia is the ability to perform 
controlled experiments and manipulate physiological variables. The use of standardised 
animal strains, alteration of the duration and severity of the insult and the ability to monitor 
and control physiological parameters such as blood pressure, gases, temperature and plasma 
glucose concentration is possible in a laboratory environment (Kirsch et al., 1996). Animal 
models allow histopathological, biochemical and physiological investigation that require 
invasive surgery and direct access to the brain. They also allow assessment of events 
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occurring within minutes of an ischaemic insult (Ginsberg & Busto, 1989). Experiments to 
establish this type of data for humans would require patient compliance and would be 
difficult to support ethically. In vitro systems such as brain slices and tissue culture are 
limited methods of assessing the pathophysiology of stroke, as the disease is the 
consequence of abnormal perfusion of the brain. The recreation of abnormal perfusion 
requires the presence of intact vasculature as an integral component of an experimental 
system (Lipton, 1999). The use of in vitro systems of cerebral ischaemia offers an insight 
into aspects of the disease process, allows investigation in a simplified environment and 
provides a starting point for further investigation. 
Stroke is a disease predominantly of middle or later life and is often complicated by other 
co- existing medical conditions. The experimental animals used to model stroke are generally 
young and may not truly represent the physiology of ischaemia in humans (Millikan, 1992; 
Recommendations for standards regarding preclinical neuroprotective and restorative drug 
development 1999). Consequently, some animal models have been developed to incorporate 
conditions such as hypertension that are associated with stroke (Ginsberg & Busto, 1989). 
Animals models of stroke model particular aspects of the disease and are essential for 
investiagtion of disease mechanisms and the evaluation of potential therapies and it should 
be noted that no stroke model exactly reproduces the human condition. The data from studies 
using different animal models has highlighted variations that exist between them (Oliff et al., 
1995; Duverger & MacKenzie, 1988). It is important to recognise that the involvement or 
contribution of one particular aspect of the pathophysiology could be an epiphenomenon of 
the stroke model. A standardised experimental approach and reproducible models are critical 
to understanding the cellular mechanisms involved in the pathology (Hsu, 1993). Variables 
such as rat strain, supplier, weight, age and anaesthetics used have an effect on the extent of 
ischaemic damage observed in different vessel occlusion methods (Brint et al., 1988; 
Duverger & MacKenzie, 1988). Physiological variables such as blood pressure, brain and 
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body temperature, blood gases and plasma glucose concentration can influence neurological 
outcome following ischaemia and should, where possible, be monitored and kept with in 
normal physiological limits (Oliff et al., 1995; Duverger & MacKenzie, 1988). 
Neuroprotective effects of compounds may also depend on the model of focal cerebral 
ischaemia and the species used for assessment (Recommendations for standards regarding 
preclinical neuroprotective and restorative drug development 1999; Takamatsu et al., 1998). 
Two other points should be considered regarding the use of animal models to model 
ischaemia. Like all biological organisms, species used experimentally are composed of 
rhythmical changing systems that may affect the response to the same stimulus depending on 
the time of day. In a study to determine the influence of circadian rhythms on infarct volume, 
Vinall et al. (2000) cautioned against the extrapolation of rat data to the human condition. 
They highlighted that the volume of infarct was correlated to body temperature linked to the 
animal's biological rhythms. Lesion volumes were greatest at the peak of activity at 041100 
and smallest (3 times smaller) at 16H00 (Vinall et al., 2000). This observation of role of 
temperature in lesion formation is supported by studies with compounds like MK -801 that 
are known to reduce temperature and infarct size (Nakanishi et al., 1994). Another 
consideration regarding the use of animal models for the assessment of ischaemic damage 
and the testing of potential neuroprotectants is that the majority of studies are performed in 
male animals because it negates that need to control for hormonal fluctuations associated 
with the female reproductive cycle (Roof & Hall, 2000). Carswell et al. (2000) demonstrated 
that female rats in pro -oestrus (high endogenous oestrogen) had smaller infarcts following 
MCA occlusion that animals in meta -oestrus (low endogenous oestrogen) (Carswell et al., 
2000). Vergouwen et al. (2000) however found that there were no significant gender 
differences but the discrepancies seen between these and other studies may be the result of 
the different occlusion methods and rat species used (Vergouwen et al., 2000). Current 
epidemiological data suggest that stroke incidence and prevalence is shared equally between 
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the sexes however more women die of stroke than men (American Heart Association 2000). 
Analysis of clear -cut differences is difficult because of all the coincident variables in the 
clinical setting (Vergouwen et al., 2000). 
SPECIES USED FOR EXPERIMENTAL MODELLING ISCHAEMIA 
Models of MCA occlusion were developed in primates as early as the 1930s and have been 
adapted and refined for use in other species (Peterson & Evans, 1937). A number of animal 
species ranging from small rodents to large sub -human primates have been used to 
investigate the disease (Ginsberg & Busto, 1989; Feuerstein & Wang, 2000). MCA occlusion 
experiments in large animals such as cats, dogs and primates have been performed for much 
of the century and have the advantage of possessing a gyrencephalic brain with extensive 
white matter like humans (Dewar et al., 1999). Rodent models are now most widely used 
experimentally because of the low cost of the animals and associated reduction in cost of 
procedures that would increase with larger body size. The homogeneity of strains that results 
from inbreeding, similarities in the cranial circulation of rodents and man, small brain size 
suitable for fixation and subsequent histological studies make rodents ideal experimentally. 
There is also greater ethical acceptability in the West that makes rodents suitable subjects for 
research purposes (Ginsberg & Busto, 1989; Macrae, 1992). More commonly now 
genetically modified animals are used to study cerebral ischaemia. Transgenic mice have 
been used to investigate the effects of over -expression or deletion of a specific gene on 
infarct development following an ischaemic insult (Chabrier et al., 1999; Chan, 1996). 
The use of rodents routinely for the studying of MCA occlusions and gerbils for forebrain 
and global ischaemia does allow comparison of data from experiments performed by 
different laboratories but in so doing has decreased variability that is perhaps more 
representative of the clinical situation. Occlusion of the MCA (proximal to the 
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lenticulostriate vessels) results in an infarct in both the ipsilateral cortex and striatum and 
most closely resembles the anatomical distribution of the most common strokes seen in 
humans (Mattson, 1997). Different aspects of pathology may be highlighted using a wider 
range of species. It should however be constantly remembered that despite the modification 
and improvement of animal models they will never truly represent the clinical condition. 
They are however crucial to the understanding of the aspects disease pathology and not the 
disease itself. 
GLOBAL VS. FOCAL ISCHAEMIA 
The MCA and its penetrating arteries are prone to infarction in man (McAuley, 1995) and 
occlusion of this vessel is the most common underlying cause of ischaemic stroke in human 
(Nedergaard, 1988). Consequently, majority of animal models have been developed to mimic 
the clinical situation. Global ischaemia is a different disease and is modelled by brief near 
complete cessation of CBF followed by reperfusion with a very different resulting pathology 
(delayed cell death in the CA1 region of the hippocampus). The most popular global model 
is the 2 vessel occlusion in the gerbil although 2 and 4 vessel occlusions (sometimes 
incorporating hypotension) are also performed in the rat (Small & Buchan, 2000). 
PERMANENT VS. TRANSIENT ISCHAEMIA 
Models of cerebral ischaemia are also classed as permanent or transient. Clinically 
spontaneous recanalisation of the vessel has been reported in the first week post -insult in 
24 -50% of patients that results in the return of blood to the ischaemic zone (Saito et al., 
1987). However, more recent studies have shown that only between 4 and 17 % of patients 
displayed unassisted recanalisation (del Zoppo & Hallenbeck, 2000). Permanent occlusion 
in humans may result from increases in vascular resistance or plugging of the vessels by 
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components of the blood such as platelets (Marchai et al., 1999). The permanent animal 
models have fundamental information about pathophysiological mechanisms responsible for 
tissue infarction, concepts of flow thresholds and assessing neuroprotectant drugs. Increased 
understanding of the clinical condition of stroke dictates that the consequences of 
reperfusion are investigated and therefore transient animal models have been developed and 
adapted to address this. The re- establishment of the blood to the hypo -perfused area is vital 
because it provides oxygen and substrates that the neurones require and it may salvage tissue 
that has not been irreversibly damaged. Alternatively reperfusion may have deleterious 
consequences and exacerbate the damage (Kristian & Siesjo, 1997) (see Core, Penumbra & 
Reperfusion Injury). 
WHITE MATTER DAMAGE 
The white matter of the brain is as susceptible to ischaemic damage as the grey matter. Focal 
ischaemia causes damage to both neurones and glial cells which is routinely evaluated by 
histology. The damage in the axons and the oligodendrocytes can also be assessed following 
an ischaemic insult by histochemical means but is often overlooked (Dewar et al., 1999). 
Axonal ischaemic damage can be visualised by immunostaining for a variety of microtubule 
proteins of the cytoskeleton or by accumulation of molecules associated with axonal 
transport (Dewar & Dawson, 1995; Yam et al., 1998). Damage to oligodendrocytes is 
marked by an upregulation of expression of the microtubule- associated protein, tau that has 
been used to show the sensitivity of these cells to permanent MCA occlusion in vivo (Stys, 
1998). 
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EXPERIMENTAL MODELS OF FOCAL ISCHAEMIA 
Each in vivo model of focal cerebral ischaemia has both strengths and weaknesses (Table 1). 
In order to achieve greater understanding of the pathology of ischaemia and develop new 
neuroprotective compounds, multiple models may give answers to a number of different 
questions by providing a more complete picture and an insight into the mechanisms of the 
disease. The guidelines for pre -clinical assessment of neuroprotectant in acute ischaemic 
stroke models suggests that different species (small and large animals) be included using 
models of both permanent and transient occlusion and that these studies be replicated by 
independent laboratories (Gorelick, 2000). Models of vessel occlusion in species where 
histological evidence and functional assessment (behaviour) can be assessed allows a more 
complete investigation of both the disease and potential therapies (Hunter et al., 1995). 
ELECTROCOAGULATION OF THE MCA 
Robinson et al. (1975) were first to described a method ligating the distal portion of the rat 
MCA exposed by frontoparietal craniotomy to cause a focal ischaemic lesion (Robinson et 
al., 1975). This model produced lesion volumes that were not reproducible and although 
occlusion affected the cortex, it often failed to affect the striatum. This method was modified 
by Tamura et al. (1981) using a sub -temporal craniotomy with removal of the zygoma to 
access the MCA proximal to the lenticulostriate branches of this artery and electrocoagulate 
it at that point (Tamura et al., 1981a). The method was further modified by Shigano et al. 
(1985) leaving the zygoma intact reducing the eating difficulties experienced by the animals 
following destructive surgery (Shigeno et al., 1985). Electrocoagulation has been shown to 
reduce cerebral blood flow to values below 25 ml .100 g "' min 1 (Tamura et al., 1981b), 
results in reproducible infarcts that affect both the cortex and striatum and has a low 
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mortality rate and was consequently historically widely used. Hemispheric infarct volumes 
of 100 -150 mm3 achieved by occlusion of the MCA proximal to the lenticulostriate branches 
in normotensive rats are representative of large infarcts observed in humans (McAuley, 
1995). 
Variation in the distribution pattern of infarct achieved using this method is attributed to 
differences in the site of the electrocoagulation (distal versus proximal occlusion of the MCA 
which varies in length) and the contribution of the lenticulostriate and other branches of the 
MCA. These factors can lead to differences in reproducibility of data obtained from this 
model making analysis of neuroprotection and other studies difficult. Alternative approaches 
have been attempted to improve the reproducibility of infarction including distal MCA 
occlusion combined with ligation of the ipsilateral common carotid (Brint et al., 1988), 
concomitant MCA occlusion with bilateral common carotid artery occlusion (Chen et al., 
1986) and bilateral common carotid artery occlusion with hypotension (Smith et al., 1984). 
Studies have been carried out using this model to assess the reproducibility of infarct size in 
different species and strains and incorporated risk factors such as hypertension (Duverger & 
MacKenzie, 1988). The drawbacks of the Tamura model include the severity of the surgery 
and the permanency of the occlusion that excludes investigation of the reperfusion. 
Modification of the method by using microclips, hooks or ligature snares allows reversal of 
the occlusion and examination of the events associated with reperfusion (Macrae, 1992). 
A disadvantage of this model, which is associated with all involving major surgical 
procedures, is the use of anaesthetic agents. They may interfere with the evolution of the 
ischaemic lesion, aggravate or reduce the damage with prolonged administration and also 
complicate evaluation of neuroprotective compounds as they may be neuroprotective in their 
own right (Kirsch et al., 1996). It is also possible that the properties of putative 
neuroprotectants may be altered by interaction with the anaesthetic compounds (Sharkey et 
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al., 1993; Sharkey & Butcher, 1995; Shapiro, 1985). Other disadvantages of this model 
include the exposure of the brain due to the craniotomy that may allow desiccation, thermal 
damage to the brain tissue, damage to the autonomic nerves of the vessel by cauterisation or 
clipping and possible instability of the thrombus induced by the electrocoagulation (Laing et 
al., 1993; Longa et al., 1989). 
INTRALUMINAL OCCLUSION OF THE MCA 
Koizumi et al. (1989) described a model of MCA occlusion in rats without craniotomy that 
can be either permanent or transient (Koizumi et al., 1986). The method involves 
introduction of monofilament suture into the internal carotid artery (ICA) via the external 
carotid artery (ECA). The monofilament is then advanced intraluminally beyond the origin 
of the MCA where it occludes blood. Cerebral blood flow in the cortex and lateral striatum is 
reduced to between 4 -19 m1.100 g'.min' (Macrae, 1992). This model does not require the 
demanding, potentially damaging surgery of the Tamura model and it has the advantage of 
allowing the restoration of blood flow by removal of the monofilament. Thermal damage and 
desiccation of the brain are avoided because craniotomy is not required and reperfusion can 
be instigated in conscious animals (Laing et al., 1993; Longa et al., 1989). A major 
disadvantage of this model is the unavoidable damage that occurs to the endothelial lining of 
the vessels. The lesion observed may therefore have a component resulting from vascular 
damage combined the consequences of the reduction in CBF. Additionally, damage to the 
vessel walls may be exacerbated on reperfusion having pathological consequences. The 
damaged vessels could also be a source of emboli that could occlude distal vessels (Macrae, 
1992; Schmid -Elsaesser et al., 1998). 
There is considerable variation observed using the monofilament model (Macrae, 1992) and 
as with the Tamura model, studies have been performed to improve the reproducibility of 
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infarct volume. In the original Koizumi method, the common carotid artery was 
permanently ligated, the monofilament was coated with silicon at its distal end and advanced 
in to the Circle of Willis without occluding the anterior communicating artery (ACA). Longa 
et al. (1989) modified the monofilament by blunting the by heating and advancing it to the 
point where it reached the proximal segment of the ACA (Longa et al., 1989). In addition, all 
the branches of the ECA and extracranial branches of the ICA were occluded to reduce 
bleeding. In 1993, Laing et al. conducted as study comparing the two methods above and 
concluded that the Koizumi method produced a more profound reduction in blood flow and 
more reproducible insult (Laing et al., 1993). Nagasawa & Kogure (1989) described a 
method of transient MCA occlusion whereby a silicon rubber cylinder was attached to nylon 
surgical thread was used. Overall mortality was high in this study with 93 % of the animal 
dying within 48 hours (Nagasawa & Kogure, 1989). A further modification of the method 
was made by Belayev et al. (1996) who coated a monofilament with a flame -blunted end 
with poly -L- lysine (polycationic amino acid) (Belayev et al., 1996b). They proposed that this 
encourage adhesion of the monofilament to the endothelium and appeared to improve the 
incidence, location and volume of infarct. The monofilament model and its variations is 
currently the most widely used experimentally (Schmid -Elsaesser et al., 1998). 
APPLICATION OF ENDOTHELIN -1 TO THE MCA 
Attempts to minimise mechanical damage to the vessel by methods such as 
electrocoagulation and insertion of an intraluminal device has led to the development of 
models using a pharmacological approach to cause an ischaemic insult. Endothelin -1 (Et -1), 
a potent vasoconstrictor, applied to the MCA exposed by craniotomy was first described by 
Robinson et al. (1990) (Robinson et al., 1990). The blood flow changes observed were 
comparable to the changes seen in the permanent electrocoagulation model. The volume of 
damaged tissue at 4 hrs following application of Et -1 was comparable to the same time point 
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in Tamura model. The advantages of this model are the lack of mechanical damage to the 
vessel and the ability to control the extent and duration of ischaemia by the altering the 
concentration of vasoconstrictor applied. There is still however the disadvantage of the need 
for craniotomy and its associated problems (Macrae, 1992). The use of the Et -1 may 
complicate the assessment of neuroprotective agents and it is important to establish 
interactions of such compounds with the vasoconstrictor and its receptors. 
In alternative approach, Sharkey et al. (1993) applied Et -1 by stereotaxic perivascular 
microinjection to cause occlusion of the MCA (Sharkey et al., 1993). The abluminal 
application of the Et -1 reduced blood flow in the ipsilateral hemisphere to values below 
10 m1.100 g'.min'. The pattern of ischaemia was similar to that reported for the Tamura 
model of permanent MCA occlusion and produced lesions with volumes of damage 
comparable to large human infarcts (Sharkey et al., 1993). 
Advantages of this model are the ability to occlude any vessel for which the stereotaxic 
co- ordinates can be determined, the surgical procedures are less invasive than the 
sub -temporal approach and the application of Et -1 can be performed on conscious animals. 
In a further development of this model, Henshall et al. (1999) described the use of 
Endothelin -3 (Et -3) administered stereotaxically as a model of transient ischaemia (Henshall, 
1999). The study compared the administration of Et -1 and Et -3 isopeptides and showed that 
the two isopeptides were equipotent in terms producing an ischaemic lesion but suggested 
that the Et -1 model was essentially a model of permanent ischaemia in which reperfusion is 
limited. The Et -3 model however provides a model in which controlled reperfusion is 
possible by administration of an Endothelin ETA receptor antagonist FR139317. Reperfusion 
caused by the administration of the antagonist was less abrupt than with other models and 
may more closely mimic the reperfusion seen clinically. Disadvantages of the Et models 
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include the need for a craniotomy and needle tract damage associated with the stereotaxic 
injection. 
THROMBOEMBOLIC MODELS OF MCA OCCLUSION 
Photochemically induced occlusion 
In this model of focal ischaemia, developed by Watson et al. (1985), occlusion of a specific 
vessel is achieved by producing an in situ thrombosis by photochemically stimulated platelet 
aggregation (Watson et al., 1985). Despite early claims about the value of this model, based 
on an embolic occlusion and thus deemed to representative of the human condition, it is not 
widely used. The method requires the retraction of the scalp but not craniotomy, intravenous 
infusion of a photosensitive dye (Rose Bengal) with simultaneous irradiation of the desired 
area with a laser set at a specific wavelength (560 nm). The reaction of the intravascular dye 
and the light generates oxygen radicals which affect lipid molecules within the endothelium 
and blood elements giving rise to a microvascular platelet aggregation (Ginsberg & Busto, 
1989). 
An advantage of this model is that it avoids invasive surgery and there is a degree of control 
over damage and site of lesion by the manipulation of the wavelength and position of the 
light and the plasma concentration of the dye (Macrae, 1992). Disadvantages include rapid 
development of damage, significant breakdown of the blood brain barrier by the free radicals 
that are generated and vasogenic oedema. Although reperfusion can occur as the clot 
resolves itself there is little control over the event and as the embolism breaks up it may 
result in multiple infarction distally (Hunter et al., 1995). 
Autologous emboli 
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In the thromboembolic occlusion models, homologous or autologous blood clots (< 100 µm) 
are introduced into the internal carotid artery via retrograde cannula circulation placed in the 
common carotid arteries without disrupting the cerebral flow (Kudo et al., 1982; Overgaard 
et al., 1992; Zhang et al., 1997). The emboli are produced by extravascular coagulation. This 
model has been used to produce strokes in larger species for many years and is attractive 
because of the little surgical manipulation that is required. The disadvantage is the lack of 
control over the distribution of the clots and consequently the uniformity and location of the 
infarcts (Hunter et al., 1995). Adaptations of the model with clots of human blood have been 
used to test the efficacy of thrombolytic agents such as the human recombinant tissue 
plasminogen activator (Ginsberg & Busto, 1989). Studies using such models have illustrated 
the benefit of reperfusion and functional recovery when embolisms are removed by 
fibrinolytic therapies and highlighted the benefit of rapid thrombolysis and early 
recirculation (Yang et al., 2000). 
Microsphere embolisation 
Calibrated microspheres (15 -30 µm) are used as an alternative embolic material. Again little 
surgical manipulation is required but there is little control over the final destination of the 
spheres and consequently no uniformity of size and location of infarcts (Hunter et al., 1995). 
Additionally an increase in cerebral oedema has been reported with this model (McAuley, 
1995) and it is now seldom used. 
In this thesis, the permanent and transient intralumnal monofilament and the Endothelin -1 
models of MCA occlusion have been used. These models have been chosen as the 
monofilament model is widely used and appears to be most useful for the investigations into 
the inflammatory response. The Et -1 model is routinely used within the laboratory and 
provides a suitably different approach to vessel occlusion. 
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Table 1. Advantages & disadvantages of animal models of focal cerebral ischaemia. 
METHOD OF 
OCCLUSION 
ADVANTAGES DISADVANTAGES REFERENCE 
Electrocoagulation/ 
ligation/clipping of 
the proximal MCA 




of large human lesions 
Reperfusion possible 
(except with 
electrocoagulation)  ) 
Thermal damage and desiccation due 
to sub -temporal craniotomy 
Mechanical damage to vessel 
Possible post -surgical feeding 
problems 
Anaesthesia required 
Tamura et al., 
1981a 




Relatively easy surgical 
procedure 
No need for craniotomy 
and associated problems 
No post surgery feeding 
difficulties 
Reperfusion can be 
achieved in conscious 
animals 
Damage to endothelium by insertion 
of monofilament 
Risk of puncturing the vessel 
Occlusion of ECA and its branches 
and pterygopalantine artery 
increasing infarct volume 
Anaesthesia required for insertion of 
monofilament although not 
necessarily for reperfusion 
Koizumi et al., 
1985 
Longa et al., 
1989 
Abluminal 
application of Et -1 
via sub temporal 
craniotomy 
Controlled reperfusion 
possible dependent on 
dose of Et -1 applied 
No mechanical damage 
to vessel 
Sub -temporal craniotomy and 
associated problems 
Anaesthesia required 
Possible interaction of potential 
neuroprotectants with ET and 
receptors 





isopeptides via dorsal 
craniotomy 
No mechanical damage 
to vessel 
Indwelling cannula can 
be used which allows 
administration of Et -1 to 
conscious animals 
Reversible model using 
Et -3 antagonist 
Craniotomy required although not as 
demanding as sub -temporal approach 
Needle tract damage 
Possible interaction of potential 
neuroprotectants with ET and 
receptors 
Sharkey et al., 
1993 





No craniotomy required 
(depends on thickness of 
the skull) 
Site of occlusion chosen 
by irradiating desired 
target area 
Possibility of thermal damage by the 
light source 
Generation of free radicals which 
affect integrity of BBB 
Instability of clot and subsequent 
multiple infraction may occur 
Inability to control reperfusion 








Embolic model useful 
for assessing 
thrombolytic treatments 
Instability of clot and subsequent 
multiple infarction may occur 
Variation in infarct volume and 
location 
Inability to control reperfusion 
Papadopoulos et 
al., 1987 
Zivin et al., 1987 
Kudo et al., 
1982 
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CURRENT TREATMENT & POTENTIAL THERAPIES FOR STROKE 
The current prognosis for patients with stroke is worse than for myocardial infarction and 
many forms of cancer (Dyker & Lees, 1998). In the US, there is no approved medical 
treatment for acute stroke except tissue plasminogen activator (tPA/Alteplase, Genetech) 
which has limited use as it must be administered within 3 hrs of an ischaemic insult and 
carries a risk of intracranial haemorrhage (Dyker & Lees, 1998; del Zoppo et al., 1997; Slow 
progress in the treatment of stroke 1998). In reality, only a few patients (5 -8 %) qualify for 
treatment with in this short time window (Barone & Feuerstein, 1999) 
An ideal neuroprotectant should reduce mortality in all types of stroke, irrespective of the 
location, severity and nature of the infarction and improve the functional and neurological 
prognosis of patients who survive (Giroux & Scatton, 1996). At all stages it must be 
remembered that volume of injured tissue following an ischaemia insult and the neurological 
outcome of the patient is dependent on the location of the occlusion, the duration of 
ischaemia, the collateral blood flow to the ischaemic zone and also the contribution of 
co- morbid illness (Black- Schaffer et al., 1999). Many pharmaceutical companies have 
focused on the development of neuroprotective drugs for the treatment of stroke and 
promising results have been achieved in a vast number of pre -clinical studies with animal 
models and more than 100 clinical trials (Table 2). Thus far however, all Phase III clinical 
trials for many compounds have been discontinued because of adverse side effects or failed 
due to lack of efficacy (De Keyser et al., 1999). The identification of a drug that could be 
administered to stroke patients requires a greater awareness of the condition and the facilities 
to provide rapid medical attention (Wester et al., 1999). One of the difficulties with people 
who suffer a stroke is their failure to recognise that they are suffering a medical crisis, as the 
symptoms are not always obvious (Wang et al., 2000; Heros, 1994). It is crucial for a rapid 
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accurate diagnosis to be made both in terms of administration of a therapeutic compound and 
also identification of suitable patients for inclusion in clinical trials for development of future 
compounds. Clinical evaluation of pharmacological therapies is a tricky issue irrespective of 
the disease at which the treatment is targeted and side effect and exposure to risk must be 
considered carefully (Albers et al., 1998). To this end, the entire approach to stroke 
management has faced re- organisation with the issuing of guidelines and greater education 
(Kaste, 1997). 
There are a vast number of therapies for acute stroke, both pharmacological and procedural, 
currently under development and many that have been abandoned. The clinical therapeutic 
goals of a neuroprotectant are three -fold: the rapid restoration of local cerebral blood flow, 
inhibition of the inflammatory sequealae of the ischaemic insult and the maintenance of 
neuronal integrity and function (del Zoppo et al., 1997; Heiss et al., 1999; Lutsep & Clark, 
1999). The complex multi- faceted nature of the ischaemic cascade provides a number of 
points for therapeutic intervention and the key to successful neuroprotection may lie in 
combination therapies (Sacchetti et al., 1997). Data has recently been published that supports 
this approach (Yang et al., 2000; Heiss et al., 1999; Asahi et al., 2000). A therapeutic 
approach not included (Table 2) that has been evaluated and like many other compounds has 
had disparate results, focuses on oedema management following stroke (del Zoppo et al., 
1997). Osmotherapy using compounds such as mannitol showed only a temporary beneficial 
effect (Hossmann, 1982). Neuroprotective agents are aimed at preservation of neurones but 
improved functional outcome does depend on protection of cortical grey matter but also 
simultaneous protection of the associated white matter (Dewar et al., 1999). Stroke therapies 
should thus be aimed at preservation of the neurones as complete functioning units. An 
alternative approach taken by pharmaceutical companies and clinicians to manage the 
disease is the use of preventative treatment that may help reduce the number of patients who 
present with a stroke (Table 3). 
66 
The Stroke Therapy Academic Industry Roundtable (STAIR) recommendations published in 
1999 proposes guidelines for the evaluation of potential therapies. These include established 
drug dose, which is important as both pharmacokinetics and pharmacodynamies may vary 
considerably between species, the use of a variety of animal models and species as well as 
verification of potential compounds by different laboratories, the routine monitoring of 
physiological variables, meaningful assessment of outcome measures and awareness of sex 
differences in stroke (Recommendations for standards regarding preclinical neuroprotective 
and restorative drug development 1999). A number of recently published commentaries 
listed the trial related factors that have doomed human trials of neuroprotectants and 
re- enforced the need for and value of the STAIR recommendations (Gorelick, 2000). These 
included inappropriate time window, inappropriate patient selection, and lack of 
communication between preclinical researchers, industry and clinicians. Difficulties in 
assessing the severity of stroke and realistic outcome endpoints together with method of 
effective drug delivery were also highlighted as potential points that may cause a trial to fail 
(Obrenovitch et al., 2000). If these issues are addressed and built into future clinical trial, 
perhaps an effective treatment for the disease will be found in the near future. 
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Table 2. Acute stroke therapy. 
Mechanism of action Subclass I Drug Company Status 
Drugs to improve blood flow 
Anti -thrombotic 
Heparin - Clinical use 
Nadroparin Sanofi III 
Tinzaparin Leo III 
Danaporoid Organon NCD 
Antiplatelet 
Asprin - ? 
Abciximab Eli Lilly & Co II 
Fibrinogen depleting Ancrod Knoll III 





Streptokinase Pharmacia NCD 







Calcium channel blockers 
Nimodipine Bayer NCD 
Flunarizine NCD 
Free radical scavengers 
Ebselen III 
Tirilazad Pharmacia & Upjohn III 





YM90K Yamanouchi Inc. NCD 
YM872 Yamanouchi Inc. II 
ZK- 200775 (MPQX) Schering AG NCD 
Kainate SYM 2081 
Competitive 
NMDA 




Aptiganel (Cerestat) Boehringer- Ingelheim NCD 
Dextrorphan Roche NCD 
Dextromethorphan 
Magnesium III 
MK -801 (Dizocilipine) Merck NCD 
NPS 1506 NPS II 





ACEA 1021 CoCeneSys NCD 




Eliprodil Synthelabo Lorex NCD 
Ifenprodil 
Growth factors 










Hu23F2G ICOS II 
Nitric oxide inhibitor Lubeluzole Janssen NCD 
Opiod antagonists Naloxone II 








5 -HT agonists Bay x 3027 Bayer AG III 
Sodium channel blockers 
Fosphenytoin Parke -Davis NCD 
Lubeluzole Janssen/Glaxo NCD 
619C89 ? 
Potassium channel opener BMS- 204352 Bristol -Myers Squibb I I I 
Unknown mechanism 
Piracetam UCB Pharma NCD 
Lubeluzole Janssen/Glaxo 
NCD - No clinical development in stroke 
References The Internet Stroke Center 2000; Koroshetz & Moskowitz, 1996; Giroux & Scatton, 1996; 
del Zoppo et al., 1997; De Keyser et al., 1999; Slow progress in the treatment of stroke 1999. 
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Table 3. Procedures. 
Procedure Action/reason Status 
Carotid endarterectomy 
Surgical therapy to reduce 
stroke risk 
Major symptomatic and asymptomatic trials 
completed. Clear benefit of endarterectomy in 
symptomatic patients with >70% stenosis. Potential 
value of surgery for 50 -69% (symptomatic) or 
60 -99% (asymptomatic) is much smaller and 
depends on surgical morbidity 
Hyperbaric oxygen therapy 
Treatment with oxygen under 
elevated atmospheric pressure 
No randomised, multi -centre trials have been 
reported. Two small pilot studies of hyperbaric 
therapy do not support the use of this treatment in 
clinical stroke patients. 
Hypothermia 
Reduce the metabolic rate of 
the brain, which may extend 




Blood exchange for stroke 
prophylaxis in sickle cell 
anaemia 
Trial was halted in September 1997 when interim 
analysis showed strong benefit for transfusion 
therapy in children with sickle cell anaemia. 
Transluminal angioplasty 
Angiographic procedure to 
dilate stenotic arteries. 
Large multi -centre trials comparing angioplasty and 
endarterectomy are underway. CAVATAS trial 
(below) showed similar results with either treatment 
References The Internet Stroke Center 2000; Koroshetz & Moskowitz, 1996; Giroux & Scatton, 1996; 
del Zoppo et al., 1997; De Keyser et al., 1999; Slow progress in the treatment of stroke 1999. 
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AIMS OF THESIS 
The primary aim of this thesis was to investigate the contribution of inflammation in the 
pathophysiology of focal cerebral ischaemia by examining three animal models of MCA 
occlusion: rat permanent and transient monofilament models and the abluminal Endothelin -1 
model. The initial hypothesis was based on observations that there are variations in animal 
models in terms of volume of damage and neuroprotective efficacy of compounds. It is 




Materials & Methods 
The methods described in this chapter are common to a number of subsequent chapters. 
Specific methods are detailed in individual chapters. 
All experimental animals, unless otherwise stated, were male Sprague Dawley (SD) rats 
(275 -315 g, aged 8 -11 weeks) supplied by Charles River, UK. Rats were housed in a 
thermostatically controlled (22 ± 2 °C), air -conditioned animal unit (12 hr day /night cycle; 
50 -60 % humidity) with food and water ad libitum. 
All surgical procedures were performed under aseptic technique. Surgical instruments and 
non -sterile instruments were routinely immersed in cold sterilising fluid (Novasapa ®, Willow 
Francis Veterinary). Surgical anaesthesia was induced by 5 % Halothane (Rhône Poulenc 
Chemicals Ltd) in a nitrous oxide: oxygen mix (70:30 v /v). Following induction of 
anaesthesia, animals were maintained at 1.5 -2 % Halothane in the same gaseous mixture. 
Rectal temperature was monitored throughout all surgical procedures and animal body 
temperature maintained at 37.0 ± 0.5 °C by a rectal probe attached to a thermostatically 
controlled heating blanket (CMA/Microdialysis AB 150). 
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MIDDLE CEREBRAL ARTERY OCCLUSION 
RAT PERMANENT MONOFILAMENT MODEL 
Focal cerebral ischaemia was induced under halothane anaesthesia using the method 
described by Longa et al. (1989) with modifications (Longa et al., 1989). The neck region of 
each animal was shaved in preparation for surgery using a Series 8900 cordless rechargeable 
animal trimmer (Wahl, USA). Midline incision and division of the omohyoid muscle 
exposed the left common carotid artery (CCA). The external carotid artery (ECA) was 
identified, dissected free from surrounding connective tissue and ligated distally with 6/0 silk 
suture (Ethicon, UK). A second 6/0 silk suture was tied loosely at the bifurcation of the ECA 
and the internal carotid artery (ICA). 4/0 silk suture (Ethicon) was placed around the ICA 
and tension applied to it to control bleeding. An angled atraumatic microvascular clip (6 mm 
micro- serrefine, Fine Scientific Tools) was placed across the CCA and a small incision made 
in the ECA at approximately the level of the origin of the occipital artery. The nylon 
monofilament (Ethicon), knotted at 18 -19 mm, coated with poly -L- lysine (Sigma) and tip 
rounded near flame was introduced into the lumen of the ICA via the ECA. The suture was 
carefully advanced through the ICA into vasculature of the brain to a point where it occluded 
origin of the middle cerebral artery (MCA) (Figure 6 & Figure 7). Silk suture at the 
bifurcation of the ECA and ICA was tightened around the monofilament in order to secure it. 
The neck wound was sutured with 4/0 silk sutures (Ethicon) and the animal allowed to 
recover in an incubator where normothermia was maintained for 1 hr by which time it had 
fully recovered. 
The post- operative care for each experiment was standard. The rats were placed in cages 
containing sawdust bedding only, returned to the animal unit and weighed daily. Animals 
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that were considered below the normal health status were supplemented with i.p. sodium 
chloride /glucose saline (0.18 % and 4 %, respectively) and/or a cereals soft based diet (e.g. 
Seven Cereals, Milupa UK). The supplementary care was only initiated 24 hrs post -lesion so 
as not to interfere with experimental procedures. 
RAT TRANSIENT MONOFILAMENT MODEL 
Surgery was performed as described for the permanent monofilament model (PMF). Two hrs 
post -occlusion unless otherwise stated, the animal was re- anaesthetised, the neck wound 
re- opened and the monofilament retracted to the point where the tip remained in the ECA 
and then cut. Blood flow in the ICA was visibly re- established in each case. Following 
surgery, the neck wound was sutured and the animal placed in an incubator to recover. 
The effect of various occlusion times on the volume of damage in the transient model (TMF) 
was examined. The monofilament was withdrawn after 30, 60, 90 and 120 minutes and the 
brains processed as described previously. In a further experiment, animals subjected to a 
30 min occlusion were allowed to survive for 14 days post -occlusion to investigate delayed 
cell death. 
Evans Blue (2 % in saline, Sigma) was injected i.v. into anaesthetised animals 10 min prior 
to perfusion fixation. The dye was used to determine the placement of the monofilament in 
the vasculature of transient MCA occlusion animals. The dye stained the endothelium 
damaged by the insertion of the monofilament that was then visible on removal of the brain. 
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Middle cerebral artery 
Internal carotid artery 
MONOFILAMENT 
External carotid artery 
Common carotid artery 
Figure 6. Placement of intraluminal monofilament for permanent and transient middle cerebral artery 
occlusion (Diagram modified from Longa et al., 1989). 
External carotid artery 
Internal carotid artery 
Superior thyroid artery 
Occipital artery 
MONOFILAMENT 
Common carotid artery 
Figure 7. Surgical exposure of the arteries in the neck of the rat and insertion of the monofilament. 
White lines represent vessels closed by tied suture. Blue line represents position of atraumatic clip 
during MCA occlusion. 
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RAT ENDOTHELIN -1 MODEL 
Occlusion of middle cerebral artery using Endothelin -1 was performed as described by 
Sharkey et al. (Sharkey & Butcher, 1995). Following induction of anaesthesia as described 
previously, the rat was placed in stereotaxic frame (Kopf Instruments) with tooth bar set at 
-3.7 mm. A midline incision was made on the scalp, the skin and periosteum retracted and 
Bregma located. The brain was exposed by a 2 mm craniotomy (0.9 mm anterior; 5.2 mm 
lateral to Bregma), the dura incised and a 26 gauge needle lowered slowly to pre -determined 
level (8.7 mm ventral to Bregma). Et -1 (150 pmols dissolved in saline) was injected in 3 µl 
over a 3 min period (Figure 8). Following the last injection, the needle was left in situ for 5 
min and then slowly withdrawn. The scalp was sutured and the animal placed in an incubator 
to recover. 
Stereotaxic needle 
150 pmols Et-1 
Figure 8. Occlusion of the MCA by stereotaxic application of Endothelin -1 (Sharkey et al., 1993). 
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MOUSE TRANSIENT MONOFILAMENT MODEL 
Dr Ailsa McGregor performed all mouse transient monofilament surgery. Male adult 
C57B/L6 mice (25 -30 g; Charles River, UK) were anaesthetised as described in the rat 
monofilament surgery protocol. Focal cerebral ischaemia was induced by occlusion of the 
left MCA using an 8 -0 nylon monofilament (Ethicon) coated with a mixture of silicone resin 
(Xantoprene, Heraeus Kulzer, Germany) and hardener (Elastomer Activator, Heraeus Kulzer, 
Germany) using the method previously described by Hata et al. (Hata et al., 1998). Briefly, 
the left CCA, ECA and ICA and branches were exposed through a midline cervical incision. 
A 6 -0 silk suture was loosely tied around the CCA proximal to the bifurcation of the ECA 
and ICA and a second suture tied around the ECA distal to the superior thyroid artery (STA). 
Both the STA and occipital artery (OA) were electrocoagulated and a microclip placed 
across the CCA. The silicone- coated monofilament (diameter 220 gm) was introduced into 
the CCA via a small incision, advanced 10 mm distal to the carotid bifurcation to occlude the 
origin of the MCA and secured (Figure 9 & Figure 10). Wounds were sutured and the animal 
allowed to recover in incubator. The monofilament was completely withdrawn under 
anaesthesia after 60 min to allow reperfusion. Animals were sacrificed 24 hrs post -occlusion 
by transcardiac perfusion. Brains were processed for histology and scored as described for 
the rat using mouse stereotaxic templates. 
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External carotid artery 
Internal carotid artery 
Superior thyroid artery 
Occipital artery 
MONOFILAMENT 
Common carotid artery 
Figure 9. Surgical exposure of the arteries in the neck of the mouse and insertion of the 
monofilament. White lines indicated vessels closed by tied suture or diathermy. 
Middle cerebral artery 
MONOFILAMENT 
Internal carotid artery 
Figure 10. Placement of the monofilament in the vasculature of both the rat and mouse brain such that 




FK506 (Fujisawa Pharmaceutical Co. Ltd, Osaka, Japan; intravenous formulation Lot: 
702144K) was dissolved in 0.9 % w/v saline (Aquapharm, Animalcare Ltd.) and 
administered at 1 mg.kg' in a 2 ml.kg' volume. FK506 vehicle (polyoxyethylene 
hydrogenated castor oil 60 (Hisatomi et al., 1993), Fujisawa Pharmaceutical Co. Ltd, Osaka, 
Japan; Lot: 713139K) was also dissolved in saline and administered at 1 ml.kg' in a 2ml.kg"' 
volume. Permanent and transient monofilament MCA occlusions in the rat were performed 
as described previously. Prior to the surgery to occlude the MCA, a polythene catheter was 
inserted into an exposed femoral vein. Drug and vehicle were infused intravenously (i. u ) 
5 min post -occlusion. Following administration, the catheter was removed, femoral wound 
sutured and the animal allowed to recover as previously described. 
In the mouse neuroprotection studies, FK506 (1 mg.kg"') and vehicle were administered 
intraperitoneally (i.p.) 30 min prior to occlusion. The data showing FK506 neuroprotection 
in the Et -1 model, included for comparison with the monofilament models, was obtained 
from experiments performed by Dr Paul Jones. 
DOXYCYCLINE 
Doxycycline (Sigma) was dissolved in 0.9 % w/v saline (Aquapharm, Animalcare Ltd.) and 
administered at 10 mg.kg' in a 2 ml.kg' volume. Saline (Aquapharm, Animalcare Ltd.) was 
administered as the control. Drug and saline were infused i.p. 2 hrs pre -occlusion. Permanent 
and transient monofilament MCA occlusions in the rat were performed as described 
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previously. A subsequent series of experiments were performed following the Clark et al. 
protocol (1997) (Clark et al., 1997). Animals received either doxycycline (10 mg.kg') i.p. or 
saline 30 min prior to occlusion followed by 10 mg.kg"' every 8 hrs until sacrificed 48 hrs 
post -occlusion. 
ADMINISTRATION OF LIPOPOLYSACCHARIDE 
Lipopolysaccharide (LPS; E. Coli 0111:B4; Sigma, Lot 78H4122) was dissolved in 0.9 % 
saline (Aquapharm, Animalcare Ltd.) and administered i.p at 2 mg.kg'. Animals were 
sacrificed by decapitation at 3 hrs post -administration, brains removed and cortex and 
striatum dissected out from both hemispheres. Samples were snap frozen and stored at -70 °C 
until required. 
HISTOLOGY 
Unless otherwise stated, animals were sacrificed 72 hrs post -surgery by transcardiac 
perfusion. The animals were deeply anaesthetised by i.p. injection of sodium pentobarbitone 
(60 mg.kg', Rhône Mèrieux). The thoracic cavity of the animal was opened and a needle 
connected to a peristaltic pump (Watson Marlow 502S) inserted through the apex of the left 
ventricle into the ascending aorta. A small incision was made in the right atrium. Animals 
were perfused initially with 20 ml heparinised (10 IU.mî-1) phosphate buffered saline (PBS, 
Appendix 1) followed by 200 ml of 4 % paraformaldehyde (PFA) in PBS at a rate of 20 
ml.min' that would not cause any artifactual histological damage. Following perfusion, 
brains were removed, placed in 20 % sucrose in PFA/PBS solution and stored at 4 °C for at 
least 24 hours. Brains were removed from sucrose/PFA/PBS solution, frozen at -42 °C in 
isopentane and mounted in plastic embedding matrix (M1 embedding Matrix, Lipshaw) on 
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an orientating chuck. 20 gm cryostat sections (Bright OT /OFT Cryostat, Bright Instrument 
Company Ltd.) were taken at -20 °C and placed on gelatin coated slides (5 %) and air dried at 
20 -30 °C. Slides were stored at 37 °C until stained. 
Sections were placed in Histoclear (National Diagnostics) initially to remove lipid and 
rehydrated through an alcohol series before being placed in thionin (0.03 %, Sigma) for 
20 min. Sections were differentiated in 0.2 % acetic acid, dehydrated through the alcohol 
series and mounted in xylene with DPX (distrene, plasticiser and xylene, BDH Chemicals 
Ltd, UK) (Drury & Wallington, 1967). 
CALCULATION OF DAMAGE 
Sections were examined under a light microscope (Leica, Galen) and the ischaemic damage 
annotated onto templates representing 9 pre -determined stereotaxic levels (Appendix 8). 
Templates were simplified from The Rat Brain in Stereotaxic Co- ordinates (Paxinos & 
Watson, 1986). The damage was quantified using a microcomputer imaging device (MCI]) 
M5+ Image Analyser, Imaging Research Inc.) and volume calculated according to the 
trapezoid model (Rosen & Harry, 1990). This method of damage calculation was validated 
before beginning experiments (Appendix 5). 
TRAPEZOID RULE 
V = E (x;+i - xi) [(yi + yi+i )/2] 
Where V is volume, x; is the distance orthogonal to the plane of the i -th section and y; is the 
cross sectional area of the i -th section (Rosen & Harry, 1990). 
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CALCULATION OF OEDEMA 
The volume of oedema was also calculated from the original brain sections by computerised 
digital morphometry using the MOD computer. The ipsilateral and contralateral 
hemispheres at the 9 levels corresponding to those scored for damage were traced and the 
area of each determined (Overgaard & Meden, 2000). The volume of oedema was also 
calculated using the trapezoid rule. Differences in the volume of oedema (A) between the 
hemispheres expressed as a percentage. 
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CHAPTER 3 
Comparison of stroke models 
INTRODUCTION 
The manipulation of lesion volume together with analysis of the differences that exist 
between and within models and species has provided an insight into and allowed 
investigation of the pathology of cerebral ischaemia. The evaluation of the volume of 
damage that occurs in a particular animal model is one of the most amenable endpoints of 
ischaemia experiments and as such is used routinely by many stroke research groups (Hunter 
et al., 1995; Overgaard & Meden, 2000; Isayama et al., 1991). To date, in studies assessing 
neuroprotective compounds, the only endpoint that has been routinely accepted is 
histological outcome although ideally neuroprotection should be manifest in improved 
functional outcome (Recommendations for standards regarding preclinical neuroprotective 
and restorative drug development 1999). The pathophysiological mechanisms involved in 
ischaemic tissue damage can be elucidated from animal models using pharmacological 
intervention or molecular biology approaches by observing the effect on the gross 
histological damage. Therefore, in studies that focus on the investigation of ischaemia and 
neuroprotection, the establishment of a consistently reproducible animal model of ischaemia 
coupled with a valid method of volumetric analysis is crucial. It is however also important to 
consider that in addition to histologically assessed neuroprotection, the functional outcome 
following an ischaemic insult can be a valuable indicator of cell survival and should not be 
overlooked (Hunter et al., 1995; Feuerstein & Wang, 2000). 
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In accordance with the aim to investigate the inflammatory mechanisms associated with 
focal cerebral ischaemia, the intraluminal monofilament model, considered by some to be 
pro -inflammatory (Henshall et al., 1999), was chosen as the primary animal model for 
investigation. This model, not previously established in Edinburgh, is widely used 
(Schmid -Elsaesser et al., 1998), now highly reproducible (Belayev et al., 1996b) and has a 
number of advantages over other models (Chapter 1). It is thought that the surgical 
procedure whereby the monofilament is advanced into and retracted (where necessary) from 
the cerebral vessels causes damage to the endothelium (McAuley, 1995). This fact is 
exploited by the use of Evans Blue to verify the correct placement of the monofilament 
(Chapter 2). As the endothelium is known to be involved in inflammatory processes 
demonstrated by cell adhesion molecule up- regulation, cytokine expression and platelet and 
leukocyte activation (del Zoppo, 1999), it is possible that any damage caused by the 
monofilament may contribute to the ischaemic damage observed and be responsible for some 
component of the ischaemic pathology. The hypothesis that inflammation is an important 
contributor to ischaemia but that there may be inflammatory differences between the 
different animal models of ischaemia and humans is supported by the differences in 
neuroprotective efficacy of anti -inflammatory strategies observed in different animal models 
(Chopp et al., 1994; Garcia et al., 1993; Zhang et al., 1995). This hypothesis may also be 
supported by the failure of clinical trials of anti -inflammatory directed approaches such as 
the anti- ICAM -1 antibody of the Enlimomab Acute Stroke Trial (Lutsep & Clark, 1999). 
Re- establishment of blood flow to ischaemic tissue may be a key component of the 
inflammatory response to cerebral ischaemia. Reperfusion may exacerbate the damage if the 
endothelium of the occluded vessels have been damaged, both as a consequence of the 
biochemical events of the induced ischaemia (Stanimirovic & Satoh, 2000) and possibly by 
the surgical manipulation. Del Zoppo et al. (2000) proposed that the cerebral 
microvasculature is not only the site of initiation of an inflammatory response during 
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ischaemia but suggested that there are events that occur there are not recovered on the return 
of blood to the ischaemic tissue (del Zoppo et al., 2000). An inflammatory response could 
therefore make a definite contribution to the ischaemic damage and be distinct from that 
attributable to reperfusion. This suggestion does however not address the direct damage 
cause by the surgical manipulation. This provided the rationale for examining the differences 
between permanent and transient occlusions in the same model and the additional 
comparison with the Et -1 model, which does not directly damage the endothelium and may 
be less inflammatory. These studies could address the question of the validity of using a 
particular model if the surgical procedure employed introduces an aspect of pathology that 
may be an epiphenomenon associated with the model used. Such studies could also support 
the case for evaluation of ischaemia and neuroprotectants efficacy in multiple stroke models 
(Takamatsu et al., 1998). Additionally, the dissection of the spatial and temporal 
relationships of the inflammatory response can provide perhaps novel approaches for 
therapeutic intervention and salvage of brain tissue. 
The initial experiments conducted were aimed at establishing a reliable protocol for the 
intraluminal monofilament model. These studies were also used to develop and validate new 
stereotaxic templates and the computerised digital morphometry for lesion volume analysis 
compared with the `cut and weigh' method used previously. Once the permanent 
monofilament model was established, the model was compared with the transient model and 
also the Endothelin -1 model established by Sharkey et al. (1993) and routinely used for 
stroke studies within the laboratory (Sharkey et al., 1993). The neuroprotective efficacy of 
FK506 was assessed in both models. FK506 was chosen both because its neuroprotective 
efficacy was demonstrated originally in the Endothelin -1 model within this laboratory but 
additionally as an immunosuppressant compound it may potentially affect components of an 
inflammatory response. If differences in the models were due to differences in the 
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inflammatory response to the insult could be reflected in the extent of neuroprotection 
achieved. 
In addition to the investigation of the volume of tissue damage it was decided to investigate 
the volume of oedema in all three models. The swelling of the brain complicates the 
disorders of the CNS and is therefore of clinical importance, is associated with inflammation 
and could be a potential therapeutic target (Chapter 1). The measurement of the extent to 
which the volume of the brain increases following an insult reflects the severity and the 
extent of damage (Plum, 1983). It is however unclear if oedema formation following an 
ischaemic insult is a cause of tissue damage that leads to infarction or the consequence of 
tissue dysfunction precipitated by the reduction in blood flow i.e. cause or consequence of an 
ischaemic insult. 
MATERIALS & METHODS 
The materials and methods for the data presented in this chapter are described 
comprehensively in Chapter 2. Volume of damage and oedema are expressed as the mean ± 
standard error of the mean (sem) in mm3 and as difference (A) between ipsilateral and 
contralateral hemispheres as a percentage, respectively. Statistical analysis was performed 
using SigmaStat. For each experiment analysis of variance (ANOVA) with post hoc 
Student- Newman -Keuls test was performed. 
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RESULTS 
VOLUME OF DAMAGE 
Ischaemic brain damage was readily discernible in the thionin stained sections 72 hrs 
post -occlusion by light microscopy (Figure 11). In all models, the lesion affected lateral parts 
of the frontal cortex extending through the parietal and into insular cortex rostrally and 
through temporal and into occipital cortex caudally. There was evidence of infarction within 
the dorsolateral caudate nucleus (striatum) (Figure 12). This pattern of damage is typical of 
an MCA occlusion and encompasses the entire vascular territory of the vessel. This is 
reflected in the volume of damage seen in the three models. In the PMF model, the overall 
volume of damage was 239 ± 20 mm3. The overall volume of damage in the TMF was 249 ± 
10 mm3 and that in the Et -1 model was 213 ± 26 mm3. Statistical analysis of the data from 
the three models revealed that there was not a significant difference in the volume of damage 
between the three. There was no evidence of damage in PMF and TMF monofilament sham 
occlusion groups. A small amount of damage (16 ± 6 mm3) in the Et -1 sham group was 
associated with the needle tract of the stereotaxic injection and was significantly different 
from the Et -1 induced occlusion (p < 0.05) (Figure 13). 
EVOLUTION OF INFARCT WITH INCREASING OCCLUSION TIMES 
The concept of the ischaemic penumbra and the 30 min insult data presented by Du et al. 
(Du et al., 1996) suggested that an ischaemic lesion should develop with time. Reperfusion 
injury would also suggest that transient models should have larger lesions. Investigation of 
the volume of damage produced by different periods of MCA occlusion by intraluminal 
monofilament revealed that 30 and 90 min of transient ischaemia caused no 
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a 
Figure 11. Thionin stained cryostat section (20 µm) showing the non -ischaemic contralateral 
hemisphere (a) and ischaemic damage in ischaemic ipsilateral hemisphere (b) following permanent 
monofilament occlusion of the middle cerebral artery. 
Figure 12. Schematic representation of the classical distribution of infarction of the cortex (red) and 






E 200 - 
an 











Figure 13. Comparison of the overall volume of damage in permanent monofilament (n = 9), 
transient monofilament (n = 8) and Endothelin -1 induced (n = 14) middle cerebral artery occlusions 
and associated shams (n = 4, 5 and 7 respectively). The volume of damage in the sham occlusions of 
all three models is significantly different from the corresponding occlusions. The small volume of 
damage in the Endothelin-1 sham is associated with the needle tract of the stereotaxic injection. Data 
represent mean ± sem. (* p < 0.05, ANOVA with post hoc Student- Newman -Keuls test). 
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significant damage to the brain parenchyma (p < 0.05 %) (Figure 14). However, 
120 min of transient occlusion produced a large lesion whose overall volume is 
indistinguishable from that of a permanent occlusion (Figure 13). Damage was initially 
observed in the striatum as early as 30 min post -occlusion. Cortical damage was observed at 
60 min although it was not significantly different from the sham group. A large lesion was 
caused by a 2 hr transient occlusion that affected both cortex and striatum. 
30 MIN TRANSIENT OCCLUSION -3 & 14 DAY HISTOLOGICAL ASSESSMENT 
Animals subjected to a 30 min transient MCA occlusion had a mean lesion volume that was 
not significantly different to the sham group (8.7 ± 6 mm3). The animals that were sacrificed 
14 days post -occlusion had a lesion (2.5 ± 2.8 mm3) that was not different from the sham 
group of the 3 day group (data not shown graphically). 
VOLUME OF OEDEMA 
Temporary occlusions are often associated with larger lesions and a greater degree of oedema 
(McAuley, 1995). The data from these experiments show that there was not a statistically 
significant difference in the volume of oedema in all three models (Figure 15). The volume 
of oedema in the Et -1 model tended to be smaller but not significantly different. There was a 
significant difference (p < 0.05) between MCA occlusion and sham -operated animals. 
Again, the small volume of oedema in the Et -1 sham operated group is associated with 
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Figure 14. Comparison of the volume of damage in the cortex and striatum in the transient 
monofilament model associated with increasing occlusion times (n = 5, 9, 12, 12 and 8 respectively). 
Only a transient occlusion of 120 min produces damage in the cortex and the striatum that is 
significantly different from the sham group. Data represent mean ± sem. (* p < 0.05, ANOVA with 
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Figure 15. Comparison of the volume of oedema in permanent monofilament (n = 9), transient 
monofilament (n = 8) and Endothelin -1 induced (n = 14) middle cerebral artery occlusions and 
associated shams (n = 4, 5 and 7 respectively). Oedema is expressed as the percentage difference in 
the volume of the ipsilateral hemisphere compared the contralateral hemisphere (A). The small 
volume of oedema in the Endothelin -1 sham is again associated with the needle tract damage. Data 
represent mean ± sem. ( *, #, O p < 0.05, ANOVA with post hoc Student- Newman -Keuls test). 
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DISCUSSION 
In addressing the role of reperfusion injury in cerebral ischaemia, three models of MCA 
occlusion were compared. The data shows that the size and distribution in all three models is 
the same in each and that when occlusion time is controlled there is essentially an all or none 
response in terms of histological damage. The standardised 72 hr post -occlusion time point 
for evaluation of ischaemic damage was chosen as the lesion is fully developed at this point 
in both the monofilament and Endothelin -1, models thereby allowing valid histological 
assessment (Overgaard & Meden, 2000; Sharkey & Butcher, 1994). Some authors have 
claimed that the lesion is maximal at 6 -12 hrs (Du et al., 1996) and others by 24 hrs (Brint et 
al., 1988; Kuge et al., 1995; Buchan et al., 1992). Thionin (a Nissl stain routinely used for 
staining in the laboratory) provided well- demarcated lesions that could be scored using the 
light microscope. The volume and distribution of the brain damage in both the permanent 
and transient monofilament model was similar to other research groups using the same 
model (Kuge et al., 1995; Oliff et al., 1995), to that following Endothelin- linduced MCA 
occlusion (Sharkey et al., 1993; Sharkey et al., 1994) and to that previously reported 
following surgical occlusion (Tamura et al., 198la). Initial studies established the 
intraluminal monofilament model as a reproducible and valid model for investigating the 
pathophysiology of focal cerebral ischaemia. The length of suture chosen (18 -19 mm) and 
method of preparation (poly -L- lysine coated with monofilament tip rounded in a flame) 
produced the classical pattern of damage seen following surgical occlusion of the MCA and 
to that seen in the Endothelin -1 model (Tamura et al., 1981a; Sharkey & Butcher, 1994). A 
small study was performed comparing poly -L- lysine coated and uncoated Ethilon sutures 
and proved there was no difference in terms of lesion volume but the lesions in experiments 
with uncoated sutures were more variable (data not shown). Poly -L- lysine is polycationic 
polymerised amino acid that adsorbs to surface thereby increasing adhesive forces between 
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the monofilament and the vascular endothelium (Belayev et al., 1999). These observations 
were comparable to those of Belayev et al. (1996) who performed a similar set of 
experiments. Coated monofilaments produced more consistently reproducible lesions 
although the lesions volumes were slightly greater (Belayev et al., 1996b). The mean lesion 
volume in the monofilament model was similar in comparison to data from experiments 
using different models (Takamatsu et al., 1998; Kuge et al., 1995; Herz et al., 1998). A 
further refinement of the transient monofilament model was the use of Evans Blue to 
confirm the correct placement of the monofilament in the vasculature. 
The surgical protocol used to occlude the MCA was performed such that when recirculation 
was instigated in the transient model, blood flow through the ipsilateral CCA was 
re- established. Some protocols for performing the monofilament surgery, including the 
original described by Koizumi et al. (1986), rely on collateral blow flow from the Circle of 
Willis for reperfusion as the CCA is permanently ligated (Koizumi et al., 1986). In these 
models, it is questionable whether pre -ischaemic blood flow levels are achieved in the 
ipsilateral hemisphere by collateral blood flow although data from the mouse monofilament 
used in house suggests that there is adequate reperfusion (Dr A. McGregor personal 
communication). In the current experiments, return of blood flow through the ipsilateral 
CCA was confirmed visibly in each experimental animal. Although successful occlusion of 
the MCA was ultimately confirmed by histological analysis, neurological deficits (rotation, 
limb weakness etc) following surgery were also noted for each animal. In the permanent 
model, the correct placement of the monofilament in the Circle of Willis such that it 
occluded the origin of the MCA was confirmed when the brain was removed from the skull. 
In the transient model, Evans Blue injected into the animal prior to perfusion fixation 
established correct placement of the monofilament in the cerebral vasculature. The damaged 
endothelium corresponding to the position of the suture retained a blue stain after fixation 
and was clearly visible when the brain was removed. The data obtained from these 
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experiments was also used for power analysis to estimate the group size of 5, 4 and 14 for 
the PMF, TMF and Et -1 models respectively that would be required to detect an 50 % 
reduction in ischaemic volume with 80 % power. 
The comparison of the three different animal models revealed no difference in either the 
volume of damage or oedema. This observation is in agreement with an investigation by 
Zhang et al. (1994). The temporal profile of ischaemic tissue damage in both the permanent 
and transient (2 hr) monofilament model was examined in the Zhang et al. (1994) studies 
and revealed that the lesion in the transient occlusion group was initially smaller than that of 
the permanent group but by 48 hrs the size and features of the final lesion were 
indistinguishable. The temporal profile of the cellular response in the two models was not 
identical and it appeared that there was slower evolution of damage in the cortex of the 
transient model during early reperfusion (Zhang et al., 1994). This observation could support 
the view that reperfusion does have a beneficial role but it is balanced by factors such as 
duration and severity of ischaemia (Duverger & MacKenzie, 1988). 
The study showing spatial development of tissue damage caused by increased occlusion time 
confirmed observations reported by others (Memezawa et al., 1992). Short periods of 
ischaemia (30 min) in the monofilament model followed by reperfusion have previously 
been shown by others to produce infarcted areas in the core of the lesion (striatum) and 60 
min occlusions to produce cortical damage (Du et al., 1996). These data are consistent with 
current observations in this thesis in terms of size and distribution of the lesion and suggest 
that early reperfusion prevents rather than promotes extension of the infarct. The small 
volume of damage seen in the cortex of the 60 min occlusion animals in the experiments in 
this thesis is not significantly different from the sham data and highlights biological variation 
of experimental subjects. In the Memezawa study, it was also demonstrated that reperfusion 
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after 90 min occlusion was beneficial however after 2 hrs return of blood to the ischaemic 




Figure 16. Theoretical maturation of an ischaemic lesion (black line) and experimental data (red 
line). 
Reperfusion injury occurs in other organs such as the heart (Park & Lucchesi, 1999; Grech et 
al., 1995; Lucchesi, 1990) and other peripheral organs such as the liver (Tredger, 1998; 
Blennerhassett et al., 1998). The data presented in this thesis suggest it does not occur within 
the brain following ischaemia and thus does not increase lesion size. It is possible that the 
lesion caused by 2 hrs of vessel occlusion is maximal and therefore no more damage can 
occur in the compromised territory. As with all comparisons with the data produced by other 
research groups, care should be exercised. Experimental protocols and details such as blood 
pressure and anaesthetic used can influence the volume of lesions produced by an insult and 
may account for differences observed. For example, in the Memezawa et al. study (1992), 
Wistar rats and a different monofilament occluder used (Memezawa et al., 1992). Careful 
control of surgery and animal physiology during anaesthesia should result in a lesion that is 
confined to the vascular territory of the MCA. Whilst reperfusion has been shown to have 
benefits in reducing lesion size (Young et al., 1997), others have reported an increase in the 
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volume of damage following reperfusion (Aronowski et al., 1997; Dietrich, 1994; Takamatsu 
et al., 2000). The efficacy of reperfusion depends on the rapidity of the restoration of blood 
flow because the survival of ischaemic tissue decreases exponentially with time but is also a 
function of the degree and duration of cerebral blood flow reduction (Jiang et al., 1998). The 
most obvious approach to investigation of the role reperfusion injury following cerebral 
ischaemia would be to produce a sub maximal lesion and assess lesion volume following 
different periods of reperfusion. As the data shows (Figure 14) this is not possible, as the 
lesion formation appears to be all or nothing event. 
The experiments that examined the differences in the lesion volume at 3 and 14 days 
post -occlusion contrasted data from a previously published study. Du et al. (1996) showed 
the development of a small lesion assessed 3 days after a 30 min MCA occlusion with 
bilateral CCA occlusion. However, when assessed 14 days post insult the lesion had 
developed and was indistinguishable from a lesion caused by 90 min occlusion of the vessel. 
Since the development of the lesion was delayed by 14 days it was suggested to be the result 
of apoptosis and this model could be used to study cell death in a purely apoptotic 
environment (Du et al., 1996). This observation could not replicated in either the 
Endothelin -1 or Endothelin -3 (Henshall, 1997) or in the mouse model (Dr A. McGregor 
unpublished data). It is possible that the combination of MCA occlusion with bilateral CCA 
is a more severe insult than MCA occlusion only. Although not causing necrosis the 
disruption in blood flow caused by this method does stimulate the apoptotic machinery in the 
cell. 
The examination of oedema in the three different models in this thesis was done by 
computerised digital morphometry to compare the volume of ipsilateral to contralateral 
hemispheres in similar manner to that described recently by Overgaard et al. (2000). The 
method of assessing the oedema associated with the ischaemic damage has a number of 
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caveats such as different fixation methods on the volume (Overgaard & Meden, 2000; Brint 
et al., 1988) but does however provide an indication of the consequences of an ischaemic 
insult. The principle conclusion drawn from the data confirms that oedema occurs following 
an ischaemic insult and that the extent of oedema is related to the volume of damage i.e. the 
greater the damage the greater the oedema (Grome et al., 1988). Analysis of the difference in 
volume of the between the hemispheres should be treated with some caution because as with 
all increases in volume within an enclosed space, in this instance the skull, there may be 
some distortion of the contralateral hemisphere which is used as a control. Cao et al. (1994) 
used a method of calculation of oedema similar to the one used in this thesis. Lesion volume 
was established by TTC staining and expressed as a percentage of the ipsilateral hemisphere 
to eliminate the contribution of oedema. The volume of both the contralateral and ipsilateral 
was calculated using computerised image analysis of the sections and the difference, deemed 
to represent oedema, was expressed as a percentage (Cao & Phillis, 1994). Other methods 
used to calculate oedema volume include the dehydration method where the pre- and 
post- dehydration weights of the brain hemispheres and gravimetry, where the specific gravity 
of the hemispheres is calculated and related to water content (Menzies et al., 1993; Schwab 
et al., 1997). Differences in oedema in the monofilament model was examined by Koizumi 
et al. (1989) who demonstrated that oedema was noticeable earlier in the model with a 
reperfusion element (Koizumi et al., 1986). The differences seen in the volume of oedema in 
the monofilament models and the Endothelin -1 model, although not significant, may be a 
consequence of the method of occlusion. It may be speculated that application of 
Endothelin -1 peptide to a cerebral vessel may have pharmacological effects on water 
transport mechanisms (Hughes et al., 1992; Phillips & Yeates, 2000) although the area of 
such an effect is probably negligible in relation to the infarct volume. Alternatively, the 
profound vasoconstriction produced by the Endothelin -1 may limit water transport. 
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The appraisal of the method of volumetric analysis previously used in the laboratory and the 
new computerised method based on quantitative morphometry proved that the new method 
was valid (Appendix 5). There was no significant difference in the volume of damage 
calculated between the previously used `cut & weigh' method and the computerised method. 
The computer -based method was however more efficient and data could easily stored and 
accessed. The use of the templates negated the need to correct the infarct volume to account 
for oedema required if morphometric volume analysis was performed using the histological 
sections. The trapezoidal rule was chosen to calculate the volume as it accounted for the 
unequal distances between the template levels chosen (Rosen & Harry, 1990). There are a 
variety of methods that are used to estimate and express the extent of an ischaemic lesion but 
this can make comparison with other studies difficult. These include measurement of 
cross -sectional area (Longa et al., 1989), measurement as a percentage of hemisphere (Longa 
et al., 1989; Zhang et al., 1997; Overgaard et al., 1992) and quantification in absolute terms 
(mm3) (Grome et al., 1988) but numerical values are more meaningful for the purposes of 
comparison with other studies. 
CONCLUSIONS 
This chapter has demonstrated the establishment and validation of three stroke models. The 
monofilament model, both permanent and transient, were established for the first time in 
Edinburgh and proved to be a reproducible and readily performable model. Studies showed 
that there was no difference in volume of damage or oedema in the 3 models at the time 
point chosen. In addition, the computer based morphometric analysis for the volume of 
damage was established and validated for use both in future studies in this thesis and for use 





In the Chapter 3, it was demonstrated that there was no significant difference in the volume 
of tissue damage or oedema in the three rat models of MCA occlusion examined. This 
observation however does not necessarily imply that in each model the same pathological 
sequence of events occur either spatially or temporally (Zhang et al., 1995). Some research 
groups have investigated the differences in models or the lack thereof by investigating 
cellular response such as the expression of particular proteins such as cell adhesion 
molecules (Zhang et al., 1994). Another approach to investigating differences between 
models is the administration of pharmacological compounds known to be efficacious in 
reducing lesion volume. These studies may reveal differences between the models, perhaps 
elucidate the differences in the damage mechanisms and allow dissection of signal 
transduction pathways (Chapter 1). It is assumed that if the mechanisms that underlie the 
observed damage in the different models are similar then putative neuroprotectants should 
have similar neuroprotective efficacy when administered following ischaemia. 
Modern immunosuppressant drugs, such as FK506 and cyclosporin -A (CsA,) are valuable 
tools for elucidating intracellular signalling systems. These compounds act at low nanomolar 
concentrations and display great selectivity for the immunophilins that potentially regulate 
the entry of gene transcription factors and participate in the ischaemic cascade to the nucleus 
(Snyder et al., 1998a; Liu, 1993). FK506 is a neuroprotective compound used routinely 
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within the laboratory and has previously shown significant neuroprotection (Butcher et al., 
1997; Sharkey & Butcher, 1994). To this end, it is used as the routinely used as a reference 
compound for potential neuroprotectants under assessment. Having established the 
permanent and transient monofilament model of focal cerebral ischaemia within the 
laboratory it was of interest to investigate the neuroprotective efficacy of the compound in 
both models and compare it with the neuroprotection in the Endothelin -1 model and a mouse 
model of MCA occlusion. 
FK506 (TACROLIMUS) 
DISCOVERY OF FK506 
Researchers at Fujisawa Pharmaceutical Co. Ltd, Tsukuba, Japan identified FK506 in 1984 
through their screening program aimed at discovering compounds of microbial origin with 
immunosuppressant properties. The in vitro assay used to screen compounds measured T cell 
and lymphocyte proliferation in mixed lymphocyte reactions. Almost 10 000 fermentation 
broth samples were screened before a culture filtrate from strain # 9993 (an actinomycete) 
was shown to inhibit lymphocyte proliferation. Because only low levels of the active 
components are produced by actinomycete strains it took over a year to isolate, purify and 
crystallise the main active component from the fermentation broth that was named 
FR900506, subsequently FK506 and then Tacrolimus (Prograf3). Mycological studies 
identified strain # 9993 and named it Streptomyces Tsukubaenisis as it was isolated from a 
soil sample collected from Mount Tsukuba near the company's laboratories (Nishiyama et 
al., 1995). 
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FK506 is a macrolide with a molecular weight of 803 and the molecular formula C4.4H69N012 
(Figure 17). The compound is soluble in methanol, ethanol, ethyl acetate and chloroform and 
is insoluble in water and hexane. As an immunosuppressant, FK506 is 
30 -100 times more potent than CsA at inhibiting T cell proliferation. CsA is another 
well -known immunosuppressant discovered in 1976 from a fungus (Tolypocladium latum) 
(Borel et al., 1976) and marketed by Novartis as Sandimmun®. The structure of CsA differs 
considerably from that of FK506 but it has a similar neuroprotective profile in a variety of 
ischaemia models although because of its poor BBB penetration is only effective at relatively 
high doses (Sharkey et al., 2000; Nakai et al., 1997). 
Figure 17. Chemical structure of FK506 (C44H69N012). 
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Sharkey & Butcher (1994) first demonstrated FK506 neuroprotection following cerebral 
ischaemic in the Endothelin -1 and Tamura rat models of MCA occlusion (Sharkey & 
Butcher, 1994). FK506 is one of the few agents that protects in almost every experimental 
model of stroke, including transient and permanent models of focal ischaemia, in both 
forebrain and global ischaemia and also in a number of different species (Table 4) (Sharkey et 
al., 2000). The compound is effective as a single dose given before the onset of ischaemia 
(e.g. 3 day pre -treatment or 30 min prior to occlusion) and has been shown to have an 
effective neuroprotective time window of up to 3 hrs in the rat. This time window may be 
greater in higher gyrencephalic species such as the cat, non -human primates and man 
(Sharkey et al., 1994; Sharkey et al., 2000; Kuroda et al., 1999; Takamatsu, 1999). 
Neuroprotection afforded by FK506 is comparable, if not slightly greater than other 
neuroprotectant compounds such as MK -801 that are routinely used in studies of cerebral 
ischaemia (Butcher et al., 1997; Stieg et al., 1999; Ma et al., 1998; McCulloch et al., 1993). 
The long duration of FK506 neuroprotection has been attributed to rapid drug accumulation 
and preferential sequestration in the CNS demonstrated by significant neuroprotection 
following 3 day pre -treatment (Butcher et al., 1997). FK506 also improves skilled motor 
deficits following MCA occlusion (Sharkey et al., 1996) and ameliorates the cognitive 
deficits associated with anterior cerebral artery occlusion (Marston et al., 2000). 
FK506 is not only cytoprotective in the brain but it has also been reported to reduce 
ischaemia/reperfusion damage in the heart and other peripheral organs such as the liver, 
kidney and the skin (Table 5). There is also in vitro evidence demonstrating that FK506 is 
protective against excitotoxicity in culture (Tsujikawa et al., 1998; Manev et al., 1993; 
Dawson et al., 1993b). The compound also has neurotrophic effects and could potentially be 
valuable as a therapeutic agent in other neurodegenerative disorders (Avramut, 2000). 
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DOXYCYCLINE 
Doxycycline, a tetracycline antibiotic, was included in the neuroprotection studies firstly 
because it has been demonstrated to afford significant protection following an ischaemic 
insult. It has been shown to be neuroprotective against global brain ischaemia in the gerbil 
when administered 30 min post insult (Yrjanheikki et al., 1998) and against transient focal 
ischaemia when administered prior to the onset of ischaemia (Clark et al., 1997). The 
compound has also proved to have a beneficial effect in ischaemia/reperfusion in peripheral 
organs such as the liver (Smith & Gabler, 1994) and the small intestine (Smith & Gabler, 
1995). The second reason for examining the neuroprotective efficacy of doxycycline is that it 
and other associated tetracycline derivatives have been shown to prevent microglial 
activation following ischaemia. As the microglia are potentially key players in the 
inflammatory response following an ischaemic insult, the modulation of their activation 
could be a potential therapeutic target (discussed in detail in Chapter 5). 
Experimental and clinical studies indicate that doxycycline maybe beneficial in the treatment 
of conditions such as rheumatoid arthritis and other inflammatory diseases ( Yrjanheikki et 
al., 1998). The compound causes the suppression of oxygen radical release from 
polymorphonuclear neutrophils (Amin et al., 1996) and inhibition of inducible nitric oxide 
synthase (Amin et al., 1997), both which have been linked to the inflammatory response. In a 
study of ischaemia /reperfusion in the liver, treatment with 10 mg.kg' doxycycline had a 
significant effect on inflammatory response inhibiting polymorphonuclear leukocyte 
migration, degranulation, super -oxide synthesis and cytotoxicity (Smith & Gabler, 1994). It 
is therefore proposed that because of its anti -inflammatory properties doxycycline may be an 
effective therapeutic agent, in a similar manner to FK506, by affecting multiple components 
of the ischaemic cascade. 
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MATERIALS & METHODS 
Materials and methods for the neuroprotection studies are described in Chapter 2. Again, as 
in Chapter 3, the volume of damage and oedema are expressed as the mean ± sem in mm3 
and as difference (A) between ipsilateral and contralateral hemispheres as a percentage, 
respectively. Statistical analysis was performed using SigmaStat. For each experiment 2 -way 
ANOVA with post hoc Student- Newman -Keuls test was performed. 
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Table 4. FK506 neuroprotection in different species & models of cerebral ischaemia (Sharkey et al., 
2000; McGregor et al., 2000). 
SPECIES ISCHAEMIA MODEL REFERENCE 
Rat 
Focal 
Surgical MCA occlusion (Tamura) 




Photothrombic MCA occlusion 
Sharkey & Butcher, 1994 
Butcher et al. 1997 
Sharkey & Butcher, 1994 
Sharkey et al., 1996 
Aoyama et al., 1997 
Bochelen et al., 1999 
Kamiya et al., 1997 
McCarter et al., 2000 
Nakai et al., 1997 
Toung et al., 1997 
Bochelen et al., 1999* 
Bochelen et al., 1999* 
Takamatsu et al., 1999 
Forebrain 
Bilateral CCA occlusion with hypotension 
Chronic bilateral CCA occlusion 
Drake et al., 1996 
Wakita et al., 1998 
Mouse Focal Transient monofilament 
Transient MCA/CCA occlusion 
McCarter et al., 2000 
Aronowski et al. 2000* 
Gerbil 
Global 
Bilateral CCA occlusion Ide et al., 1996 
Katayama et al., 1997 
Tokime et al., 1996 
Yagita et al., 1996 
Hemispheric Unilateral CCA occlusion Takana et al., 1997 
Monkey Focal Transient surgical MCA occlusion Takamatsu et al., 1999 
* No observed protection MCA = middle cerebral artery = common carotid artery 
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Table S. FK506 protection in other organs (Sharkey et al., 2000). 
ORGAN REFERENCE 
Liver 
Dhar et al., 1996,1993,1992 
Garcia-Criado et al., 1997 
Jin et al., 1996 
Kawano et al., 1996,1995,1994, 1991 
Kim et al., 1994 
Okano et al., 1994 
Sakr et al., 1993,1991 
Sawada et al., 1992 
Suzuki et al., 1993 
Wakabashi et al., 1994, 1992 
Heart 
Morishita et al., 1996 
Nishinaka et al., 1993 
Kidney 
Sakr et al., 1992 
Cacciarelli et al., 1994 
Nalesnik et al., 1990 
Intestine/bowel 
Cicalese et al., 1996 
Kubes et al., 1991 
Sakr et al., 1992 




In both species and in the different rat models of focal cerebral ischaemia examined, the 
occlusion of the MCA in the vehicle treated animals resulted in a large and reproducible 
lesion restricted to the vascular territory of the vessel encompassing dorsal and lateral 
neocortex and lateral aspects of the striatum. In the rats subjected to permanent occlusion of 
the MCA, the mean volume of cortical and striatal infarction was 166 ± 22 mm3 and 
49 ± 1 mm3, respectively. Animals subjected to a transient occlusion of the MCA exhibited 
similar cortical (151 ± 13 mm3) and striatal (46 ± 3 mm3) lesions. The data from the Et -1 
model neuroprotection studies, included for comparison with the monofilament models, 
revealed a mean cortical lesion of 120 ± 15 mm3 and striatal lesion of 35 ± 2 mm3 
The administration of FK506 significantly reduced the volume of cortical damage in the rat 
permanent by 34 % compared with vehicle treated controls (Figure 18) and by 65 % in the 
transient (Figure 19) monofilament models. In the Et -1 model, FK506 reduced the cortical 
damage by 65 % (Figure 20). FK506 significantly reduced striatal damage by 42 % in the 
transient model and by 19 % in the permanent model although the latter reduction did not 
attain statistical significance. In the Et -1 model, FK506 reduced striatal damage by 37 % 
although this too was not significantly different from the vehicle treated controls. The overall 
neuroprotection afforded by FK506 (Figure 21 & Table 6) in the transient model (59 % with 
respect to vehicle treated controls) was almost double that observed in the permanent model 
(34 %) but was similar to that observed in the Et -1 model (63 %) and to data previously 
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Figure 18. Neuroprotective efficacy of FK506 (1 mg.kg 1, i.v. 5 min post -occlusion) in the permanent 
monofilament middle cerebral artery occlusion model (n = 12) compared with vehicle treated 
controls (n = 11). There is a significant reduction in the volume of damage in the cortex (34 %) in 
this model but not the striatum. Data represent mean ± sem. (* p < 0.05, 2 -way ANOVA with post hoc 
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Figure 19. Neuroprotective efficacy of FK506 (1 mg.kg -1, i.v. 5 min post -occlusion) in the transient 
monofilament of middle cerebral artery occlusion (n = 11) compared with vehicle treated controls 
(n = 8). There is a significant reduction in the volume of damage in both the cortex (65 %) and the 
striatum (41 %) in this model. Data represent mean ± sem. (* p < 0.05, 2 -way ANOVA with post hoc 
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Figure 20. Neuroprotective efficacy of FK506 (1 mg.kg 1, i.v. 5 min post -occlusion) in the 
Endothelin -1 induced middle cerebral artery occlusion (n = 8) compared with vehicle treated controls 
(n = 6). There is a significant reduction in the volume of damage in the cortex (65 %) but not the 
striatum. Data represent mean ± sem. (* p < 0.05, 2 -way ANOVA with post hoc 
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Figure 21. Comparison of the neuroprotective efficacy of FK506 (1 mg.kg 1, i.v. 5 min 
post -occlusion) in the permanent monofilament (n = 12), transient monofilament (n = 11) and 
Endothelin -1 induced (n = 8) middle cerebral artery occlusion models and corresponding vehicle 
treated controls (n = 11, 8 and 6 respectively). Data represent mean ± sem. ( *, #, e p < 0.05, 2 -way 
ANOVA with post hoc Student- Newman -Keuls test). 
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The ischaemic damage in the control mouse transient model was similar in distribution to 
that in the transient rat model displaying both a cortical (18 ± 4 mm3) and striatal 
(9 ± 1 mm3) component (Figure 22). FK506 administered 30 minutes prior to MCA occlusion 
significantly reduced cortical damage by 72 % and striatal damage by 29 % although this 
again was not significantly different from vehicle treated controls. FK506 treatment reduced 
overall damage by 61 % (Figure 23) that was similar to the lesion volume reduction seen in 
the transient monofilament and Et -1 models. 
Table 6. Neuroprotective efficacy of FK506 (1 mg.kg'') compared with vehicle treated controls in four 
different models of middle cerebral artery occlusion. 
MODEL 
VOLUME OF DAMAGE (mm) NEUROPROTECTION 
VEHICLE FK506 (1 mg.kg') 
Permanent monofilament 245 ± 10 162 ± 24* 34 
Transient monofilament 216 ± 18 88 ± 32# 59 
Endothelin -1 176 ± 22 66 ± 14° 63 
Mouse transient monofilament 28 ± 6 11 ± 4' 61 
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Figure 22. Neuroprotective efficacy of FK506 (1 mg.kg 1, i.p. 30 min pre -occlusion) in the mouse 
transient middle cerebral artery occlusion (n = 6) compared with vehicle treated controls (n = 5). 
There is a significant reduction in the volume of damage in the cortex (72 %) but not in the striatum. 
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Figure 23. Comparison of the neuroprotective efficacy of FK506 (1 mg.kg 1, i.p. 30 min 
pre -occlusion) in the mouse transient monofilament middle cerebral artery occlusion (n = 6) 
compared with vehicle treated controls (n = 5). The reduction in the lesion volume in the mouse 
following FK506 administration is similar to that observed in the rat permanent monofilament model. 
Data represent mean ± sem.(* p < 0.05, 2 -way ANOVA with post hoc Student- Newman -Keuls test). 
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EFFECT OF FK506 ON OEDEMA IN THE RAT 
Calculation of the volume of oedema following FK506 administration in the three models 
revealed that there was a similar significant percentage reduction (p < 0.05) in the volume in 
the permanent and transient monofilament models (43 and 48 %, respectively) and a greater 
reduction in the Endothelin -1 model (75 %) compared with the corresponding vehicle 
controls (Table 7). The volume of oedema in the permanent occlusion vehicle group was 
greater than that of both the transient and Et -1 models 
Table 7. Comparison of the volume of oedema following FK506 (1 mg.kg ') administration in three 
models of middle cerebral artery occlusion. 
MODEL 
A HEMISPHERE VOLUMES ( %) A OEDEMA 
VEHICLE FK506 (1 mg.kg') 
Permanent monofilament 35 ± 2 20 ± 2* 43 
Transient monofilament 25 ± 3 13 ± 4" 48 
Endothelin -1 24 ± 10 6 ± 28 75 
Data represents mean ± sem. *' "'e p < 0.05, 2 -way ANOVA with post hoc Student -Newman -Keuls test) 
DOXYCYCLINE 
The administration of doxycycline (10 mg.kg'; 2 hr pre -treatment) (Figure 25) in either the 
permanent and transient monofilament occlusions had no effect on the volume of damage 
compared with saline treated controls. Replication of the Clark et al. experiments (1997) 
which involved both pre- and post -occlusion treatment (see Chapter 2) also showed no 
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Figure 24. Comparison of the effect of FK506 (1 mg.kg 1, i.v.) on the volume of oedema in permanent 
monofilament (n = 12), transient monofilament (n = 11) and Endothelin -1 induced (n = 8) middle 
cerebral artery occlusion models and corresponding vehicle treated controls (n = 11, 8 and 6 
respectively). There is a significant difference between the vehicle of permanent monofilament and 
the other two models although it is not marked. Data represent mean ± sem. ( *, #, O p < 0.05, 
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Figure 25. Comparison of the neuroprotective efficacy of doxycycline (10 mg.kg -1, i.p.) in the 
permanent (n = 8) and transient (n = 8) monofilament middle cerebral artery occlusion models and 
corresponding saline treated controls (n = 6 and 9 respectively). Data represent mean ± sem. 
















Figure 26. Neuroprotective efficacy of doxycycline (10 mg.kg', 30 min pre -treatment i.p; 10 mg.kg'' 
LA 6 x 8 hr post -occlusion) in the transient monofilament middle cerebral artery occlusion (n = 5) 
model and saline treated controls (n = 5). Data represent mean ± sem. (* p < 0.05, 2 -way ANOVA 
with post hoc Student- Newman -Keuls test). 
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DISCUSSION 
The experiments performed in this thesis were the first to show neuroprotection afforded by 
FK506 in the permanent monofilament model of focal cerebral ischaemia. This has allowed 
comparison of this data with that for transient model permanent model data obtained here 
and with data from other research groups (Aoyama et al., 1997; Bochelen et al., 1999; 
Kamiya et al., 1997; Nakai et al., 1997; Toung et al., 1997). The data from the transient rat 
model revealed neuroprotection in the striatum. This observation contrasts that reported by 
Butcher et al. (1997) but agrees with data produced by Bochelen et al. (1999) (Bochelen et 
al., 1999; Butcher et al., 1997). In the Butcher et al. (1997) paper, failure to see significant 
neuroprotection in the striatum may be associated with the statistical analysis (power effect) 
and increasing the experimental number could reveal a significant neuroprotection in this 
brain region. The studies in the mouse transient monofilament are the first show FK506 
neuroprotection in this species. The data obtained for the transient and permanent models 
confirms the observations in Chapter 3 that the size and distribution of the lesions the 
vehicle treated animals in the different rat models of MCA occlusion are similar. The 
neuroprotective efficacy of FK506 in the two models was however different. 
The overall reduction in brain damage seen in the transient model (65 %) is similar to that 
reported by other groups and to that previously described by this laboratory using the 
Endothelin -1 model of MCA occlusion (Sharkey & Butcher, 1994; Sharkey et al., 2000). 
The degree of neuroprotection in the rat permanent monofilament model (34 %) was smaller 
than that observed in the transient model and is comparable with that observed following 
occlusion of the MCA by electrocoagulation (Sharkey & Butcher, 1994; Takamatsu et al., 
1998). FK506 afforded a similar degree of cortical neuroprotection when administered either 
30 minutes prior to or 60 minutes post -occlusion verifying adequate brain penetration of the 
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compound (Butcher et al., 1997; Sharkey & Butcher, 1994). The current studies also confirm 
that FK506 is effective in reducing lesion volume despite route of administration (Brecht et 
al., 1999). 
The different levels of neuroprotection afforded by FK506 in the permanent and transient 
models may hint at the fact that cellular mechanisms that underlie tissue damage and 
ultimately cell death in the different models being substantially different. Zhang et al. (1995) 
demonstrated that antibodies directed at intracellular adhesion molecule (ICAM -1) were 
effective after transient but not permanent monofilament model, supporting the idea of a 
different cellular response despite the ultimate lesion observed (Zhang et al., 1995). It is not 
inconceivable that such variations could be due to difference in the inflammatory response in 
the various models and again raises the question of role of reperfusion following ischaemia. 
The reduction observed in the permanent model suggests that FK506 has direct actions on 
the cells in the compromised tissue. The additional protection afforded by the compound in 
the transient models may result from the combination of direct neuroprotective effects 
coupled with anti -inflammatory actions, targeting responses associated with reperfusion. In 
the search for clinically effective treatments for stroke, the use of agents that interfere with 
the inflammatory cascade appear to confer protection only in those models that have a 
reperfusion component and the degree of protection (< 40 %) offered by these agents is less 
than that previously demonstrated for FK506 (Asahi et al., 2000; Zhang et al., 1995; Zhang 
et al., 1999a). This suggests that FK506 neuroprotection may be multimechanistic i.e. 
modulation of the inflammatory response combined with direct cellular actions. This idea is 
supported by data published by Kung & Halloran (2000) contradicting the idea that 
immunophilins are abundant and not limiting for the inhibition of calcineurin by FK506. 
Inhibition of calcineurin was not complete, either in vitro or in vivo in various tissues and 
especially in the brain. They propose that FK506 may inhibit immune function without 
completely inhibiting calcineurin that may suggest inhibition of immune function is not 
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mediated by a general inhibition of calcineurin but by a subset of the phosphatases (Kung & 
Halloran, 2000). 
It is important in a discussion regarding FK506 neuroprotection in cerebral ischaemia to start 
with a discussion of potential mechanisms that have been cited. The immunosuppressant 
activity of FK506 is thought to be mediated principally by the inhibiting T -cell activation 
and consequently the expression of cytokines such as interleukin -2 (IL -2) involved in the 
co- ordination of an immune response (Schreiber & Crabtree, 1992). The expression of IL -2 
results from the interaction of a number of nuclear transcription factors such as nuclear 
factor of activated T cells (NF -AT), NF-KB and activating protein -1 (AP -1) with the IL -2 
enhancer. FK506 has also been shown to inhibit lymphocyte migration in vitro, block the 
secretion of chemotactic factors and inhibit B -cell activation (Schreiber & Crabtree, 1992; 
Ho et al., 1996). 
FK506's cellular target is the FK506 binding protein FKBP12, a 12 kDa member of the 
ubiquitously expressed and highly conserved immunophilin family of proteins that also 
includes the cyclophilins, the CsA binding proteins. To date, around 20 mammalian FK506 
binding proteins (FKBPs) have been identified (Hamilton & Steiner, 1998) and although the 
actual cellular roles of many are unknown they have been implicated in such diverse 
processes as gene transcription, protein secretion, intracellular Cat+ release, steroid -hormone 
complex formation and have neurotrophic effects (Snyder et al., 1998b; McGregor et al., 
2000). The peptidylpropyl cis -trans isomerases or immunophilins as they were termed, were 
first discovered in 1984 and displayed rotamase enzyme activity catalysing the isomerisation 
of peptide proline residues between cis and trans conformations (Fischer et al., 1984). 
Generally referred to as immunophilins, these enzymes were originally classed by their 
ability to bind either cyclosporin -A ( cyclophilins) or FK506 (FK506 binding proteins). 
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Rapamycin, another immunosuppressant compound binds to FKBP 12 with greater affinity 
than FK506 but unlike CsA and FK506 it has no neuroprotective efficacy (Sharkey & 
Butcher, 1994; Snyder et al., 1998a). The conversion of the cis and trans rotamers of the 
amide bonds by the enzymes can influence protein folding /conformation, stabilisation and 
docking and may be responsible for the immunosuppressive properties when bound to 
corresponding immunosuppressant ligand (Hamilton & Steiner, 1998; Steiner et al., 1992). 
Interestingly, FKBP12 is upregulated in neurones of the ischaemic penumbra and in 
leukocytes /macrophages in the infarction, which has led to the suggestion that increased 
expression may help the neurones of the penumbra to survive and implicated the 
immunophilins in the inflammatory process after ischaemia (Kato et al., 1999). 
FKBP12 is the most abundantly expressed member of the FKBP proteins particularly in the 
brain (10 to 50 -fold that observed in the immune system) and was the first member of the 
FKBP immunophilins to be identified (Steiner et al., 1992). The protein is present in many 
cell types and is well conserved from plants to yeasts to humans (Snyder et al., 1998a). 
FKBP 12 participates in a number of cellular processes including transmitter release, neural 
NO production, nerve growth and intracellular Cat+ release via the ryanodine receptor (RyR) 
and the inositol 1,4,5,trisphosphate receptor (IP3) (Bultynck et al., 2000). Many proteins that 
have rotamase activity and bind to immunophilins do not have immunosuppressive 
functions. Studies with 506BD, a non -natural immunophilin ligand which strongly inhibits 
FKBP12 rotamase activity but is not an immunosuppressant, suggest that the inhibition of 
the rotamase activity is in itself not responsible for the immunosuppressive actions of the 
compound (Bierer et al., 1991; Soldin et al., 1993). In addition to this, immunosuppressant 
compounds often act at low nanomolar concentrations and tissue levels of immunophilins are 
almost micromolar, only a tiny percent of rotamase activity would be inhibited (Snyder et al., 
1998a). The immunophilins must therefore interact with a second protein that when bound to 
the drug confers immunosuppressive characteristics to the complex. This protein was 
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identified as calcineurin (CaN), a type 2B Cal' calmodulin- activated serine /threonine protein 
phosphatase that is inhibited by the FKBP12/FK506 complex (Snyder et al., 1998b). The 
co- localisation of FKBPs and CaN in most regions of the brain supports their potentially 
important role in the central nervous system (Steiner et al., 1992; Dawson et al., 1994). 
Calcineurin is a heterodimer consisting of a 59 kDa A subunit with calmodulin and catalytic 
sites and a 19 kDa B subunit with four calcium binding sites (Morioka et al., 1999; Price & 
Mumby, 1999; Rusnak & Mertz, 2000). First detected by Wang & Desai (1976) the enzyme 
was termed calcineurin on the basis of its Caz+ binding properties and localisation to 
neuronal tissue (Kato et al., 1999; Wang & Desai, 1976). CaN is widely distributed in 
mammalian tissue but the highest levels are detected in the brain. Different isoforms are 
found in other organs (Rusnak & Mertz, 2000). The immunophilins are able to bind to CaN 
in the absence of immunosuppressant compounds but binding is potentiated by the presence 
of the appropriate drug (Cardenas et al., 1994). The FKBP12/FK506 complex does not 
impinge on the active site of CaN but binds to an adjacent site and sterically inhibits the 
approach and dephosphorylation of CaN substrates (Husi et al., 1994). Strong evidence 
supporting the involvement of CaN in FK506 neuroprotection comes from observations that 
the immunosuppressant sirolimus (rapamycin) which binds to FKBP12 with similar affinity 
to FK506 but does not inhibit CaN activity and is not neuroprotective (Bochelen et al., 1999; 
Sharkey & Butcher, 1994). It could be concluded from this evidence that 
immunosuppression and neuroprotection are not necessarily linked phenomena although a 
number of biological events that are associated with organ rejection that are suppressed by 
FK506 may occur in the brain following an ischaemia i.e. cytokine expression, free radical 
production and monocytes /leukocyte infiltration (Chapter 1). Another potential mechanism 
by which FK506 may mediate neuroprotection through the calcineurin pathway revolves 
around protein phosphorylation. A detrimental imbalance of protein phosphorylation can 
occur following an ischaemic insult as various kinases are activated (Drake et al., 1998). 
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Morioka et al. (1999) suggest that calcineurin is a bi- directional enzyme in the cell death 
cascade, having both protective and neurotoxic actions (Morioka et al., 1999). 
The mechanism by which FK506 attenuates damage in cerebral ischaemia has not yet been 
fully elucidated although many putative mechanisms have been proposed (Figure 27) 
(Sharkey et al., 2000). It is not unreasonable to suggest that FK506 neuroprotection 
following an ischaemic insult is the result of multi- mechanistic actions of the compound 
(Dumont, 2000). 
Effect on physiological parameters 
The direct effect of FK506 on physiological parameters of experimental animals causing 
reduction in ischaemic damage has been discounted. FK506 does not appear to have a direct 
cardiovascular effect or influence brain or core body temperature (Butcher et al., 1997). It is 
also unlikely that the effects of FK506 are mediated through alterations in blood flow, as 
administration of the drug in normal rats had no noticeable effect on the regional CBF in 
autoradiography studies (J. Sharkey - unpublished observations). There is some recent 
evidence to suggest that FK506 may improve haemodynamics following stroke by producing 
a beneficial change in cerebral oxygen metabolism and oxygen extraction fraction 
(Takamatsu, 1999). It is however difficult to dissect if the observations are the cause or the 
effect related to FK506 administration. The improvement in cerebral blood flow and thus 
delivery of substrates required by the brain may be the consequence of the alterations in 
vascular reactivity and plugging by leukocytes. This could be linked to NO production and 
expression of adhesion molecules on the endothelial surface which both may be affected by 
FK506 administration (Tsujikawa et al., 1998). Alternatively, the changes in cerebral oxygen 
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Figure 27. FK506 - proposed mechanisms of action. 
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Calcineurin mediated actions 
The disturbances in ion homeostasis, in particular Calf, are pivotal in the pathophysiology of 
cerebral ischaemia (Chapter 1) and therefore Calf dependent enzymes such as CaN 
potentially have a pivotal role in the ischaemic damage cascade. As a target for the 
FK506/FKBP 12 complex, CaN mediated responses may be altered and therefore provide 
neuroprotection. CaN actions in the cell include presynaptic inhibition of spontaneous 
cortical cell firing. Inhibition by FK506 would therefore cause an increase in glutamate in 
the synapse with potentially detrimental consequences (Snyder et al., 1998b; Nichols et al., 
1994; Steiner et al., 1996). Post -synaptically, CaN has been shown to modulate NMDA 
receptor function by reducing the open time of the channel. FK506 binding to calcineurin 
inhibits this function and causes the ion channels to remain open (Lieberman & Mody, 
1994). This observation contrasts the observation that FK506 is protective in neuronal 
cultures exposed to glutamate (Dawson et al., 1993a; Manev et al., 1993), as increased open 
time of the NMDA channels would lead to a greater of Cat+ with 
deleterious effects and cell death. The evidence that supports the hypothesis that the 
neuroprotective effects of FK506 are mediated through the inhibition of calcineurin include: 
drugs that inhibit CaN such as FK506 and the ascomycin derivative SDZ ASM 981 reduce 
infarct volume in a dose dependent manner, the compounds with lower affinity are 
proportionately less neuroprotective, rapamycin which also binds to FKBP12 fails to protect 
against ischaemia and its co- administration with FK506 with rapamycin prevents FK506 
neuroprotection (Bochelen et al., 1999; Dawson et al., 1993b). Non -immunosuppressant 
FKBP ligands (V -10, 367, GPI 1046 and VX853) do not inhibit calcineurin activity but are 
neuroprotective and neuroregenrative in models of peripheral neuropathy and following 
axotomy in the CNS, although not in cerebral ischaemia (Herdegan et al., 2000; Gold et al., 
1998; Gold et al., 1997). These observations suggest that calcineurin independent 
mechanism may also be involved on FK506 neuroprotection. This notion of a calcineurin 
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independent mechanism is also supported by the observation that CsA failed to protect the 
neurones of the hippocampus in a transient global model of ischaemia where FK506 was 
effective (Hamilton & Steiner, 1998). 
The transcription factor NF -AT is an important calcineurin substrate in T cells, B cells, mast 
cells and other immune cells (Aramburu et al., 1998). NF -AT stimulated the transcription of 
a number of genes such as IL -2 that are required for cell `proliferation'. NF -AT, usually 
located in the cytoplasm, is unable to enter the nucleus unless dephosphylated by calcineurin. 
Consequently, inhibition of CaN phosphatase activity by FK506 /FKBP12 complex prevents 
nuclear translocation of NF -AT. NF -KB although not structurally similar to NF -AT does 
possess functional similarities (Rao, 1994). NF -KB is a member of a family of related 
proteins and was first described as a nuclear factor that bound to the K light chain in B cells. 
It is in fact widely expressed and regulates the expression of a variety of genes, the majority 
of which encode proteins that are important in immunity and inflammation (Abraham, 2000; 
Carroll et al., 1998). NF -KB is found both in the periphery and in the CNS and in the latter it 
has been suggested to play a unique role in process such as neuronal plasticity, 
neurodegeneration and neuronal development (O 'Neill & Kaltschmidt, 1997). The molecular 
mechanism for controlling and regulating the immediate early gene expression in the 
myocardium during ischaemia and reperfusion has recently been proposed to be NF -KB 
mediated (Squadrito et al., 2000) and could therefore have a similar in the ischaemic brain. 
The prototypic inducible form of NF -KB is a heterodimer composed of NF -KB 1 and Rel -A 
subunits. Inactive NF -KB is present in the cytoplasm complexed with an inhibitory protein 
IKBa. NF -KB is considered to be a stress sensor molecule as its activation occurs within 
minutes of the stimulation and it appears that a number of stimuli can activate it including 
cytokines, oxidative stress and reactive oxygen species (O 'Neill & Kaltschmidt, 1997). On 
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receiving an activating stimulus, NF -KB is released from IKB inhibition through the 
phosphorylation of the IKB protein with is ubiquitinated and degraded by proteosomes. 
NF -KB is then translocated into the nucleus, binds to the KB motif of the target gene and 
causes activation of several factors involved in the inflammatory response (Squadrito et al., 
2000). It has been shown that FK506 prevents NF -KB activation by inhibiting calcineurin 
that indirectly induces IKBa degradation through phosphorylation (Okamoto et al., 1994). 
Inhibition of calcineurin blunts calcium dependent events such as NF -KB activation, TNFa 
gene transcription, nitric oxide synthase activation, cell degranulation, apoptosis and 
ICAM -1 expression (Squadrito et al., 2000). 
Calcium 
FK506 may mediate neuroprotection by interaction with other CaZ+ mediated mechanisms or 
by directly affecting the CaZ+ metabolism of the cell. FKBP12 immunoprecipitates with the 
300 kDa inositol 1,4,5, triphosphate receptor (IP3R) and the 565 kDa ryanodine receptor 
(RyR), which are both found in the brain and regulate the release of CaZ+ into the cytosol 
from internal stores such as the ER (Hamilton & Steiner, 1998; Jayaraman et al., 1992). 
FK506 disrupts FKBP12 interaction with RyR receptor increasing the probability of opening 
and the mean open time of the channel and renders the receptor `leaky' to CaZ+ ions (Snyder 
et al., 1998a). FKBP12 interacts directly with the IP3 thereby modulating the flux through 
the channel with FK506 having different effect in different tissues and it is thought that 
FK506- FKBP12 may fine tune the CaZ+ fluxes through the channel (Bultynck et al., 2000). 
FKBP12 does not appear to be required for channel function but it does appear to influence 
receptor stability (Brillantes et al., 1994). FK506 neuroprotection may therefore be explained 
by the prevention of cellular CaZ+ overload during reperfusion period (Nakai et al., 1997). 
Mitochondrial function 
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The mechanisms that underlie the direct neuroprotective effect of FK506 are unclear 
although it has recently been proposed that the drug acts through the stabilisation of the 
mitochondria (Friberg et al., 1998). Mitochondrial failure caused by the lack of oxygen and 
glucose results in the pronounced decrease in cellular energy (ATP) levels during an 
ischaemic insult (Chapter 1). The mitochondria act as a calcium sinks during ischaemia, 
sequestering cytosolic Calf until a critical level is reached whereupon respiration ceases, free 
radicals are produced and the contents of the cells are released into the cytosol (Fiskum, 
1985). When mitochondria are exposed to high concentrations of Caz+ ions a large 
proteinaceous megachannel also named the mitochondrial transition pore opens in the inner 
mitochondria. It is the opening of this pore that allows the passage of solutes up to 
1500 kDa to flow across the membrane into the cytoplasm (Chapter 1). Evidence to support 
the formation of the MTP and its role in the ischaemic cascade comes from observations that 
CsA prevents formation of the MTP by blocking translocation of cyclophilin -D to the inner 
membrane thereby decreasing sensitivity to Caz+ ions. CsA, as mentioned previously, is 
neuroprotective but at higher concentrations because of its poor BBB penetration (Friberg et 
al, 1998). Results from in vitro experiments suggest that FK506 is less effective that CsA as 
an inhibitor of MTP - related Caz+ release. FK506 mechanisms preventing mitochondrial 
dysfunction are different and at present are unknown but it is suggested that FK506 protects 
mitochondria by indirectly affecting Cal' uptake (Nakai et al., 1997). The MTP is thought to 
be an early event in apoptosis in some cells and possibly the trigger for cell death in 
ischaemia -reperfusion damage although recent data suggests the brain mitochondria may be 
highly resistant to MTP formation and that pore opening is not crucial to the release of 
apoptotic factors such as cytochrome c (Berman et al., 2000; Ouyang et al., 1999; 
Perez -Pinzon et al., 1999). The restoration of substrates that occurs with reperfusion allows a 
preliminary partial recovery of mitochondrial respiratory function and ATP synthesis 
(Almeida et al., 1995). This is however followed by a subsequent secondary mitochondria] 
degeneration during the first few hours of reperfusion that is associated with the generation 
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of free radicals that can damage cellular components (Chan, 1996). FK506 has been shown 
to prevent secondary mitochondrial dysfunction following transient ischaemia in the rat 
(Nakai et al., 1997). 
It is plausible that the differences observed in the permanent and transient models with 
respect to the efficacy of FK506 may be due to an improvement of post -ischaemic 
mitochondrial function associated with reperfusion. Studies by Folbergrova et al. (1995) 
showed that following 2 hrs of MCA occlusion there was an initial partial recovery of the 
bioenergetic state of the focal and penumbral tissues (1 hr) with a secondary deterioration at 
a later point (4 hrs). The secondary bioenergetic failure was thought to be due to delayed 
mitochondrial dysfunction (Folbergrova et al., 1995). The notion of secondary mitochondrial 
failure is supported by the observation that phenyl -N -tert-butyl nitrone, a free radical spin 
trap, ameliorated damage even when administered 1 -3 hrs after recirculation (Zhao, 1994). 
Drugs and antibodies that show beneficial effects in terms of damage reduction if given 
1 -3 hrs post -reperfusion are either free radical scavengers or curb the inflammatory response. 
Both free radicals and inflammation can be associated with mitochondrial dysfunction and 
are linked to one another (Nakai et al., 1997). Nakai et al. (1997) demonstrated that FK506 
ameliorated the secondary mitochondrial dysfunction and improved post -ischaemic 
respiratory rates in vitro, which could explain the difference in the degree of neuroprotection 
observed in these studies (Nakai et al., 1997). 
Suppression of apoptosis 
As discussed in Chapter 1, the contribution of apoptosis to ischaemic cell death is a 
much -debated topic and consequently compounds that may affect the apoptotic mechanisms 
are of interest. The opening of the MTP in the mitochondria following an ischaemic insult 
releases apoptotic effectors such as cytochrome c, apoptosis inducing factor and Cat+ which 
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are all capable of initiating the cell death cascade (Cassarino et al., 1997; Susin et al., 1997). 
FK506 could potentially influence apoptosis through a number of calcineurin- mediated 
events linked to mitochondrial dysfunction. The anti -apoptotic bc1-2 protein is closely 
associated with the mitochondria and under ischaemic conditions can increase the amount of 
Ca'+ that can be sequestered by the mitochondria (Murphy et al., 1996). Bc1-2 not only 
improves the capacity of the mitochondria to handle calcium overload but also to protect 
from the adverse effects of calcium accumulation thereby influence mitochondrial 
vulnerability (Shibasaki & McKeon, 1995). BcI -2 forms a complex with calcineurin that 
inhibits its phosphatase activity and may explain the anti -apoptotic actions of bc1 -2. The 
binding of FK506 /FKBP12 complex to calcineurin could potentially influence cell survival 
in two ways. By binding to calcineurin there is sustained inhibition of the enzyme and 
additionally the bcl -2 protein is released and may interact with and inhibit the actions of the 
pro -apoptotic proteins such as BAX (Yang et al., 1995) via the cytochrome c /caspase 
pathway and via interactions with other apoptotic mechanisms. BAD, a pro -apoptotic 
member of the Bcl -2 family, is also a substrate for calcineurin and its dephosphorylation 
enhances heterodimerisation with anti -apoptotic proteins and leads to apoptosis (Rusnak & 
Mertz, 2000). There are also a number of observations from both neuronal and non -neuronal 
cells that may suggest FK506 affects apoptotic cell death either directly or indirectly by 
mechanism that do not involve calcineurin. These mechanisms include modulation of the 
MAP kinase pathways (Winter et al., 1998) and ceramide induced apoptosis (Herr et al., 
1999). 
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Nitric oxide production 
One of the most cited mechanisms of FK506 mediated neuroprotection is the attenuation of 
NO- related free radical production via the inhibition of nitric oxide synthase (Ide et al., 
1996; Tanaka et al., 1997; Tokime et al., 1996; Yagita et al., 1996). As described previously 
in Chapter 1, NO combines with other superoxide free radicals forming reactive species that 
cause cellular damage through peroxidation of lipids, oxidation of sulphydryl groups, 
perturbations of membrane permeability and enzyme function. FK506 inhibits 
NMDA- stimulated NOS production and blocked NMDA- induced neurotoxicity in cultured 
neurones (Manev et al., 1993; Dawson et al., 1993a). In these experiments, FK506 is thought 
to provide neuroprotection, in part, by preventing the dephosphorylation and the activation 
of neuronal NOS by calcineurin (Dawson et al., 1993a). In vivo data however contradict 
these results. FK506 failed to prevent excitotoxic damage resulting from intracerebral 
microinjections of NMDA or quinolate suggesting that protection is mediated by other by 
other mechanisms (Butcher et al., 1997; Globus et al., 
neuronal NOS inhibitor following an insult had a less pronounced effect than that of FK506 
suggesting that FK506 may ameliorate ischaemic damage through other mechanisms (Nakai 
et al., 1997). The contribution of NO to the pathology of stoke is a confused area of research 
and consequently the efficacy of FK506 may be embroiled in this confusion. Recently 
however, it has been shown that FK506 did not alter NO production during ischaemia and 
early reperfusion measured by microdialysis suggesting that neuroprotection is not mediated 
through inhibition of NO production (Toung et al., 1999). The interaction of FK506 with NO 
synthases following an ischaemic insult may potentially be the mechanism for 
neuroprotection although there are somewhat confused results regarding this mechanism. 
Toung et al. (1999) demonstrated that FK506 administration had little effect on the total 
NOS activity following ischaemia when measures indirectly by assaying for 
arginine- to- citrulline conversion. They speculated that the isoforms measured in the 6 hours 
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following MCA occlusion were principally neuronal and endothelial but did not account for 
the inducible /immunological isoform iNOS (Toung et al., 1999). It is feasible that FK506 
may prevent the activation of iNOS and preventing the maturation of the lesion as it may be 
activated beyond the first few hours of reperfusion. This hypothesis would fit with 
observations that FK506 suppresses the production of iNOS in cultured macrophages (Conde 
et al., 1995). With respect to the permanent and the transient models, the differences seen in 
the response may reflect the involvement of iNOS if it is assumed that the inflammatory 
response in the permanent model is less pronounced than in the transient model. If this were 
to be the case, the mechanisms of damage that occurred in the two models would be a 
consequence of different pathways but result in similar lesion sizes. 
Anti -inflammatory Actions 
In peripheral organs such as the heart, liver, gut and skin and within in vitro experiments 
FK506 has been shown to have effects on components of the inflammatory cascade. 
drug attenuates cytokine expression, inhibits neutrophil infiltration into tissue (Nishinaka et 
al., 1993; Kubes & Ward, 2000; Sakuma et al., 2000), reduces free radical production from 
monocytes and PMNLs and alters macrophage /microglial response to noxious stimuli 
(Hortelano et al., 1999; Andersson et al., 1992a; Keicho et al., 1991; Matsuda & Baba, 1998; 
Wakita et al., 1998). Ischaemia experiments in the heart suggest that FK506 affects a 
number of components of the inflammatory response. It blocks the early activation of 
NF -KB, suppresses ICAM -1 gene activation, reduces leukocyte accumulation and protects 
against myocardial damage (Squadrito et al., 2000). FK506 has also been shown to inhibit 
neutrophil infiltration into ischaemic tissue in the CNS. Tsujikawa et al. (1998) employed a 
novel approach to investigate the effect of FK506 of leukocyte accumulation. The procedure 
was non -invasive and looked at the effect of FK506 on leukocyte dynamics following retinal 
ischaemia (Tsujikawa et al., 1998). The conclusions drawn from the experiments suggested 
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that FK506 had an inhibitory effect on leukocyte rolling and subsequent accumulation 
resulting in reduction of damage. The alterations in leukocyte dynamics could be explained 
in a number of ways as the recruitment of these cells is a multistep process but this could 
also provide insight into the mechanism of FK506 neuroprotection. Reduced rolling of the 
leukocytes may result from a reduction in the cell adhesion molecules on the PMNLs or the 
endothelium whose expression could be FK506 sensitive. FK506 could be acting by 
affecting NO production and altering vasoactivity or suppressing the release of cytokines that 
attract the leukocytes and the expression of cell adhesion molecules (Tsujikawa et al., 1998). 
FK506 also affects other elements of the immune system such as the microglia within the 
CNS. In vivo experiments demonstrated that FK506 protected white matter in the brain by 
the attenuation of glial cell response (Wakita et al., 1998). The effect of FK506 on microglia 
has also been demonstrated in vitro where it re- transformed LPS activated microglia to their 
ramified state, down regulated NO production and IL -6 synthesis, proposed to occur through 
NF -KB -DNA binding inhibition (Herdegan et al., 2000). FK506 has been shown to affect 
expression of inflammatory signalling molecules in other scenarios. In a model of chronic 
joint inflammation, FK506 was shown to significantly reduce the expression of IL -6 and NO 
thereby reduce joint swelling (Fuseler et al., 2000). FK506 also reduced an increase in 
tumour necrosis factor a (TNFa) following 6- hydroxydopamine lesioning in rats. In vitro, 
FK506 potently inhibited TNFa and IL -113 production by human peripheral blood 
mononuclear cells, as well as suppressing adhesion molecules on vascular endothelial cells 
(Sakuma et al., 2000). This observation supports a report that demonstrated that FK506 
inhibited neutrophil chemokinesis and suggested it was calcineurin mediated adhesion 
molecule expression that was the target for the drug (Hendey et al., 1992). The conclusions 
from experiments with FK506 and components to the inflammatory response tend to suggest 
the compound affects multiple components of the immune response. 
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In all three models, the reduction in the volume of oedema was similar. It is difficult to 
establish whether the reduction in oedema is purely the consequence of the reduction of 
damage or if the actions of FK506 in some way alter the development of oedema associated 
with ischaemic damage. Oedema measurements for the mouse model were not performed, as 
the mouse monofilament model is not central to the thesis but included as an interesting 
comparison in terms of neuroprotection afforded by FK506. 
Doxycycline has been reported to afford neuroprotection in rat MCA occlusion models 
(Clark et al., 1997; Yrjanheikki et al., 1999), in global ischaemia in the gerbil ( Yrjanheikki 
et al., 1998), in rabbit models of spinal cord ischaemia and arterial air embolism (Clark et 
al., 1994b; Reasoner et al., 1997) and in peripheral organs like the liver and the intestine 
(Smith & Gabler, 1994; Smith & Gabler, 1995). The neuroprotection studies performed with 
doxycycline revealed that there was no difference in the volume of damage in either the 
transient or the permanent model with drug treatment. These observations contradict the 
observations mentioned above. It is possible that the doxycycline dose administered in the 
initial studies (10 mg.kg') was not sufficient to mediate neuroprotection. This treatment 
regime was based on protocols used previously in peripheral tissues (Smith & Gabler, 1994; 
Smith & Gabler, 1995) given as a single dose administered 2 hrs pre -ischaemia to allow 
brain penetration in order to assess this treatment regime in the rat. In previous studies of 
global and focal ischaemia, multiple doses of doxycycline were been administered in the 
gerbil and rat (Yrjanheikki et al., 1998; Yrjanheikki et al., 1999) and perhaps this dosing 
regime was required for the drug to enter the brain. However, the experiments with multiple 
does of doxycycline (pre- and post insult) based on the Clark et al. protocol (1997) also 
showed no neuroprotection (Clark et al., 1997). It is possible that multiple dosing 8 hours 
post insult is beyond the therapeutic window for neuroprotection. The reasons for the failure 
to show neuroprotection in these studies are however essentially unclear. 
132 
CONCLUSIONS 
FK506 is neuroprotective in both the transient and permanent monofilament models of focal 
cerebral ischaemia, the Endothelin -1 model and additionally in the mouse monofilament. 
The difference in the neuroprotective efficacy of FK506 in the two different rat models 
suggests that there are different pathological processes between the two models and it is 
proposed that the differences may be due to a difference in the post -ischaemic inflammatory 
response. The final volume of damage may not be different but the processes involved in the 
development of the damage respond differently to the drug. One potential cellular candidate 
identified as a possible target for FK506, is the microglial cells and their response to an 
ischaemic insult and drug administration may explain the different degrees of FK506 
neuroprotection observed. Whilst there have been several reports of the anti -ischaemic 
efficacy for doxycycline in three species and in a variety of tissues, this protection was not 






The data presented so far have established that the permanent and transient models of focal 
cerebral ischaemia, whilst producing a similar volume of damage, respond to differently to 
neuroprotectants such as FK506. The observations in Chapter 4 with respect to the 
percentage reduction in damage in different models of MCA occlusion raised the question of 
the possibility of different cellular responses following insult that lead to infarction. Three 
major cells types within the brain parenchyma are thought to be involved in the 
inflammatory processes that occur in the brain following an insult: endothelial cells, 
astrocytes and microglia and there has been much investigation into the roles of each of these 
cell types in CNS injury such as cerebral ischaemia (Gebicke -Haerter et al., 1995; Giulian et 
al., 1993; Stoll et al., 1998). Infiltrating cells such as the leukocytes begin to enter the 
damaged parenchyma around 12 hrs post insult and monocytes /macrophages enter at an even 
later time point. Both cell types are present in the brain at times beyond the therapeutic 
window of neuroprotection perhaps making them a less likely candidate for acute tissue 
damage (Hallenbeck, 1996; Garcia et al., 1994). 
The microglia, as stated previously, respond rapidly to insults to the brain and parallel the 
onset of earlier neuronal damage (Kato & Walz, 2000; Gehrmann et al., 1992; Kreutzberg, 
1996). In this thesis, the focus of investigation is the microglial cells primarily because of 
their rapid response to injury that has been reported by others (Kato & Walz, 2000) making 
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them an attractive therapeutic target. Astrocytes are generally regarded as having a beneficial 
role (Kato et al., 1994; Raivich et al., 1999) (see Chapter 1) and were not studied in 
preference for the microglia, those role is potentially deleterious. PMNL contribution to 
ischaemic damage is thought to be a more delayed event in relation to the response of the 
endogenous cells and therefore not of interest in this instance (Hallenbeck, 1996; Garcia et 
al., 1994). Closely linked to the leukocytes and their infiltration are the endothelial cells (site 
of adhesion of rolling leukocytes) and thus outwith area of direct interest. If inflammation is 
detrimental to the brain tissue and to be the target of pharmacological agents, the earlier the 
intervention in the pathophysiological cascade the more beneficial effects a particular 
treatment may have. 
Microglial cells are distributed throughout the brain although more common in grey than 
white matter, they constitute 5 -12 % of the cells in the CNS (20 % of the glial population) 
and are considered to be the resident macrophages of the brain (Gehrmann et al., 1992; 
Zielasek & Hartung, 1996). Within the brain, there are a number of populations of microglia. 
The majority are found in the parenchyma but there are other populations associated with the 
vasculature, the choroid plexus and the meninges that are distinguished by slight differences 
in morphology, expression of different cell surface antigens and location (Perry & Gordon, 
1988; Perry et al., 1994). Recent data suggests that microglia from different regions of the 
brain have different densities and susceptibility to noxious stimuli (Kim et al., 2000). This 
view has been supported by the observation that microglial gene expression of inflammatory 
mediators depends on their localisation in the brain and on interactions with other neural cell 
types (Ren et al., 1999). The perivascular cells are considered by some investigators not to 
be true microglia but a population of perivascular monocytes that are not part of the brain 
parenchyma and function as professional phagocytes (Graeber & Streit, 1990; Streit et al., 
1999). 
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Microglial cells were first described by Nissl in 1891 but were defined as a distinct cell type 
within the nervous system, with characteristic morphology and specialised staining features 
that differentiated them from the other glial cells and the neurones, by Rio -Hortega in 1932 
(Gonzalez -Scarano & Baltuch, 1999; Moore & Thanos, 1996). The cellular origin of the 
microglia has been debated for many years and the prevailing view currently is that they 
arise from monocytes derived from the bone marrow. The cells migrate into the developing 
brain before the formation of the BBB where they are maintained as a pool with a low 
turnover during adulthood (Davis et al., 1994; Kreutzberg, 1996; Perry & Gordon, 1988; 
Thomas, 1992). A unique property of the microglia is their ability to proliferate thereby 
maintaining a constant population size in the adult brain (Davis et al., 1994). There is 
however another view suggesting that microglia are renewed by invading peripheral blood 
borne macrophages (Lawson et al., 1992). 
MICROGLIAL FORMS 
Morphologically, microglia have been described as amoeboid, ramified and reactive (Figure 
28) and are considered to be different forms of a single cell type (Thomas, 1992; Streit et al., 
1999). Amoeboid microglia are seen in developing brain tissue and have a broad flat 
morphology with pseudopodia and are the precursors to the ramified form. During 
embryonic development there is considerable cell death which has lead to the idea that, 
within the CNS, the microglia are involved in the removal of cellular debris following this 
natural cell death that is usually apoptotic in nature (Moore & Thanos, 1996). Ramified (or 
resting) microglia are seen in the normal adult brain. They have a small cell body (5 -10 µm) 
with several thin branching processes and are considered to be downregulated under normal 
physiological conditions, in keeping with the idea of the immune privilege status of the brain 
and reflecting the specialised microenvironment of the CNS (Kreutzberg, 1996). Reactive 
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microglia appear in adult tissue following injury or infection and are characterised by oval or 
rod shaped morphology with no ramified process, their ablilty to migrate to the site of 
damage or infection and their phagocytic capabilities (Thomas, 1992). Some authors 
distinguish between activated and reactive microglia when the microglial cells become 
upregulated. Activated microglia appear as swollen ramified cells and are characterised by a 
larger cell body and shorter stouter processes and are not necessarily phagocytic (Davis et 
al., 1994). The activation of microglia does not always result in full blown phagocytes 
(Thomas, 1992; Kreutzberg, 1996). Streit et al. (1999) also describe a hyper -ramified state of 
the microglia that they suggest signifies the beginning of the microglial hypertrophy in acute 
pathological events and which is also seen in ageing brains and may contribute to the 
formation of senile plaques (Streit et al., 1999). 
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Reactive (activated) Phagocytic microglia 
(brain macrophages) microglia 
Hyper -ramified microglia 
(intermediate stage) 
Figure 28. Morphological forms of microglia (Streit et al., 1999). 
137 
MICROGLIAL ACTIVATION 
The precise activation mechanisms of microglial cells are, as yet, not fully elucidated 
(Nakamura et al., 1999). The microglia are under strict control in vivo and the signals that 
activate microglia are unclear, although there are many potential candidates. As suggested 
earlier, chemical messengers released from injured neurones may cause activation although a 
massive insult to the brain may activate the cells. The expression of immediate early genes in 
both the neurones and microglial could suggest that they are directly affected by the 
ischaemic insult (Streit, 1993). It has been proposed that the reduction in blood flow may 
directly activate the microglia following studies in the hippocampus where the strongest 
microglial activation was seen in areas with the densest capillary network suggesting 
reduced flow in well supplied areas cause more serious alterations than in less well supplied 
zones (Abraham & Lazar, 2000). This observation is in keeping with the idea of a graded 
response of microglia to the severity of injury, as this region would suffer the most damage 
due to the most severe reduction in blood flow. The microglia themselves may actually 
produce potent activators of their own cell type. Cytokines such as IL -1ß and TNFa may 
cause activation in disease situations including ischaemia where they are known to be 
produced (Gebicke -Haerter et al., 1996). Streit et al. (2000) have recently provided evidence 
that IL -6 serves as a signalling molecule that induces microglial proliferation (Streit et al., 
2000). Mabuchi et al. (2000) demonstrated the possibility of microglia contributing the 
gradual expansion of the infarct through IL-1f3 production (Mabuchi et al., 2000). 
Another potential activator of the microglial cells is the high extracellular potassium levels 
that are known to accompany both neuronal necrosis following ischaemia and also in 
situations were spreading depressions occur (Nedergaard & Hansen, 1988). In vitro studies 
show the microglia possess potassium channels that make them sensitive to depolarising 
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events (Zhang et al., 1997). Other microglial mitogens such as macrophage colony 
stimulating factor (M -CSF), chemokines, neuropeptides and neurotransmitters may also play 
a role in activation (Perry et al., 1994; Thomas, 1992; Kreutzberg, 1996). Fractalkines, a 
recently discovered class of chemokines that are cleaved from the cell membrane during 
ischaemia, have become a potential candidate as an activator of microglia following 
ischaemia (Chapman et al., 2000; Zujovic et al., 2000). In vitro experiments with 
gangliosides, glycoshingolipid -containing sialic residues that are particularly rich in neuronal 
membranes and may regulate the function of several inflammatory cells suggest that they can 
activate microglia (Pyo et al., 1999). 
ASSESSING MICROGLIAL ACTIVATION 
Activated microglia are distinguished not only by changes in morphology (hypertrophy and 
proliferation) but also by marked changes in phenotype including upregulation of existing 
(CR3 complement receptor) and de as 
histocompatibilty complex (MHC) molecules (antigen presenting proteins on immune cells) 
(Streit, 1993; Lehrmann et al., 1997). Monoclonal antibodies against the cell surface 
antigens, such as OX -42 against the CR3 receptor, have allowed the definition of microglial 
activation in terms of immunophenotypic changes (Thomas, 1992). OX -42 is a reliable, 
widely used marker of the microglia and its staining is sensitive enough to show even slight 
changes in microglial activation (Abraham & Lazar, 2000). The complement receptors such 
as CR3 are on cells that participate in immune reactions and are found on both resting, 
activated and phagocytic microglia and it is the intensity of staining combined with the 
morphological assessment that allows the various forms to be distinguished from one 
another. OX -42 was chosen as the marker for microglial activation in this thesis primarily 
because it had previously been used within the laboratory but also because it is widely used 
by other researchers. (In this thesis, no attempts to distinguish the sub -populations of 
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microglia found in the brain were made). Other antibodies such as those raised against the 
ED1, MHC and lectins antigens and phosphotyrosine have also been used to investigate 
microglia (Table 8) (Kato et al., 1996; Korematsu et al., 1994; Thomas, 1992; Barron, 1995). 
Using a panel of antibodies to known microglial /macrophage antigens, Lehrmann et al. 
(1997) also demonstrated the differential progression and demarcation of the infarct and the 
penumbral zones by the immunophenotype of the cells and confirmed the suggestion that 
there is a spatiotemporal pattern of microglial activation that accompanies neuronal injury 
and that also reflects severity of insult (Lehrmann et al., 1997). Until recently microglial 
activation has primarily been assessed by histological methods (immunoregulatory molecule 
expression) which is a suitable method for studying the extent of a lesion but if considered in 
conjunction with the changes in gene transcription it may be possible to elucidate the 
functional mechanisms of the activation process (Streit et al., 1999; Gebicke -Haerter et al., 
1996; Spleiss et al., 1998). Gene expression (mRNA levels) of the substances known to be 
released by the microglia such as the inflammatory cytokines may fluctuate in an injury 
specific manner (Streit et al., 1999). Experiments that link changes in microglial morphology 
to the changes in gene expression may help to elucidate the functional sequealae of 
activation. These molecular mechanisms may provide targets for intervention that may 
reduce damage (Raivich et al., 1999). 
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OX -42 + + + + + 
Mac -1 + + + + + 
OX -18 + _ + 
OX -6 + _ + 
Ed -1 ++ _ ++ 
F4/80 + + + + + 
CD4 + + + + 
Vimentin + + _ + + 
Lectin 
B4 isolectin + + + + + + 
Agglutinin -120 + + + + + + 
Receptor 
Fc receptor + + + + + 
Acetylated LDL receptor + + - + + 
Silver impregnation + + + + + + 
Enzyme 
Non -specific esterase + + - + + 
Thiamine pyrophosphatase + + + + + + 
OX -42 - CR -3 complement receptor 
OX -6 - MHC class II antigen 
MICROGLIA IN CEREBRAL ISCHAEMIA 
OX -18 - MHC class I antigen 
ED -1 - macrophage cytosol protein 
Ischaemic cell death is accompanied by, and generally preceded by, the activation of the 
microglia. Activation tends to exceed the area of the ischaemic lesion and differing 
morphological responses have been shown suggesting different roles of the cells in the 
different regions (i.e. core vs. remote ipsilateral cortex) (Schroeter et al., 1999). These cells 
therefore can be viewed as an early, sensitive and reliable marker of threatening neuronal 
damage (Gehrmann et al., 1992; Rupalla et al., 1998). The functional changes in neurones 
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that occur within seconds of an ischaemic insult may initiate the changes in the microglia. 
Ábráham & Lázár (2000) propose that the changes in the neurones which may be reversible 
if counter -acted makes the early microglial reaction more important than previously thought 
(Abraham & Lazar, 2000). 
Morioka et al. (1991) conducted the first examination of the microglial response to 
ischaemia in 1991 in a rat transient forebrain model using antibodies against the 
microglial/macrophage marker Griffonia simplicifolia B4 isolectin and showed an early 
activation of the cells (20 min post insult) (Morioka et al., 1991). This study was followed by 
an examination of microglial activation following permanent MCA occlusion in the rat. 
Although cell death in global and focal ischaemia are known to be different, the microglial 
response was found to be similar, displaying early activation and progressive expression of 
immunomolecules that peaked at 2 days (Morioka et al., 1993). The second Morioka (1993) 
study concentrated only on the neocortex and thalamic areas, with no mention of the 
microglial activation state in the striatum. In a transient model of MCA occlusion, Lehrmann 
et al. (1997) noted progressive changes in the activation of the microglia and claimed to be 
able to define the penumbral tissue of both the cortex and striatum. An acute striatal response 
(within hours) was distinguished from the later protracted reaction in the cortex (24 -72 hrs) 
(Lehrmann et al., 1997). Zhang et al. (1997) examined the temporal profile of microglial 
response following transient (2 hr) MCA occlusion and also showed the paralleled 
progression of microglial response and progression of neuronal damage similar to that seen 
in the permanent model. In this study, there were differences in the microglia in mildly and 
severely damaged tissue. Microglia were absent in rapidly necrotic tissue such as the core of 
the infarct with ramified cells found at the ischaemic boundary (Zhang et al., 1997). In the 
centre of the ischaemic insult, where infarction develops, it is difficult for any brain cells of 
any type to survive and it therefore presumed that the lack of staining in these regions is due 
to the failure of the microglia to survive (Kato et al., 1996). The chronological course and 
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severity of neuronal cell death in the ischaemic area are reported to be different in the 
permanent and transient models of focal ischaemia and it is suggested that an earlier 
microglial reaction in the transient model may be due to differences in the severity of the 
ischaemic insult between the two models (Korematsu et al., 1994). The difference between 
the endogenous macrophages of the brain and invading cells is difficult to determine because 
they express similar cell surface antigens and therefore a potential cavaet to microglia 
investigations. Studies have proved that there is no early change in number of macrophages 
suggesting that the macrophages that appear must be of microglial origin (Korematsu et al., 
1994). Recruitment of blood borne monocytes is however a delayed process occurring 
beyond 24 hrs of ischaemia/reperfusion (Mang et al., 1994) with massive infiltration after 
2 -3 days (Kato et al., 1996). 
MICROGLIA IN CULTURE 
Many studies have been conducted using isolated microglia in order to dissect the 
mechanisms that lead to activation, to analyse secreted products and to ultimately assess the 
contribution of the cells to either neurodegeneration or neuroregeneration (Sudo et al., 1998; 
Ren et al., 1999; Nakamura et al., 1999; Petrova et al., 1999; Sawada et al., 1989; Daval et 
al., 1995; Dawson et al., 1993b; Chao et al., 1992; McMillian et al., 1994). In vivo, it is 
difficult to attribute direct functional meaning to observations made from tissue sections, 
whereas in vitro it has been virtually impossible to establish the relevance of observations in 
a culture dish and relate them to the whole organ (Streit, 1993). Investigations on cultured 
microglia, including slice preparations, are useful to test hypotheses and additionally can 
help to reduce the number of animals used experimentally (Gebicke -Haerter et al., 1996). It 
is important to set up methods for assessing morphology and in situ localisation of microglial 
secretory products in the whole brain but the use of simplified systems as far as is feasibly 
possible can help to construct arguments before moving to a more complex scenario. In this 
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manner it may be possible to build a complete picture in a stepwise and clearly identify 
components of a multifaceted cascade such as that of microglial activation. 
MICROGLIA & FK506 
FK506 as described before (Chapter 4) ameliorates neuronal necrosis in both global and 
focal models of ischaemia and in a number of species. Wakita et al. (1998) demonstrated that 
FK506 prevents microglial activation in the white matter of animals subjected to chronic 
cerebral ischaemia (bilateral CCA occlusion) and attenuated lesion formation (Wakita et al., 
1998). Immunosuppressive drugs including FK506 have been shown to downregulate 
mRNA expressions of proteins such as CD4 molecules that are expressed by the microglia 
(Sawada et al., 1992). In vitro studies by Herdegen's group in Kiel have shown that FK506 
prevents the activation of microglia by LPS and causes LPS activated microglia to become 
ramified again (Mielke et al., 1999). FK506 exerts moderate inhibition of iNOS expression 
in LPS /IFNy activated peritoneal macrophages and prevents apoptosis through inhibition of 
caspase 3 and an alteration in the levels of bcl -2 family proteins (Hortelano et al., 1999). 
Experiments on cultures of macrophages from the periphery showed that FK506 inhibited 
the production of NO by affecting nitric oxide synthase (Conde et al., 1995; Wakita et al., 
1998), suppressed IL -2 production and inhibited inflammatory cytokine production (Sakuma 
et al., 2000; Wakita et al., 1998). These mechanisms may explain the neuroprotective 
capabilities of FK506 in the brain through similar actions. It is appreciated that peripheral 
macrophages are not identical to microglia of the CNS but it does illustrated the sensitivity 
of these cells, sharing a common lineage with microglia, to the administration of FK506 and 
may hint at a possible mechanism of neuroprotection. 
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An additional set of experiments have been included in this chapter examining the effect of 
hypoxia on pure neuronal cultures and neurones cultures with different glial populations. 
This is a continuation of work already performed in the laboratory and is directly related to 
the assessment of the inflammatory response to cerebral ischaemia. 
MATERIALS & METHODS 
NEUROPROTECTANTS & MICROGLIAL ACTIVATION 
Animals were subject to MCA occlusion as described in Chapter 2. FK506 and its vehicle 
were administered as previously described. In an additional experiment to complement the 
doxycycline neuroprotection studies, doxycycline (10 mg.kg I, Sigma) was administered to 
following both transient and permanent MCA occlusion to investigate its effect on microglial 
activation. A further experiment with doxycycline was also performed to assess microglial 
activation. Animals received 45 mg.kg ' of the compound 12 hrs prior to MCA occlusion and 
were sacrificed at 3 hrs post insult. 
MICROGLIAL IMMUNOSTAINING 
For the immunostaining of microglial cells, animals were deeply anaesthetised by i.p 
injection of Euthatal and transcardially perfused as previously described with heparinised 
PBS followed by periodate- lysine -paraformaldehyde (PLP, Appendix 1). Brains were 
removed and placed in PLP /20 % sucrose for approximately 3 hrs at room temperature 
before being transferred to 20 % sucrose solution overnight. Free floating cryostat sections 
(30 µm) were placed in PBS, washed and incubated in 1 % hydrogen peroxide for 15 min. 
Ipsilateral and contralateral hemispheres of the brain were marked prior to cryostat 
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sectioning. Sections were washed 3 times in PBS -5 % polyoxyethylene- sorbitan monolaurate 
(Tween 20, Sigma) and incubated with 4 % normal horse serum (Vectastain Elite ABC 
Mouse Immunoglobulin G (IgG) Kit, Vector Laboratories) diluted in PBS -Tween 20. 
Following an overnight incubation at 4 °C in the primary antibody OX-42 (1:2 000 dilution; 
Mouse IgG2a - MCA275G, Serotec) the sections were washed 3 times in PBS and incubated 
for 1 hr at room temperature in horse anti -mouse biotin labelled secondary antibody (1:250 
dilution; Vector). Sections were washed and incubated for 1 hr in Avidin- Biotin Complex 
(ABC) Elite (Vector) at room temperature. Sections were washed twice in PBS. Antibody 
staining visualised with diaminobenzidine (DAB, Vector). Sections were cleared in 
Histoclear and mounted in DPX (BDH Chemicals Ltd, UK). 
MICROGLIAL CULTURES 
The protocol for microglial cultures was adapted from Levison & McCarthy (Levison & 
McCarthy, 1989). Cortices were removed from 12 -16 one day old (range PO -P2) rat pup 
brains. The meninges were removed and the tissue chopped finely with a sterile razor blade. 
The dissection stage was carried out in Hank's Balanced Salt Solution (HBSS, GibcoRPL, 
Life Technologies) without calcium, magnesium or phenol red. The chopped tissue was 
placed in HBSS containing 0.25 % filter sterilised trypsin and 0.025 % filter sterilised 
deoxyribonuclease 1 (DNase, Sigma) and incubated at 37 °C for 15 -20 min. An equal volume 
of complete Basal Medium Eagles (BME) culture medium (Appendix 2) containing 0.025 % 
DNase was added and the suspension triturated through a fine bore pipette in order to disrupt 
the tissue. Following every 9 or 10 triturations, the tissue was allowed to settle and the cells 
in suspension removed. The collected suspension was centrifuged at 500 x (gravity) g for 
10 min (Mistral 2000, MSE) and the pellet resuspended in an appropriate volume of 
complete BME culture medium. The suspension was then filtered through sterile nylon 
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gauze (125 µm, Lockertex) to remove clumped cells then plated out into 75 cm2 filter top 
flasks (NUNCTM A Surface, Life Technologies) at approximately 1 x 107 cells per flask. 
Flasks were kept in the CO2 incubator (5 % CO2, 37 °C and 99 % relative humidity, LEEC) 
with the medium changed after 1 day and then every 3 days until the cells were confluent 
(7 -10 days). The medium, conditioned by the cells in the mixed cultures, was retained and 
filter sterilised for use in subsequent experiments. 
Microglia were isolated from the mixed cultures after approximately 14 days in culture. 
Microglia were detached by shaking the flasks in a temperature controlled orbital shaker 
(Grant SS40 -2, Grant Instruments) at 37 °C at 200 rpm for 90 min. The medium was removed 
and centrifuged at 500 x g for 5 min and the pellet was resuspended in glial conditioned 
medium. The microglia were placed in 75 cm2 NUNC filter top flasks at a density of 5 x 106 
cells in glial conditioned medium for 24 hrs before treatment. 
LPS STIMULATION 
Microglial cultures were challenged with LPS (1 p.g.ml -1) for both 3 and 24 hrs and 
compared with saline treated control cultures. The activation state of the cells was assessed 
by morphology and photographed (Axiovert 135 Microscope, Zeiss; Contax 167MT camera; 
Kodak Tmax 100 Pro). At the appropriate time points, protein or total RNA was extracted 
from the cells for use in reverse transcription polymerase chain reaction (RT -PCR) and 
immunoblotting, respectively (Chapter 6). 
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EFFECT OF FK506 ON LPS STIMULATION 
FK506 (5 µM) and vehicle respectively were added to the LPS stimulated cells immediately 
following LPS administration. Again morphology was noted and protein or RNA extracted 
for analysis at 3 and 24 hrs. 
IN VITRO `ISCHAEMIC INSULT 
Primary cultures of rat cerebrocortical neurones were prepared from the cortices of 
embryonic day 17 (E17) Sprague Dawley rats. Cortices were dissociated for 12 min in HBSS 
containing 0.09 % trypsin and 500 lU /ml DNase, triturated in HBSS containing 500 lU /ml 
DNase and plated out at 1600 cells /mm2 in Neuronal Plating Medium (containing 5 % 
heat -inactivated horse serum, 5 % heat -inactivated foetal bovine serum) onto poly -D- lysine 
coated 15 mm wells. After 24 hrs, the medium was replaced with B27 medium and thereafter 
partly refreshed twice weekly. On day 5, the cultures were treated with 5 mM 
cytosine ß -D- arabino -furanoside (ara -c, Sigma), which as a mitotic agent resulted in a pure 
neuronal culture. Cultures were used for experimentation at 11 -15 days in vitro. To establish 
neurone and astrocyte or microglia only cultures, neurones were plated over the respective 
glial culture. 
To establish astrocytic monolayers, cultures were prepared as described for microglial 
cultures described above. Mixed culture flasks were shaken in the orbital shaker for 90 min 
to detach the microglia (collected and plated) and then shaken further overnight. The 
remaining adherent population was then trypsinised and replated onto 24 well plates 
(5.6 x 104 cells per well) and returned to the incubator for 7 days until confluent. Neurones 
were then plated over the astroglial layer and used for experimentation after a further 11 -15 
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days. Neuronal/microglia only cultures were established from the collected medium from the 
first shake. Microglia were plated as described in the microglial culture section above. 
Neurones were plated over the microglia at both 1 day and 7 days post initial microglial 
plating as the cells did not appear to become confluent and comparison was made between 
1 and 7 days. The natural mixed glial population was obtained by not treating the original 
E17 primary cultures with ara -c that were plated into 24 well plates and used for 
experimentation 11 -15 days. Glial content of these cultures was estimated previously to be 
12 -20 % by immunostaining. 
Cultures were subjected to anoxia (0 % 02, 5 % CO2, 94 % N2, 37 °C) for 30, 60, 90, 180, 
360 and 1440 min in an anoxic chamber (Don Whitely Scientific MACS VA) followed by 
the appropriate recovery time in the CO2 incubator at 37 °C until assessed by MAP -2, 
fluorescein isothiocyanate (FITC) immunostaining at 24 hrs for neurones and mixed cultures 
and lactate dehydrogenase (LDH) cytotoxicity assay (CytoTox 96®, Promega) staining for 
the microglial and astrocyte only cultures. Briefly, cells were washed with PBS and fixed 
with PLP (Appendix 1), washed and permabilised with 0.25 % triton in PBS. Cells in the 
plates were blocked in 10 % BSA in PBS for 20 -30 min and incubated in primary antibody 
(anti -MAP -2, Sigma) diluted 1:1000 in 3 % BSA for 2 hrs at room temperature. Cells were 
washed and incubated with the FITC linked secondary antibody dilutes 3 gg.ml -1 in 3 % 
bovine serum albumin (BSA) in PBS for 1 hr at room temperature in a dark chamber. Plates 
were washed with PBS and the signal read using a Fluoroskan Ascent plate read using an 
excitation wavelength of 485 nm and emission wavelength of 520 nm. LDH assay was 
performed according to manufacturer's instructions (Technical Bulletin) and the absorbance 
read at 490 nM in the Dynex Technologies plate reader. 
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RESULTS 
IN VIVO MICROGLIAL ACTIVATION 
The staining of the microglia with the OX -42 monoclonal antibody took several months to 
establish. In the initial experiments, staining on slide- mounted paraformaldehyde fixed 
20 µm sections was not consistent and it was difficult to visualise the microglia. The 
experiments with 30 µm free floating PLP perfusion fixed sections provided a better -defined 
stain of the cells. By marking the contralateral hemisphere of the brain before sectioning, it 
was possible to correctly orient the brain when the sections were slide mounted. It was also 
discovered that the post -perfusion fixation in 20 % sucrose /PLP had to be limited to 3 hrs 
where upon the brains were removed and placed in 20 % sucrose in PBS solution overnight. 
Exclusion of the primary OX -42 antibody confirmed the specificity of the OX -42 staining 
for microglia. 
Once established, the visualisation of the microglial cells showed activated microglia with 
enlarged cell bodies and retracted process (Figure 29) in both the cortex and striatum of the 
ipsilateral hemisphere following a 3 hr MCA occlusion. Staining of sections from animals 
that had undergone anaesthesia only was diffuse (Figure 30) confirming that microglial 
activation did not occur with routine anaesthesia and that the change in morphology and 
therefore staining in the occlusion animals was indeed a consequence of the ischaemic insult. 
The staining of both the cortex and striatum of the contralateral hemisphere was diffuse 
indicating no activation of the cells and therefore valid as a control (Figure 31 & Figure 32). 
In one of the three sham animals, the morphology of the cells was not completely ramified 
like that of the anaesthetic only control sections nor did they show the activated morphology 
seen in lesioned tissue (upper left panel in Figure 32). 
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FK506 vehicle had no effect on microglial activation. In the FK506 treated animals, the 
morphology of the microglia was similar to that of the sham and the anaesthetic only groups 
suggesting that the drug may prevent microglial activation (Figure 33). In the striatum, 
similar observations regarding the activation state of the microglia were made (Figure 34). 
The administration of FK506 appeared to make no difference to the morphology of the cells 
in the contralateral hemisphere, which was not unexpected, as they did not display an 
activated morphology. 
The administration of doxycycline at both doses (10 and 45 mg.kg') had no effect on the 
activation state of the microglia which was consistent with the neuroprotection studies where 
no reduction in lesion volume was seen (data not shown). 
Following these initial positive results, subsequent experiments looking at microglial 
activation using the OX -42 antibody produced spurious results. Staining was not consistent 
suggesting that the activation of the cells was not consistent making assessment of drug 
effects virtually uninterpretable. Permanent occlusion experiments (3 hrs) were repeated and 
studies extended to the transient model (2 hr occlusion plus 1 hr reperfusion). In an 
experiment with LPS, known to activate microglia, the results were also inconsistent. Fresh 
primary, secondary antibodies and DAB were used in order to improve the staining with little 
success. The possibility of the monofilament having not occluded the MCA was ruled out in 
each permanent model experiment by the verification of placement on removal of the brain 
amd in the transient model by Evans Blue staining. No other variables had been changed in 
the experimental procedure. 
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IN VITRO MICROGLIAL ACTIVATION 
Initial studies examined the effects of culture conditions on microglial morphology. Media 
conditioned by the cells of the primary mixed cultures proved to be better than freshly 
prepared media and was therefore routinely retained during the culturing process for the 
experiments that followed. NUNC plates provided a better surface (in comparison with 
Falcon plates and poly -L- lysine coated dishes) for the cells to adhere to and ramify. The 
plating density of the cells was also varied and optimum density in 75 cm2 flasks was 
approximately 5 x 106 cells. Initially, microglia were allowed to settle and ramify for 72 hrs 
once dissociated prior to LPS stimulation. This time was shortened to 24 hrs as the cells 
looked healthier and more ramified at the earlier time point. 
Although cells in culture did not resemble those in vivo, processes could clearly be seen in 
the resting cells (Figure 35) and upon LPS stimulation there was a noticeable change in the 
morphology (Figure 36). FK506 administration appeared to affect the activation of the cells 
assessed subjectively under the microscope. OX-42 immunostaining and Griess reagent were 
used to assess the activation state of the cells and to detect changes following both LPS 
stimulation and FK506 administration. The OX -42 antibody used the cells in vivo did not 
stain the cells in vitro. Griess reagent used to detect NO produced by cells in culture (Pyo et 
al., 1999) as a marker of microglial activation was also unsuccessful. 
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Figure 29. Typical activated microglia visualised with OX -42 (40 x magnification) following 3 hrs 











Figure 30. Comparison of ipsilateral and contralateral cortex and striatum (10 x magnification) in a 




Figure 31. Comparison of microglial activation following a 3 hr permanent monofilament MCA 
occlusion in the contralateral cortex of a sham, occlusion, FK506 vehicle treated and an FK506 treated 
animal (10 x magnification). 
Figure 32. Comparison of microglial activation following a 3 hr permanent monofilament MCA 
occlusion in the contralateral striatum of a sham, occlusion, FK506 vehicle treated and an FK506 
treated animal (10 x magnification) 
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Figure 33. Comparison of microglial activation following a 3 hr permanent monofilament MCA 
occlusion in the ipsilateral cortex of sham, occlusion, FK506 vehicle treated and an FK506 treated 
occlusion (10 x magnification). 
Figure 34. Comparison of microglial activation following a 3 hr permanent monofilament MCA 
occlusion in the ipsilateral striatum of an anaesthetic control, occlusion, FK506 vehicle treated and an 
FK506 treated occlusion (10 x magnification). 
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Figure 35. In vitro ramified microglial cells (20 x magnification). 
Figure 36. Activated microglia in culture following 3 his LPS stimulation (20 x magnification) 
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IN VITRO `ISCHAEMIC INSULT 
Exposure of pure neuronal cultures to OGD caused cell death within 30 min. The presence of 
glia (12 -20 %) co- cultured with the neurones significantly prolonged the survival time of the 
neurones, reaching the same extent of cell death as the pure neuronal cultures by 90 min. At 
30 min approximately 50 % of the neurones were still viable. Analysis of neurones 
co- cultured with pure astrocytes evaluated at 7 days post plating with the neurones showed a 
similar profile to the natural mixed population (Figure 37). Exposure of neurones co- cultured 
with microglia, evaluated 7 day post plating with the neurone, showed a similar viability 
profile to the mixed glial population and the pure astrocyte co- culture with approximately 
55 % of the neurones still viable at 30 min (Figure 38). Interestingly, neurones cultured with 
pure microglia and assessed 1 day post plating with the neurones survived longer (30 min) 
than those assessed 7 days post plating. Following 30 min of OGD, 70 % of the neurones 
were still viable and 50 -55 % at 60 min. By 90 min the extent of cell death in these cultures 
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Figure 37. OGD induced cell death (0 % 02/0.5 mM glucose for time points between 30 amd 
1440 
min assessed at 24 hrs post insult) in cultured rat cortical neurones, neurones cultured 
with astrocytes 
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Figure 38. OGD induced cell death (0 % 02/0.5 mM glucose for time points between 30 amd 1440 
min assessed at 24 hrs post insult) in cultured rat cortical neurones, neurones cultured with 7 day old 
microglia and neurones cultured with natural mixed glia (2 -12 %). 
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Figure 39. OGD induced cell death (0 % 02/0.5 mM glucose for time points between 30 amd 1440 
min assessed at 24 hrs post insult) in cultured rat cortical neurones, neurones cultured with 1 day old 
microglia and neurones cultured with natural mixed glia (2 -12 %). 
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DISCUSSION 
A defining characteristic feature of microglial cells, recognised for over a century 
(Gonzalez -Scarano & Baltuch, 1999), is their rapid, concerted activation in response to even 
the smallest change in the brain environment, often preceding reactions of other cell types 
(Kreutzberg, 1996; Rupalla et al., 1998; Perry et al., 1994). Microglial activation is seen in 
response both to brain injury and trauma and in other neurodegenerative diseases that can 
affect the CNS such as HIV infection and AIDS, multiple sclerosis, Alzheimer's and 
Parkinson's Disease (Kim et al., 2000; Giulian et al., 1993; Moore & Thanos, 1996). The 
activation of the microglia in response to injury becomes more pronounced and widespread 
with more severe insults (Raivich et al., 1999) although the cells appear to exhibit a 
non -specific upregulation in response to different types of damage (Davis et al., 1994; 
Kreutzberg, 1996). Although much attention has been focused on the microglia as the 
macrophages of the brain following injury or infection it has also been suggested that they 
may also have a constitutive function. The ramified cells could function in cleaning the 
intracellular fluid, be involved in transmitter inactivation and therefore have a role in normal 
brain functioning (Glenn et al., 1991; Booth & Thomas, 1991). 
Early microglial activation following ischaemia, as signified by the morphological changes 
and associated production of diffusible toxic molecules is closely linked with the 
development of damage following ischaemia even though the cells are not yet phagocytic 
and do not cluster around ischaemic neurones (Zhang et al., 1997). Kim et al. (2000) 
provided in vivo evidence for the neurotoxic nature of microglia in a study where the greatest 
cell death was seen in regions of the brain containing the greatest number of microglia in 
response to intracerebral administration of LPS (Kim et al., 2000). Microglia have also been 
implicated in secondary selective neuronal degeneration following ischaemia in regions (e.g. 
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the thalamus and substantia nigra) distal from those involved in the primary lesion (Rupalla 
et al., 1998) and also in delayed neuronal damage through the production neurotoxins 
released by the reactive cells (Giulian & Vaca, 1993; Lees, 1993). The cellular source of the 
huge increases in extracellular glutamate that occur during ischaemic cell death has 
previously been thought to be neuronal in origin but it has been suggested that from culture 
experiments that the microglia release massive amounts of the excitatory neurotransmitter 
and therefore may contribute to ischaemic injury (Wood, 1995). In situ hybridisation 
experiments for the pro -inflammatory cytokines suggest that they are produced primarily in 
the activated microglia and also show that the profile of expression is different following 
different insults i.e. motorneurone axotomy compared with traumatic spinal cord injury. This 
could perhaps suggests a different role in the different situations (Bartholdi & Schwab, 1997; 
Streit et al., 1999). Following ischaemic insult the upregulation of the pro- inflammatory 
cytokines is usually of very short duration suggesting tight regulation of the response and 
providing support for the idea that the microglia may actually have a beneficial role (Buttini 
et al., 1994; Woodroofe et al., 1991). 
Microglial activation in the brain is triggered by signals from injured neurones and may 
indeed be beneficial in certain scenarios i.e. where neurones are not lethally damaged (facial 
motor neurone lesions or in the ischaemic penumbra) they may play a role in tissue recovery 
and repair (Moore & Thanos, 1996; Raivich et al., 1999). It has been proposed that transient 
activation is beneficial for brain repairing processes and chronic reactivity of the cells 
detrimental (Petrova et al., 1999). In vitro findings that activated microglia produce 
neurotrophins such as nerve growth factor (NGF) and transforming growth factor 13 (TGF -ß) 
suggest involvement in neuronal regeneration (Elkabes, 1996; Giulian et al., 1993; 
Gebicke -Haerter et al., 1996; Wahl et al., 1991). The neuroprotective role of microglia is 
supported by the observation that in global cerebral ischaemia, neurones in the hippocampus 
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do not degenerate despite pronounced microglial activation (Abraham & Lazar, 2000). In 
vitro data clearly shows that in behaving as macrophages, microglia can secrete substances 
with proven neurotoxic actions suggesting that activation can be detrimental (Streit, 1993; 
Giulian et al., 1993). Activated microglia in culture release reactive oxygen species, 
cytokines, glutamate, proteases, arachadonic acid derivatives and other small neurotoxic 
molecules (Paris et al., 2000; Banati et al., 1993; Colton & Gilbert, 1987; Wood, 1995; 
Giulian et al., 1993; Gonzalez -Scarano & Baltuch, 1999). The extrapolation of in vitro data 
and interpretation of the results of various intervention studies in animal models that have 
been directed at molecules have lead to the idea that these molecules are produced by 
activated microglia in vivo (Lehrmann et al., 1997). 
The analysis of OX -42 stained sections clearly showed activation of the microglial cells 
following an ischaemic insult. OX-42 is generally a reliable marker of microglia and has 
previously been prove& to be sensitive enough to show slight changes in microglial 
activation (Abraham & Lazar, 2000). Although taking sometime to establish, the initial 
experiments with the antibody showed clearly activated microglia in the ipsilateral cortex in 
the sections from animals that had been subjected to MCA occlusions. The administration of 
FK506 appeared to cause a de- activation or prevent activation of the cells in both the cortex 
and striatum. The 3 hr time point was initially chosen to examine the microglial response 
with a view to then examining any differences that might have occurred as a consequence of 
an hour reperfusion following a 2 hr transient occlusion. The idea that FK506 may mediate 
its differential neuroprotective effects demonstrated in the two models in Chapter 4 through 
its action on the microglia. Unfortunately the staining of the cells as not consistent and did 
not allow such examination to be conducted. The problems with staining in the subsequent 
experiments were not due to the reagents used as these were changed and there was some 
staining of the sections although it was not consistent. The conclusions drawn from these 
experiments was that FK506 definitely caused an alteration in the activation state of the 
161 
microglia. Others, both in vivo and in vitro, have reported this observation. Herdegen et al. 
(2000) demonstrated microglial response to FK506 in vitro making the in vivo response of 
interest (Herdegan et al., 2000). Following LPS stimulation in vitro, FK506 administration 
was able to prevent activation of microglial cells and addition cause re- ramification of 
activated cells following LPS exposure (Mielke et al., 1999). FK506 administration in vivo 
has also been shown to reduce the microglial activation in the white matter of drug treated 
animals compared with vehicle treated controls (Wakita et al., 1998; Herdegan et al., 2000). 
Further attempts to gain insight into the role of microglia in focal cerebral ischaemia using 
doxycycline were unfruitful. Doxycycline was included as it has previously been reported to 
completely prevent microglia activation and was neuroprotective in global brain ischaemia 
(Yrjanheikki et al., 1998; Yrjanheikki et al., 1999). The administration of the tetracycline 
compound in the monofilament MCA occlusions appeared to have no effect on the activation 
state of the microglia at either the 10 or 45 mg.kg'. This observation is in keeping with the 
results of the neuroprotection studies (Chapter 4) where doxycycline administration in both 
the permanent and transient monofilament MCA occlusions had no effect on the volume of 
ischaemic damage. 
It was decided to simplify the experiments with the microglia and establish the activation 
state and effect of FK506 in culture with a view to interpreting the in vivo data. Using a 
culture system it has been possible to attempt to establish a relationship between morphology 
and function response (Nakajima & Kohsaka, 1998). In culture, isolated microglia assume 
the amoeboid morphology initially and with time they settle and take on more diverse 
morphologies. Difficulties in keeping isolated microglia in the resting state has been reported 
by other and it appears that the cells are extremely sensitive to the composition of the culture 
medium (Nakamura et al., 1999). The conditions used to achieve ramification of the cells in 
vitro seem to vary between research groups with differences in media and flask types used 
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for culturing (Tanaka et al., 1998; Tanaka et al., 1999; Kim et al., 2000; Petrova et al., 1999). 
Some researchers have reported ramified microglia are best cultured in serum free medium 
on poly -L- lysine coated coverslips (Sudo et al., 1998). Other authors suggest that non -coated 
glass and plastic substrates are strong activators of microglia and that coating with poly -L- 
lysine induces the ramified shape of microglia (Sudo et al., 1998). In the experiments 
performed for this thesis, ramification was achieved in NUNC flasks using glial- conditioned 
medium having tried a number of different types of flask, different medium compositions 
and times between plating and experimentation. It may be difficult to interpret the 
morphological changes of cultured microglial as the cells may have already undergone 
activation through the somewhat brutal culturing procedure. They take on a typical 
macrophage -like phenotype and are therefore sometimes termed microglia derived brain 
macrophages (Streit, 1993; Streit et al., 1999). Some authors report that microglia cultured 
on astrocytes monolayers become ramified and show morphology closer to that of resting 
microglia in the normal brain (Kloss et al., 1997). In the normal brain, microglia are 
sometimes in contact with neurones and other cell types and it is suggested that the culturing 
process may alter the microglial response because of the altered physical relationship 
between cell types. Factors released from astrocytes and other cells in the brain may be 
absent in culture and so may alter the microglial response (Sudo et al., 1998). 
LPS is routinely used to investigate the activation of microglia in vitro (Nakamura et al., 
1999; Giulian & Vaca, 1993; Puffenbarger et al., 2000; Sanz & Di Virgilio, 2000; Possel et 
al., 2000; Zielasek & Hartung, 1996) and this was confirmed in the experiments conducted 
in this thesis. LPS has been shown to increase the production of cytokines, NO and the like 
when administered to cultured microglia (Loughlin & Woodroofe, 1996; Streit, 1993). 
Nakamura et al. (1999) reported changes in morphology of the cells in pure microglial 
cultures as early as 3 hrs after LPS stimulation (Nakamura et al., 1999). Kim et al. (2000) 
injected LPS stereotaxically into the rat brain to investigate microglia reactivity and neuronal 
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susceptibility. They showed that there was region specific neuronal susceptibly to LPS 
induced neurotoxicity and suggested that this was related to the differences in microglial 
number and levels of inflammation related products produced by these cells (Kim et al., 
2000). The cultured microglia showed an altered morphology but this was difficult to assess 
quantitatively and was subjective. A more definitive answer would have been preferable. 
The staining with the OX -42 was unsuccessful despite reports by others of its use in vitro. 
OX-42 was previously been shown to intensely stain in microglia in primary cortical cultures 
(Booth & Thomas, 1991). Griess reagent, used to detect changes in NO (an indicator of 
activation) used to assess microglia in culture by others (Pyo et al., 1999) and previously in 
this laboratory, provided no data in these experiments. It was thought that the lack of colour 
change that is the marker for production of NO was because the signal that was not sufficient 
to be detected. The number of cells was increased in the culture wells to increase the signal 
with little success. The administration of FK506 affected the morphology of the cells that 
were LPS stimulated although this again was a subjective assessment but was in keeping 
with the observations from Herdegen's group (Mielke et al., 1999). 
A series of experiments concerning the microglia and their contribution to the progression of 
ischaemic damage was performed with the technical help of Mrs Joyce McLuckie. With the 
increasing awareness of the use of animals in scientific experiments there have been attempts 
to simulate in vivo ischaemia experiments in the test tube i.e. in vitro (Home Office 
Recommendations). A number of experiments had previously been performed with the 
laboratory using an anoxic chamber to establish suitable protocols that mimicked the loss of 
substrates (glucose and oxygen) that occurs during an ischaemic insult and allowed 
assessment of neuronal viability with FITC -linked MAP -2 immunostaining. As stated 
before, in vitro systems have the advantage in terms of simplification and ease of 
manipulation but is an artificial environment and there observation made may not be truly 
representative of the in vivo state (Streit, 1993). 
164 
The previous oxygen -glucose deprivation (OGD) experiments showed that exposure to 0 % 
02 and 0.5 mM glucose produce neuronal cell death with 60 min and that the cells could be 
protected by MK -801 administration, which confirmed the excitotoxic nature of the cellular 
demise. FK506, which as stated before is a potent neuroprotectant, failed to protect the 
neurones from the insult (G. May - unpublished data). A further series of experiments 
proved that the addition of serum in the culture medium required longer OGD exposure 
times to produce neuronal death, proved MK -801 was still as effective at preventing 
neuronal cell death but still showed FK506 to have no effect. It was suggested that the effect 
of the serum on neuronal viability was related to its Cat+ buffering capacity in the medium 
thereby reducing the severity of the insult (Kristian & Siesjo, 1998). 
It has been established that the interaction of neurones and glial cells in culture can affect 
their response to stimuli (Tanaka et al., 1999; Sudo et al., 1998) and the previous studies on 
pure neuronal cultures, although providing some answers neglected the effect of the glial 
cells on neuronal survival. In order to investigate the effect of the glial cells, in particular the 
beneficial vs. detrimental role of microglia on neuronal survival, co- cultures of neurones and 
mixed natural glia and astrocytes and microglia alone were established and subjected to 
OGD. The hypoxia experiments that examined the effect of the glial cells in vitro suggested 
that the microglia had a beneficial effect, if only initially on neuronal viability. Although the 
neurones eventually all died by 90 min exposure to OGD it does suggest that the microglia 
were in some way supporting the neuronal cells. If this action of the microglia could be 
enhanced it could not only potentially have a beneficial effect on the outcome following 
insult but also suggests that the neurones that remain viable could also be targeted in an 
attempt to promote their survival. If the microglia are beneficial in the ischaemic brain it 




The main conclusion from this chapter is that FK506 has an effect on microglial activation 
both in vivo and in vitro. In vivo data could suggest that microglial activation is deleterious 
and that deactivation by FK506 could potentially be the mechanism of observed 
neuroprotection. The in vitro ischaemic insult data suggested may that the microglia are 
beneficial immediately following an ischaemic insult. The time and effort spent in 
establishing the ramified microglial cultures was important for other work continuing in the 
laboratory investigating microglial activation. The activation state of the cell assessed by 
morphology was difficult to interpret conclusively but provide a lead for further investigation 





Cytokines are soluble factors, active at picomolar concentrations that can have diverse and 
frequently opposing effects on different cells. They are low molecular weight proteins that 
act as intracellular messengers in growth and differentiation and in immune responses in the 
CNS. They are generally produced in response to tissue injury and inflammation (Legos et 
al., 2000; Rothwell et al., 1996) and orchestrate immune responses of the body (Schobitz et 
al., 1994; Sawada et al., 1995; Kim, 1996; Arai et al., 1990). The term cytokine was initially 
suggested in 1979 by Cohen et al. to define proteins that are derived for cells and influence 
the actions of other cells (Cohen et al., 1979). This terminology united the ideas from as far 
back as the end of the 19`h century that extended well into the 1960s, that molecules in the 
blood secreted by cells of the immune system affected other cell populations both in the 
immune system and outwith. The modern definition of the term cytokine is `an inducible 
polypeptide /protein (glycoproteins) of molecular weight greater than 5 kDa that produces 
specific receptor mediated effects on target cells or on the producer cell' (Henderson & 
Poole, 1994). For a long time, the involvement of cytokines in brain injury was questioned 
(in keeping with the concept of immune privilege of CNS tissue (Becher et al., 2000)) but it 
is now widely held that cytokines have diverse actions in the brain, modulating and 
mediating responses to disease and local changes related to inflammation, injury and 
infection (Rothwell, 1999). 
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The cytokines are classed pro- or anti -inflammatory depending on the sum total of their 
effects on immune cells (Vitkovic et al., 2000). The pro- inflammatory cytokines include 
interleukin -1 ß (IL-1[3), interleukin -6 (IL -6) and tumour necrosis factor a (TNFa) (Clark, 
1997) and are of particular interest in this thesis because of their involvement in the acute 
inflammatory response and their potential role in the development of ischaemic brain 
damage. In the periphery, the biological effects of these particular cytokines include wound 
healing, elimination of antigens, inflammation, vasodilation and haematopoiesis, whilst 
centrally they affect functions such as body temperature, feeding, nausea and sleep (Schobitz 
et al., 1994). The specific role of an individual cytokine can shift from being beneficial to 
deleterious depending on the nature of the pathological state in which cytokines are involved 
(Turrin & Plata -Salaman, 2000; Van Wagoner & Benveniste, 1999). 
The basal levels of expression of the cytokines in the normal brain are low but levels 
increase in response to injury or infection (Yu & Lau, 2000; Sharma & Kumar, 1998; 
Henderson & Poole, 1994; Rothwell, 1999). Cytokines both activate glial cells and cause the 
production and release of other cytokines in response to stimulation in vitro (Arvin et al., 
1996). Cytokines are involved in the development of the nervous system but have also been 
implicated in the pathology of autoimmune diseases of the CNS such as multiple sclerosis. 
Cytokines can enhance inflammation and exert direct toxic effects on cells and thereby 
promote the expansion of lesions playing a key role in the development of damage. 
Alternatively they may also limit the immune response and promote cell growth (Merrill & 
Benveniste, 1996). They are involved in the recruitment of leukocytes and increase the 
expression of adhesion molecules on leukocytes and endothelial cells (Arai et al., 1990; 
Clark et al., 2000). 
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The analysis of cytokine expression following focal cerebral ischaemia sometimes appear a 
confused issue as different authors suggest different time points at which the cytokines are 
first detected, peak and then subside. While these discrepancies may reflect the differences in 
different models and species used, they may be a consequence of the methods used to 
analyse the production and expression of the cytokines. However, the general consensus has 
led to speculation that the early induction of IL -113, IL -6 and TNFa appears to initiate the 
inflammatory cascade following cerebral ischaemia (Kim, 1996). 
THE ROLE OF CYTOKINES IN FOCAL CEREBRAL ISCHAEMIA 
Focal cerebral ischaemia has been shown to elicit a notable cytokine response in the brain 
(Arvin et al., 1996; Clark, 1997). The evidence for the involvement of cytokines in the 
pathology of focal ischaemia comes from clinical studies where elevated levels of the 
cytokines have been detected in the cerebrospinal fluid (CSF) and plasma of stroke patients 
which has been correlated with infarct size (Legos et al., 2000). Evidence from pre -clinical 
studies supports the involvement of the cytokines in ischaemic damage and leads to the idea 
that anti -cytokine strategies may be of use in reducing lesion size. 
INTERLEUKIN-1 E3 
Interleukin -1 exists in two separate isoforms (a and p) which are the products of separate 
genes and play an important role in mediating the acute immune response (Hofman & 
Hinton, 1990). In the periphery, IL -la and IL -113 are believed to exert identical actions 
(Dinarello, 1998). The IL -la isoform remains membrane bound suggesting it has localised 
actions, whereas the 3 form is secreted (Schobitz et al., 1994). Inactive or partially inactive 
precursors are produced by the cells and are then activated by cleavage by specific proteases. 
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Pro -IL -1a is biologically active whereas the IL -1ß precursor is not and must be cleaved by 
IL -lß converting enzyme (ICE) (Rothwell, 1999). IL -1ß is found as an inactive 31 -33 lc Da 
precursor, pro-IL-1[3, which when cleaved produces a 17 kDa mature protein (The Cytokine 
Catalogue 2000). IL-113 expression appears to be associated with an increase in the 
expression of ICE and cleavage of the precursor (Bhat et al., 1996). IL -13 receptor 
antagonist (IL -lra) is an endogenous receptor antagonist that blocks the actions of the IL-1f3 
and IL -1 a in both the periphery and the brain (where it is mainly found in neurones) and 
functions as a very useful pharmacological tool to study IL -1 functions (Rothwell, 1999). A 
third member of the IL -1 family, interferon gamma inducing factor, also known as IL -18, 
was identified and cloned from mouse liver. Due to its close homology with the others 
members of the family, it was termed IL -ly (Bazan et al., 1996). In contrast to the other two 
isoforms, IL- ly /IL -18 is constitutively expressed in the brain (Culhane et al., 1998) although 
the exact function of this cytokine in CNS physiology and pathophysiology has not been 
fully determined (Touzani et al., 1999). 
The ß isoform of IL -1 is constitutively expressed at a low level in the normal brain and is the 
predominate form expressed upon pro -inflammatory stimulation (Eriksson et al., 2000; 
Touzani et al., 1999). IL -lß is thought to be produced by various elements of the CNS 
including neurones, microglia, astrocytes and the endothelium (Rothwell, 1991). In addition, 
mice deficient in the ICE gene have smaller lesions and are not able to process IL -113 and 
have altered expression of ICAM -1 suggesting these two proteins are related following 
ischaemia (Yang et al., 1999). 
At the pharmacological level, IL -1 acts via two main receptors. The type I receptor is present 
in many cells and binds the two isoforms of IL -1 with similar affinity. The type II receptor is 
found on the surface of immune cells such as neutrophils and macrophages and has greater 
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affinity for IL -lß (Dinarello, 1991). The intracellular signal transduction cascade following 
the IL -113 binding to its receptors in immune cells includes a cyclic AMP (cAMP) and 
protein kinase C response followed by protein phosphorylation (Dinarello, 1991). This is 
then followed by the induction of immediate early genes such as c-jun and c-fos (Vitkovic et 
al., 2000). 
Induction of IL -1ß has been demonstrated following both permanent (Buttini et al., 1994; 
Liu et al., 1993) and transient MCA occlusion (Wang et al., 1994a) although attempts to 
detect IL-1P in the blood of stroke patients have not be successful, presumably because the 
levels are low in the plasma (Fassbender et al., 1994). In experimental ischaemia, IL -1ß 
mRNA expression occurs as early as 15 min post -occlusion, peaks rapidly (3 -6 hrs) and 
return to basal levels at 12 hrs in the ischaemic zone. Expression appeared to be more 
pronounced in the transient model (Buttini et al., 1994; Wang et al., 1994a). In a study using 
a multiprobe RNAse protection assay, Hill et al. (1999) showed the temporal expression of 
IL-1P, TNFa and IL -6 in mouse models of focal ischaemia. They demonstrated that TNFa 
and IL -6 were elevated early in both the transient and the permanent model. IL-1P showed a 
temporal shift that was model dependent where reperfusion in the transient model was 
associated with the delayed expression of the cytokine (Hill et al., 1999) (Figure 40). IL-1P 
protein has been shown, by bioactivity assay, to be maximal 6 -8 hours in the ischaemic 
hemisphere following an insult (Rothwell, 1999). Davies et al. (1999) demonstrated by 
immunocytochemistry that IL-1P protein was localised to microglia/macrophages 1 hr 
following permanent MCA occlusion in the rat, with delayed expression associated with 
invading immune cells and astrocytes (Davies et al., 1999). 
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Figure 40. Schematic representation of mRNA expression in the mouse following transient focal 
cerebral ischaemia. Theoretical model of gene expression of the temporal relationship of TNFa, IL-113 
and IL -6. In the permanent model the mRNA of the three cytokines is detected slightly later (Hill et 
al., 1999). 
Experiments in vitro to elucidate the mechanism of IL -1[3 actions in cell death have provided 
conflicting results. In primary neuronal cultures, IL- lra does not inhibit cell death induced 
by NMDA or AMPA receptor agonists nor does IL -113 enhance it (Rothwell, 1999). 
Exogenous IL -113 proved to be neuroprotective in the nM range whereas higher 
concentrations (mM) proved neurotoxic (Rothwell & Strijbos, 1995). In mixed cultures, 
IL -1(3 is toxic at picomolar concentrations, which is thought to be due to the release of 
secondary mediators such as NO and free radicals (Benveniste, 1992; Chao et al., 1995; 
Chao et al., 1996). IL -113 is however not toxic to normal adult brain in vivo (Rothwell, 1999) 
and as always in vitro data should be interpreted with caution. The administration of 
recombinant IL-1[3 prior to MCA occlusion caused increase damage, BBB breakdown, 
leukocyte infiltration and oedema formation whereas antibodies against IL -lß appeared to 
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reduce damage (Yamasaki et al., 1995). Experimental treatment with IL -lra has been shown 
to reduce neurological deficit and infarct size (Relton et al., 1996). 
INTERLEUKIN-6 
IL -6 is a 26 kDa cytokine derived from one gene and first identified as a B cell stimulating 
factor (The Cytokine Catalogue 2000). It is thought to be produced by neurones, astrocytes 
and microglia as well as infiltrating leukocytes, although there is much discussion 
concerning its cellular origin (Loddick et al., 1998; Legos et al., 2000). Its wide range of 
biological actions is similar to those of IL -10 and like IL -113 expression also occurs in 
different models of brain injury. However, in contrast to IL-1[3 and TNFct, it has been 
suggested that IL -6 has both pro- and anti- inflammatory properties (Arvin et al., 1996) with 
both neuroprotective and neurotrophic actions (Block et al., 2000). IL -6 initiates biological 
activity by binding to a high affinity complex of two membrane glycoproteins, low affinity 
80 kDa membrane bound receptor (IL -6R) and a high affinity 130 kDa component (gp130) 
(Clark, 1997). In stroke patients, increased levels of IL -6 have been detected in the plasma 
and CSF and were associated with larger infarcts (Tarkowski et al., 1995). 
In both mixed and pure neuronal cultures, IL -6 dose dependently protected the cultures from 
the NMDA toxicity that was blocked by a competitive IL -6 inhibitor but did not protect 
against serum withdrawal and staurosporine induced apoptotic cell death. These results 
suggest that IL -6 may be involved in endogenous neuroprotection in NMDA mediated injury 
(Ali et al., 2000). It has been suggested that IL -6 may mediate neuroprotection by inhibition 
of IL -1ß production (Schindler et al., 1990) or through the induction of IL- 1ra (Mg et al., 
1994). Cortical neuronal cultures pre -treated with IL -6 were resistant to excitatory amino 
acid induced toxicity (Rothwell & Strijbos, 1995). Higher concentrations of the cytokine 
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have however also been shown to be toxic to cultured cells and mice that overexpress IL -6 
show early neurodegenerative changes (Clark et al., 2000). In studies of neuronal 
regeneration following axotomy in rat facial neurones, IL -6 was shown to be upregulated 
which was associated with a microglial reaction. Regeneration supporting the idea that IL -6 
is beneficial and neuron derived IL -6 causes microglia to proliferate (Streit et al., 2000). 
TUMOUR NECROSIS FACTOR a 
In the periphery, TNFa is involved in septic shock, haematopoiesis and has anti -tumour 
effects and a diverse array of biological activities including acute phase protein secretion, 
vascular permeability and activation of inflammatory cells (Tracey & Cerami, 1993). 
Produced predominately by activated monocytes /macrophages, human TNFa is synthesised 
as a 25 kDa pro -cytokine, which is processed to yield an active 17 lc Da product (Hofman & 
Hinton, 1990). During ischaemia, TNFa is synthesised as a precursor peptide 
pro -TNFa, which is membrane bound and then cleaved by proteolytic enzymes (Shohami et 
al., 1999). TNFa effects are mediated via specific receptors of which the death receptors 
(p75 and p55 proteins) are the best known (Smith et al., 1994). Binding of TNFa to its 
receptors stimulates activation of a variety of kinases via the recruitment of a number of 
adapter proteins and the activates of several transcription factors including NF-KB known to 
be involved in the expression of both adhesions molecules and other cytokines (Heller & 
Kronke, 1994). 
TNFa has been shown to be elevated in several models of brain injury including LPS 
administration, trauma and administration of neurotoxins by RT -PCR, by western blotting 
and by bioactivity assay (Shohami et al., 1999; Shohami et al., 1994; Arvin et al., 1996). 
TNFa plasma levels have been found to be higher in acute stroke patients than control 
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patients supporting its role in the pathology of the disease (Elneihoum et al., 1996). During 
the early phase of indirect brain injury such as that occuring following the facial axotomy, 
TNFa is absent which may suggest that its function is restricted to severe forms of brain 
pathology (Raivich et al., 1999). In a permanent model of cerebral ischaemia, elevated levels 
of TNFa mRNA have been detected in the infarcted zone as early as 1 hr post -occlusion 
(prior to influx of PMNLs), peaking at 12 hrs and persisting for 5 days (similar expression to 
IL -1(3) with no expression in the contralateral hemisphere (Liu et al., 1994). The cellular 
source of TNFa is also a debated topic. Liu et al. (1995) propose that neurones initially 
produce the cytokine followed by infiltrating inflammatory cells whereas others suggest 
neurones, astrocytes and microglia (Botchkina et al., 1997; Liu et al., 1994; Tseng & Chang, 
1999). Uno et al. (1997) reported that TNFa was expressed in both microglia and astrocytes 
but the spatial and temporal expression was different perhaps indicating different functions 
in the release of the cytokines by these two cells types (Uno et al., 1997). Buttini et al. 
(1996) identified the upregulation of TNFa mRNA and protein in activated microglia and 
macrophages (Buttini et al., 1996) suggesting that TNFa is part of the endogenous 
inflammatory response. In this respect, TNFa may play a primary role in setting the stage for 
inflammatory and immune reactions elicited by cerebral ischaemia (Feuerstein et al., 1994). 
TNFa may prime the brain for subsequent damage by activating capillary endothelium to a 
pro- adhesive state (del Zoppo et al., 2000) by upregulating the expression of cell adhesion 
molecules (Arvin et al., 1996). Shohami et al. (1999) suggested that TNFa knockout animals 
showed improvement in function and smaller lesion size initially supporting the toxic nature 
of TNFa acutely but pointed out that the animals greater neurological dysfunction at a later 
point implying that the cytokine may be required for repair mechanisms following the insult 
(Shohami et al., 1999). 
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Studies where TNFa was administered prior to the occlusion of the vessel in ischaemia 
showed exacerbation of damage (Arvin et al., 1996). TNFa antibodies have been shown to 
attenuate tissue damage which strengthens the case for the involvement of the cytokine in the 
development of the lesion (Barone et al., 1997; Lavine et al., 1998; Pettigrew et al., 1999). 
Conversely, evidence from a study in mice showed that when TNFa was pre- administered it 
appeared to have a protective effect against the ischaemic insult (Nawashiro et al., 1997). 
Further evidence for a role of TNFa in ischaemia is supported by findings from studies with 
transgenic animals. Mice lacking both the p77 and p55 TNFa receptors develop greater 
infarcts supporting the protective role of the cytokine (Bruce et al., 1996). Interestingly, the 
microglial immunoreactivity in the TNFa knockout animals was reduced, perhaps 
implicating the cytokine in microglial activation. It has been suggested that TNFa, in a 
beneficial role, may act synergistically with IL-113 to produce NGF and exert neuroprotective 
actions (Gadient et al., 1990) and can induce the production of IL -6 ( Hofuran & Hinton, 
1990). Others, utilising knockout technology, propose that TNFa expression is not related to 
or upregulated by IL -113 (Yang et al., 1999). Like IL -113, TNFa could act as a cytotoxic 
agent or a growth factor as in culture it can cause cells to proliferate or die ( Hofman & 
Hinton, 1990). Recently, Hu et al. (2000) showed IL-1[3 and TNFa together resulted in 
marked neuronal injury through the production of NO (Hu et al., 2000). It has been 
suggested that the appropriate setting of mediators following brain injury determines whether 
TNFa is protective or toxic (Shohami et al., 1999). 
MOLECULAR ANALYSIS OF CYTOKINES 
In summary, the data concerning cytokine expression during and following an ischaemic 
insult is, at best confusing, both in terms of the source and in terms of action. In the previous 
chapter where the microglial response to an ischaemic insult was examined histologically, 
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both in vivo and in vitro, the results were inconclusive. Another approach was sought in 
order to analyse the microglial response. The aim of these experiments was to establish the 
protocol for culturing microglia and assessing their morphology. The response of the cells to 
an LPS challenge was then examined to serve as a benchmark for the cytokine response. The 
aim was then to extend these studies to examine the effect of LPS stimulation in vivo and 
from there into the in vivo stroke models. In both the in vitro experiments and the MCA 
occlusion experiments, the effect of FK506 on the production of cytokines was also of 
interest in an attempt to extend the idea of the drug acting by inhibition of an inflammatory 
response. 
MATERIALS & METHODS 
CYTOKINE mRNA ANALYSIS 
TISSUE PREPARATION FOR RT -PCR 
Brain samples from LPS /saline treated animals 
LPS or saline was administered to experimental animals as detailed in Chapter 2. Animals 
were sacrificed by decapitation and in each case the brain was rapidly removed, placed in a 
brain block and sectioned. The 2 mm section at the level of the MCA was selected and the 
right (ipsilateral in occlusion animals) cortex and striatum and corresponding left 
(contralateral in occlusion animals) regions were dissected out and snap frozen. Samples 
were stored at -70 °C until required. Tissue was thawed on ice in 350 µl of Buffer RLT 
(Qiagen). Samples were homogenised using a rotor stator homogeniser (Powergen 35, Fisher 
Scientific) and the lysates stored at -70 °C. When required, the frozen lysates were thawed, 
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incubated at 37 °C for 10 min and centrifuged at maximum speed for 3 min (eppendorf 
Centrifuge 5415C). The supernatants were retained and used in the subsequent steps. 
Brain samples from MCA occlusion animals 
Brain samples were obtained as described for LPS and saline treated animals detailed above. 
Microglial cell culture samples 
Culture flasks were scraped with a cell scraper (Costar 3010) to remove attached microglial 
cells. The medium was collected and centrifuged at 500 x g for 10 min (Mistral 2000, MSE). 
Supernatants were removed the pellet from centrifugation of the culture medium containing 
microglial cells was disrupted by the addition of the appropriate volume (350 µl) of Buffer 
RLT. Lysates were homogenised using QlAshredder columns (Qiagen) centrifuged at 
maximum speed. 
EXTRACTION OF RNA 
The manufacturer's protocol for the isolation of total RNA using RNeasy reagents (Qiagen) 
was followed. An equal volume of 70 % ethanol was added to the brain tissue supernatants 
and the homogenised microglial lysates and mixed well using a pipette. 700 ¡al of each 
sample was added to an RNeasy mini spin column and centrifuged at 8000 x g for 15 s. Each 
column was washed by addition of 700 µl of Buffer RW1 followed by centrifugation at 
8000 x g for 15 s. The RNeasy columns were transferred to new 2 ml collection tubes and 
500 ml of Buffer RPE added and the columns centrifuged as before. 500 µl of Buffer RPE 
was added to the columns that were centrifuged at maximum speed for 2 min to dry the 
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membranes. Columns were transferred to a 1.5 ml collection tubes and 30 µl of RNase -free 
water added directly to the membranes and centrifuged at 8000 x g for 1 min to elute the 
RNA. An aliquot of each sample was diluted 1:50 in RNase free water and used to quantify 
and determine purity the total RNA by spectrophotometry (Double Beam Spectrophotometer 
CE 594, Cecil Instruments). One absorbance unit at 260 nm (A,60) corresponds to 40 µg.ml"' 
of total RNA and the ratio of the absorbance at 260 nm and 280 nm (A,80) gives an estimate 
of RNA purity. The remaining samples were stored at -70 °C. 
FORMALDEHYDE AGAROSE GEL ELECTROPHORESIS 
The quality and intactness of the extracted RNA was checked on an agarose gel. 
Formaldehyde agarose gels (Appendix 3) were poured, placed in the electrophoresis chamber 
(GibCoBRL Horizon 58, Life Technologies), covered by 1 x RNA running buffer (Appendix 
3) and the samples loaded. Gels were run at 1 -5 V /cm (typically 100 V) for approximately 
1 hr. The gel was photographed using a 3UVTM Transilluminator and Polaroid Camera with 
Polaroid Black and White film type 667 (Sigma). 
REVERSE TRANSCRIPTION 
Reverse transcription to synthesise a template (copy DNA, cDNA) for the amplification of 
the genes of interest by polymerase chain reaction (PCR) was performed using 
First -Strand cDNA Synthesis reagents (Amersham Pharmacia Biotech). Total RNA from the 
test sample (1 -5 µg) was placed in a 0.5 ml eppendorf centrifuge tube and RNase -free water 
added to bring the volume to 8 µl. The mixture was heated to 65 °C for 10 min and then 
chilled on ice. The heat denatured RNA was added to 5 of Bulk First -Strand cDNA 
Reaction Mix, 1 µl of DTT solution and 1µl of Not I- d(T)18 at a final concentration of 0.2 
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pipetted gently to mix and incubated at 37 °C for 1 hr. Samples were stored at 4 °C 
until required for PCR. 
OLIGONUCLEOTIDE PRIMERS 
The experiments to analyse inflammatory cytokine expression from both microglial cultures 
and rat brain tissue required oligonucleotide primers for 3 cytokines of interest to be 
designed. The primers for IL -13, IL -6 and TNFa were based on the sequences in a paper by 
Delgado -Rizo et al. (1998) (Appendix 3) (Delgado -Rizo et al., 1998). The primers were 
designed to contain a high GC component because of the stability this lends to the annealing 
steps of the PCR process as a consequence of the triple bonds formed they form. The 
sequences were also chosen to limit primer dimer formation. The primers were synthesised 
by Life Technologies. The primers for the (3-actin routinely used in the laboratory were 
purchased from Promega and were based sequences from Yamamura et al. (1991) 
(Yamamura et al., 1991). 
Below are detailed the sequences for the sense and antisense primers for each cytokine, the 
size of the expected fragment in base pairs (bp), the Genbank accession number and the 




Genbank Acc. #: E01884 
Tm 61.9 °C, 59.8 °C 
Sense 5' A GGA TGA GGA AAG A 3' 
Antisense 3' TTT GT GTT A AG T 5' 
Interleukin-6 Genbank Acc. #: M26744 
(496 bp) Tm 59.8 °C. 59.8 °C 
Sense 5' TT A G AGT TG TT T 3' 
Antisense 3' GG GGT TGA AGG TTA GA GAG 5' 
Tumour Necrosis Factor a Genbank Acc. #: X66539 / S40199 
(468 bp) Tm 64 °C, 64 °C 
Sense 5' GA GTG A A AG G TAG 3' 
Antisense 3' GTC GA G A A AGT AGG 5' 
0-Actin (285 bp) Tm 62°C, 65.1°C 
Sense 5' T A TGA AGT GTG A G TTG A A T GT 3' 
Antisense 3' T AGA AG ATT TG GGT G A GA TG 5' 
POLYMERASE CHAIN REACTION 
RT samples were heated at 90 °C for 5 min to denature the cDNA and inactivate the reverse 
transcriptase. A master mix (Appendix 3) was prepared for each cytokine and added to the 
2 -3 Ill of the template to give 50 µl of reaction mix. In each experiment, negatives control 
(no template), positive controls where available and a house -keeping gene (13- actin) were 
included. Reaction mixtures were placed in Hybaid Touchdown PCR machine. Amplification 
conditions were as follows: 94 °C for 5 min (denaturation), 30 cycles of 94 °C for 30 s, 55 °C 
for 1 min, 72 °C for 1 min (denaturation, annealing and polymerisation) and finally 72 °C for 
7 min. 
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AGAROSE GEL ELECTROPHORESIS 
Agarose gels (Appendix 3) were poured, submerged in the electrophoresis chamber 
(GibCoBRL Horizon 11 -14, Life Technologies) in sufficient 1 x 
Tris- [hydroxymethyl]- aminomethane (Tris) acetate EDTA buffer (TAE, Appendix 3) and the 
samples loaded. The gel was run at 1 -5 V /cm typically 100 V for approximately 1 hr. The gel 
was photographed using a 3UVTM Transilluminator and Polaroid Camera with Polaroid 
Black and White film type 667 (Sigma). 
MULTIPLEX PCR ANALYSIS 
The initial experiments with the primers that had been designed in house looked promising 
but the availability of new reagents, the experiments were altered and a multiplex PCR 
(MPCR) system used. This allowed analysis of a number of genes in a single reaction 
thereby increasing output. 
Total RNA was extracted, purified and quantified as described before using RNeasy reagents 
(Qiagen). MPCR reactions were set up with the test samples and the positive control 
(supplied), MPCR buffers (Appendix 3) and the appropriate primer mixtures from the 
Multiplex PCR Kit for Rat Inflammatory Genes Set 1 (rINF1G -MPCR Cat #: INF- M210G, 
Maxim Biotech, Inc., USA). 
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rINF1G -P001 10x rINF1G MPCR Rat Primer Mixture 
rINF1G-GMC (GM-CSF) 
rINF1G-TGF (TGF-(3) 
rINF1G- IL1 (IL-lß) 
rINF1G-TNF (TNFa) 
rINF 1 G-IL6 (IL-6) 
rINF1G-GAP (GAPDH) 
PCR Product Size Genbank Acc. # Tm (°C) 
210 bp U00620 68.5, 71 
250 bp X52498 66.3, 69 
294 bp M98820 66, 69 
351 bp X66539 70.4, 69.8 
453 bp M26744 66.4, 68.2 
532 bp M17701 64, 65 
A `hot start' PCR protocol was used. Amplification conditions were as follows: 2 cycles of 
96 °C for 1 min, 59 °C for 4 min followed by 30 cycles of 94 °C for 1 min, 59 °C for 2.5 min, 
70 °C for 10 min and finally a 20 °C soak. The products of the MPCR were separated by 
electrophoresis on a 2 % agarose gel and the photographed as previously. 
`QUANTIFICATION' OF MPCR ELECTROPHORESIS 
A system was devised to interpret the results of the MPCR electrophoresis to allow graphical 
analysis of the gels. Ideally analysis of gene products run on electrophoretic gels should be 
quantified with equipment such as a phosphoimager. At the time of these experiments such 
technology was unavailable in the laboratory. Each gel photograph was analysed by eye by 
two independent observers (Jennifer McCarter and Lorraine Kerr). The expression of each 
gene was independently assessed and assigned a number between 1 and 3 depending on the 
intensity of the band relative to the other bands. Results from the two observers were then 
compared, all bands were then normalised against the GAPDH signal and plotted using 
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SigmaPlot. The use of GAPDH as a house -keeping gene has been demonstrated previously 
and is a valid marker against which expression can be normalised (Chapman et al., 2000). 
CYTOKINE WESTERN ANALYSIS 
TISSUE PREPARATION FOR WESTERN ANALYSIS 
Brain samples from MCA occlusion animals 
Tissues from MCA occlusion operated and sham animals for western analysis was obtained 
in the same manner as described in Tissue Preparation for RT -PCR. For homogenisation, 
samples were thawed on ice, homogenised with a hand -held homogeniser (Kontes) in 50 µ1 
of extraction buffer (EB) (Appendix 4). 2 pl of homogenate was withdrawn for a protein 
assay and the remaining homogenate stored at -70 °C. 
Microglial cell culture samples 
Culture flasks were scraped with a cell scraper (Costar 3010) to remove attached microglial 
cells. The medium was collected and centrifuged at 500 x g for 10 min (Mistral 2000, MSE). 
Supernatants were removed and retained and the pellet homogenised with a hand -held 
homogeniser in 30 pl of EB. Again 2 pl of homogenate was withdrawn for a protein assay 
and the remaining homogenate stored at -70 °C. 
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PROTEIN ASSAY 
2 pl of each homogenate was diluted 1:50 in EB containing no inhibitors or PMSF. 
Colourimetric bicinchoninic acid (BCA) protein reagent (Pierce and Warriner UK Ltd) was 
used to determine protein concentration. 10 pi of supernatant was incubated with 200 pl of 
BCA reagent (mixed 1:50 as per instructions) at 37 °C for 30 min. All samples were assayed 
in duplicate and EB was used as a blank. BSA protein standards (supplied with BCA 
reagent) were included on the microtitre plate (0.03 -1 mg.m1 -1). Colour changes were 
measured at 560 nM in a Dynatech MRX machine and Revelation software. 
WESTERN BLOTTING 
For each immunoblotting experiment, a 12 % acrylamide gel with a 4 % acrylamide stacking 
gel was placed in Hoefer Mighty Small SE250 /SE260 mini -gel apparatus with running buffer 
(Appendix 5). Samples for analysis, previously diluted in sterile PBS and aliquotted to give 
60 µg of protein per lane and stored at -70 °C, were defrosted on ice. Rat recombinant 
cytokine standards, IL-1[3, IL -6 and TNFa (R &D Systems), were diluted from the relevant 
stock solutions to give 10, 20 and 25 ng respectively (appropriate protein concentration to 
allow detection). The volume of the samples and standards was doubled with sample buffer 
(Appendix 5) and all were heated to 95 °C in Hybaid PCR machine for 20 min, subjected to a 
pulse spin and loaded onto the gel. Full range colour molecular markers (Amersham RPN 
756) were loaded. 
The gels were routinely run at 70 V initially and then at 150 V (Hoefer Mighty Slim SX250) 
for 2 -3 hrs. The gels were removed, rinsed gently in transfer buffer (Appendix 5) and placed 
on prepared Millipore Immobilon -P polyvinylidene fluoride membrane (PDVF, 0.45pm) 
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between filter paper soaked in transfer buffer. Each gel sandwich was placed in the semi -dry 
transfer apparatus (Sigma- Aldrich) which was run at 15 V for 1 hr. Membranes were 
removed from transfer apparatus and placed in 5 % milk powder (BioRad) in Tris buffered 
saline -Tween 20 buffer (TBST, Appendix 5) for 1 hr at room temperature on a rotating 
platform to block non -specific sites. Initially, blotted gels were stained with Coomassie 
Bright Blue (Sigma) or silver stained (Appendix 5) to confirm effective protein transfer to the 
membrane. 
Following blocking, membranes were incubated with appropriate anti -rat anti -cytokine 
antibodies (R &D Systems) diluted 1:500 (final concentration of 0.4 mg.mF') in TBST /milk 
powder overnight at 4 °C on rotating platform. Membranes were washed twice (2 x 10 min) 
in TBST and then incubated with an anti -goat/sheep IgG peroxidase conjugate monoclonal 
secondary antibody (Sigma, 1:10 000 in TBST /milk powder) for 2 hr at room temperature on 
rotating platform. Membranes were washed twice (2 x 10 min) in TBST and then in TBS pH 
8. Protein bands on the membranes were visualised LumiGLO (New England BioLabs Inc.) 
and Hyperfilm ECLTM (Amersham 3114H). 
CYTOKINE ENZYME -LINKED IMMUNOSORBENT ASSAY 
Brain tissue samples were collected as described previously (see Tissue Preparation for 
RT- PCR/Western Analysis). Each sample was homogenised with a hand -held homogeniser in 
100 pi extraction buffer containing no inhibitors (Appendix 4) and then centrifuged briefly 
(Micro Centaur, MSE). Supernatants from each sample were collected and assayed to 
establish protein concentration (see Protein Assay). 
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Cytokine ELISA assays were performed using Quantikine® M Murine Rat IL -13 (RTA00) 
and TNFa (RLBOO) Immunoassay reagents (R & D Systems) according to the 
manufacturer's protocol (Appendix 6). Briefly, 50 gl of appropriate Assay Diluent was added 
to each well of a microplate pre- coated with cytokine monoclonal antibody for relevant 
cytokine followed by 50 pl cytokine standard or sample (150 gg of protein added per well) 
in duplicate, covered with an adhesive strip and incubated for 2 hrs at room temperature. 
Each well was aspirated and washed 5 times with 350 µl of Wash Buffer. Rat antibody 
conjugate (100 µl) for either IL -1ß or TNFa was added to the wells in the microplate that 
was covered and incubated at room temperature for 2 hrs. The aspiration/wash step was 
repeated followed by the addition of 100 ml of Substrate Solution and 30 min incubation at 
room temperature. The reaction was halted by the addition of 100 µl of Stop Solution and the 




CYTOKINE mRNA ANALYSIS 
Initial experiments using the primers that had been designed and synthesised were promising 
(Figure 41). Cortical tissue from the LPS treated animals showed gene fragment products 
corresponding to the sizes expected (-522 bp for IL-113; -496 bp for IL -6 and 285 bp for 
ß- actin). However, no clear signal was seen for TNFa suggesting that either the 
amplification conditions were not optimal and would need refining or that there was no 
TNFa response. For each cytokine, a non -reverse transcription sample and control water 
sample was included confirming no contamination of the samples during the assay. The 
presence of the f3-actin fragment as a house -keeping gene also confirmed successful reverse 
transcription from the mRNA. 
In 1999, multiplex PCR reagents for the cytokines of interest became commercially 
available. A principle advantage of multiplex assays is that they permit the analysis of a 
number of gene products from a single sample and reduce tissue required. Initial results with 
the MPCR reagents using LPS /saline treated rat brain tissue confirmed the results from the 
earlier experiments with the primers designed in -house (Figure 42). In the LPS stimulated 
tissue, IL -6, TNFa and IL -1ß at 3 hrs post stimulation. The detection of a TNFa response 
using the MPCR reagents supports the view that the amplification conditions in the initial 
experiments with synthesised primers were not optimal. The effect of LPS on the cytokine 
expression was evident in both cortical and striatal tissue. The expression of TGF-13 was also 
elevated in all regions of the brain following LPS stimulation (Figure 43). 
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The effects of MCA occlusion on cytokine mRNA levels in the cortex (Figure 44) and 
striatum (Figure 46) was then performed using MPCR reagents. In the transient 
monofilament, TNFa expression in the cortex was detected at 3 but not at 24 hrs. There was 
IL-1f1 expression in the transient model at 3 and 24 hrs. There was no expression of IL-113, 
IL -6 or TNFa in the cortex in the permanent model at 3 hrs but both IL -1 f3 and TNFa were 
present at 24 hrs (Figure 45). Interestingly, whilst IL -6 was detected in LPS treated animals, 
it was not detected in either of the MCA occlusion models at either time point. The 
expression of the inflammatory cytokines in the striatum of transient monofilament occlusion 
at 3 hrs was no different from that seen in the sham group. At 24 hrs the expression of IL -6 
and IL -lß had decreased, as had TGF -13. Similarly in the striatum of both the 3 and 24 hr 
permanent MCA occlusion groups, there was no expression of IL -113, TNFa or IL -6 and 
TGF -ß expression (Figure 47). 
MPCR experiments conducted with the microglial cultures showed an increase in IL -6 
expression following LPS stimulation at both 3 and 24 hrs (Figure 48). IL-113, TNFa and 
TGF -ß showed no change in expression levels between the two treatments at 3 hrs although 
there appeared to be an increase at 24 hrs in IL -1ß and TNFa. Granulocyte macrophage 
colony stimulating factor (GM -CSF) expression was increased by LPS administration at both 
3 and 24 hr. The administration of FK506 and its vehicle had little effect on the expression of 
any of the gene analysed at 3 hrs. At 24 hrs post LPS stimulation, FK506 administration 
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Figure 41. Agarose gel photographs showing PCR fragments for IL -1(3 and IL -6 (a) and TNFa and 
[3-actin (b) in rat cortical tissue following saline or LPS stimulation. For each cytokine, a non -reverse 
transcription sample for each treatment group (lanes 4, 5, 9, 10, 16,17, 21, 22) and a control water 
sample (lanes 11, 23) were included. Positive signals are visible in the LPS stimulated tissue for IL-113 
(522 bp; lane 3) and IL -6 (496 bp; lane 8). No clear signals were detected in the TNFa sample (lane 
15) suggesting that the amplification conditions were not optimal. A 285 bp fragment for the 
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Figure 42. Agarose gel photograph showing the results of multiplex PCR for the inflammatory 
cytokines in tissue from an LPS and saline treated rat. 
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Figure 43. Graphical analysis of MPCR electrophoresis gel showing expression of inflammatory 




















Figure 44. Agarose gel photograph showing the results of multiplex PCR for the inflammatory 
cytokines in the cortex of animals subjected to sham, transient (TMF) and permanent (PMF) 
monofilament MCA occlusion (3 and 24 hrs). 
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Figure 45. Graphical analysis of MPCR electrophoresis gel showing expression of inflammatory 
cytokines in the cortex following sham, transient (TMF) and permanent (PMF) MCA occlusion at 3 



















Figure 46. Agarose gel photograph showing the results of multiplex PCR for the inflammatory 
cytokines in the striatum of animals subjected to sham, transient (TMF) and permanent (PMF) 
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Figure 47. Graphical analysis of MPCR electrophoresis gel showing expression of inflammatory 
cytokines in the striatum following 3 hrs of LPS stimulation. 
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CYTOKINE WESTERN ANALYSIS 
Having demonstrated changes in cytokine mRNA expression by MPCR following LPS 
administration and in ischaemic tissue, subsequent studies were performed to determine 
whether the message (mRNA) detected was translated into protein in the ischaemic brain. 
However, western analysis experiments looking at cytokine expression produced no 
conclusive results. The technology for western blotting is well established within the 
laboratory and was therefore not thought to be the problem with obtaining results. Initial 
experiments were conducted using antibodies raised against the cytokines supplied by 
Stephen Poole at the National Institute of Biological Standards and Controls. New antibodies 
for each cytokine were obtained, together with recombinant protein control samples, but the 
experiments were still unsuccessful. Fresh secondary antibodies were also purchased with 
little success. Commercially available antibodies with corresponding recombinant protein 
positive controls were purchased from R &D Systems. Experiments with these reagents gave 
mixed results where, on majority, of occasions even the positive control was not apparent. 
In an attempt to overcome these difficulties, assay conditions were altered (BSA in place of 
Blotto as blocking agent in TBS), concentrations of both primary and secondary antibodies 
was increased, adequate transfer from gel to membrane was confirmed by Coomassie and 
silver staining, concentration of protein loaded was increased, protein samples in loading 
buffer were heated at 95 °C for given periods of time, different membranes were tried (PDVF 
and nitrocellulose), different visualisation reagents (Enhanced Chemiluminescence (ECL) vs. 
LumiGLO) and higher sensitivity film were used to achieve a signal, all with little success. 
Occasionally bands were seen on the gel for IL -1 ß at 33 kDa, which may correspond to the 
precursor protein, but again this was not consistently seen. 
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CYTOKINE ENZYME -LINKED IMMUNOSORBENT ASSAY 
The availabilty of improved ELISA reagents for the measurement of the cytokines of interest 
in 2000 led to the analysis of IL -113 and TNFa using this technology. Data from an ELISA 
that discriminated between the pro- and mature forms of the proteins would provide the most 
conclusive answers to questions regarding the expression and functional status of the 
proteins following injury. IL-1[3 reagents for the human isoform of cytokine are available and 
although not available for the rat isoform, they are currently in development. At the time of 
the experiments for this thesis, rat IL -6 reagents were not available. 
Data from experiments on tissue from MCA occlusion experiments showed an IL-1[3 
response when assayed at 3 and 24 hrs post -insult with a more pronounced response at 24 
hrs. The transient model tended to produce a greater response at both time points although 
not significantly different from the other models (Figure 50). The administration of FK506 
appeared to have no effect on the expression of IL-1f3 in either the transient or the permanent 
model at either time point. Analysis of TNFa expression in the same models suprisingly 
showed that there was no expression of the cytokine following an ischaemic insult in any 
model or following any treatment (Figure 51). LPS treated tissue was included as a positive 
control for both IL-1[3 and TNFa and confirmed the ability to detect increase protein levels 
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Figure 50. Concentration of IL-113 ( pg.mg of protein-) detected by ELISA following 3 and 24 hrs 
sham, permanent and 2 hr transient MCA occlusion (n = 3 for each) with and without FK506 
treatment. Data represent mean ± sem. (* p < 0.05, 2 -way ANOVA with post hoc Student- Newman- 
Keuls test). 
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Figure 51. Concentration of TNFa (pg.mg of protein-) detected by ELISA following 3 and 24 hr 
sham, permanent and 2 hr transient MCA occlusion (n = 3 for each) with and without FK506 




There is still much controversy regarding both the role and origin of cytokines in cerebral 
ischaemia (Yu & Lau, 2000; Legos et al., 2000; Zhai et al., 1997; Sharma & Kumar, 1998; 
Yamasaki et al., 1996). Dissection of the cytokine response following brain injury appears to 
be a complicated quest and to date no non -invasive methods of cytokine detection and 
quantification have been devised (Vitkovic et al., 2000). The experiments performed in this 
thesis concentrated on the microglial cells in order not only to characterise their 
morphological response (Chapter 5) but also establish the molecules they release in a 
pathological situation and extend this to stroke tissue. As discussed in the previous chapters, 
microglia respond within minutes of an ischaemic insult and are a potential source of the 
pro -inflammatory cytokines. They are therefore considered to be deleterious cells. Recently 
Vitkovic et al. (2000) detected IL- 1 ß immunoreactivity in the human brain and localised 
expression to the glial cells of the cortex and not the neurones (Vitkovic et al., 2000). A 
therapeutic agent directed at the microglia that could `switch off', attenuate the cellular 
response in pathological situations, or alternatively target the release of molecules such as 
the cytokines could be useful in the management of ischaemia. Potential points of 
intervention in cytokine signalling cascades include the modulation of activation, modulation 
of pathways of synthesis and processing, antagonism or neutralisation of soluble cytokines in 
blood or extracellular fluid or the modulation of signalling pathways in the target cells 
(Henderson & Poole, 1994). These approaches require some knowledge of the temporal 
response of cytokine production following an ischaemic insult. Analysis of gene expression 
following the manipulation of a biological system is important in terms of characterising the 
response and provides a starting point for further investigation. It is important however to 
note that the presence of mRNA does not always imply that the protein coded by the 
message is present. This strengthens the need for conformation of translated protein in the 
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tissue by techniques such as western analysis or ELISA. Another consideration regarding 
protein is whether it is functional, particularly in a disease setting and can be assessed by 
bioassay. 
The analysis of the mRNA for the pro -inflammatory cytokines was initially conducted in 
LPS stimulated rat brain in order to prove that the technology employed detected the relevant 
genes of interest and changes therein. Two of the three primers designed and used initially 
for RT -PCR on LPS stimulated tissue would have been suitable for analysis of the responses 
in ischaemic tissue once optimal conditions had been established. The availability of the 
multiplex PCR system however allowed the analysis of a number of genes of interest in one 
reaction thereby saving tissue, reagents and time. The graphical analysis of the 
electrophoresis gels although not ideal, allowed the results to be interpreted. Quantification 
of PCR products can be done using equipment such as a phosphoimager or machines such as 
Taqman (Applied Biosystems) but at the time these experiments were performed such 
equipment was not available in the laboratory. 
LPS stimulated tissue was again used to prove that the system was able to detect the genes of 
interest before the analysis of MCA occlusion tissue. LPS administration (3 hrs) caused 
changes in gene expression in cytokines with the most notable increase in IL-1[3, particularly 
in the striatum. Eriksson et al. (2000) suggested that LPS could cause stimulation by either 
passing through the blood brain barrier and having a direct effect on cells of the parenchyma 
or by causing the release of the cytokines from microglia which have been activated by 
factors released from the endothelium (Eriksson et al., 2000). IL -6 and TGF -ß were detected 
in both the cortex and the striatum following LPS administration. Multiplex PCR 
experiments were also performed on the in vitro microglia that had been exposed to LPS for 
3 or 24 hrs. The only changes detected at 3 hrs were an increase in IL -6 and GM -CSF 
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expression. The administration of FK506 to the cultures appeared to have no effect at 3 hrs. 
At 24 hrs the only detectable change is a reduction in the level of IL -6. 
Experiments were conducted on ischaemic tissue from both the transient and permanent 
monofilament model and on microglial cells in culture. In the initial experiments 
contralateral hemisphere tissue was included and no changes in expression were noted and 
therefore only ipsilateral cortical and striatal tissue was analysed in subsequent experiments. 
Although other researchers have noted changes in gene expression in the contralateral 
hemisphere, damage was not routinely detected. Changes that can occur contralaterally may 
be the consequence of physical deformation of the contralateral hemisphere by oedema 
within the ischaemic hemisphere (Loddick et al., 1998). Although changes contralaterally to 
the lesion occur, the ipsilateral hemisphere is the main site of ischaemic damage and these 
studies focused primarily on changes detected in this tissue. This decision is supported by 
data from Jander et al. (2000) who showed that showed no changes in cytokine expression in 
the contralateral hemisphere using quantitative RT -PCR (Jander et al., 2000). 
Analysis of the genes expressed in the cortex of the transient and permanent models and 
associated shams at 3 and 24 hrs revealed that TNFa was produced at 3 hrs in the transient 
model but only at 24 hrs in the permanent occlusion model. 1L-113 expression in the transient 
model was greater than both the sham and the permanent occlusion model. These results 
could suggest that an inflammatory response occurs more rapidly in the transient model, 
which would be consistent with an endogenous cell response associated with reperfusion 
(Legos et al., 2000). The greater IL -113 response at 24 hrs in the transient model and delayed 
expression of TNFa and IL-1I3 in the permanent model could be associated with an 
exogenous infiltrating peripheral cell response. In the striatal tissue, both the sham and the 
transient model showed identical expression of the cytokines of interest at 3 and 24 hrs 
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although there was no IL -6 expression in either of these experimental groups at 24 hrs. The 
IL -6 gene expression differs from that seen by other investigators at 24 hrs (Hill et al., 1999). 
This may not be that surprising as the striatum is the region that does experience the most 
severe reduction in blood flow following MCA occlusion. Expression in the sham animals is 
more difficult to explain however the brain is exquisitely sensitive to changes and all 
experimental procedures do perturb it in some manner which may potentially cause a minor 
induction or upregulation of the cytokines (Vitkovic et al., 2000). In the permanent model, 
no cytokines except TGF -ß were detected at 3 or 24 hrs. This observation could be explained 
by absence of cells in the tissue capable of producing the cytokines. It is worth considering 
that the evolution of the penumbra is a dynamic three- dimensional event and this may be 
sampled differently in different experimental subjects. The detection of TNFa mRNA at 3 
hrs post -insult is consistent with other reports of early detection (Liu et al., 1994). 
TGF -ß was only analysed because it was included in the reagents chosen in order to examine 
IL -1 ß, TNFa and IL -6. TGF -ß has been suggested to play an anti -inflammatory role in tissue 
modelling following ischaemia and be involved in tissue remodelling (Lehrmann et al., 
1995). Previous studies have showed that it shows a more delayed expression that than 
IL -1ß, TNFa and IL -6 and parallels the accumulation of monocyte /macrophages in the 
ischaemic cortex (Wang et al., 1995a). The observations here regarding TGF-13 suggest that 
it is expressed as early as 3 hrs. Lehrmann et al. (1998) showed by immunohistochemistry, 
that TGF -ß mRNA was localised to the microglia (Lehrmann et al., 1998). 
In summary, the analysis of cytokine mRNA expression in these experiments demonstrated 
that ability to detect the responses described above. The expression of the cytokines 
following LPS administation was different to that seen in the stroke tissue which is not 
unsurprising given the different nature of the cellular challenge. For the in vivo experiments, 
tissue from one animal of each experimental group was used in the multiplex PCR 
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experiments. Ideally more experiments would be performed for each group to verify the 
observations but the reagents are extremely costly. Pooling tissue was considered but 
discounted because an overall clear cut result could not be guaranteed. IL -13 expression in 
vivo is stimulated by activation of excitatory amino acid receptors by excitotoxins in a 
similar fashion to that seen following ischaemia (Pearson et al., 1999). In a recent study, 
Jander et al. (2000) demonstrated for the first time that cytokine induction following 
ischaemia is by NMDA receptor signalling pathways. This induction occurrs at sites distant 
from the lesion and was independent of cell death. This observation which strengthen a case 
for cytokines having a protective role depending on the environment in which they are 
expressed (Jander et al., 2000). Infusion of IL -lra with the excitotoxins inhibits brain 
damage implicating IL-1[3 in excitotoxic cell death (Rothwell, 1999). IL -113 has highly 
site -specific neurodegenerative actions in the brain. IL-1[3 injected into the striatum 
exacerbates damage in both the cortex and striatum of rats subjected to MCA occlusion but 
has no effect when administered into the cortex (Stroemer & Rothwell, 1998). Although 
IL -1 a is increased in the brain by stimuli similar to those that induce IL -113 expression it is at 
lower levels and after the 13 isoform and it is suggested that IL-1[3 is the primary mediator of 
neurodegeneration (Rothwell, 1999). 
The present data regarding IL -6 expression differs from that seen by others. In the rat, IL -6 
mRNA is detected at 3 hrs after permanent MCA occlusion peaks at 12 hrs and remains high 
for at least 24 hrs (Wang et al., 1995b). Ali et al. (2000) showed upregulation of IL -6 mRNA 
following ischaemia with no effect on the transcription of its receptors (Ali et al., 2000). It 
has been reported that IL -6 expression levels are highest in ischaemia reperfusion models 
(Clark et al., 2000) with a peak in the cortical regions at 24 hrs (Suzuki et al., 2000). The 
rapid induction of IL -6 suggests that it is produced by the resident cells of the brain and not 
infiltrating cells (Loddick et al., 1998) although the peak at 24 hrs would suggest circulating 
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cell contribution. Suzuki et al. (1999) demonstrated IL -6 expression in reactive microglia 
and neurones but stated that the main localisation of the protein was in neurones (Suzuki et 
al., 1999). IL -6 expression in the ischaemic penumbra occurs at 1 day post insult and is 
localised to the microglia although neurones have been shown to express the protein under 
certain pathological conditions (Block et al., 2000). Transgenic animals with the IL -6 gene 
deleted have an attenuated astrocytic response (assessed by GFAP staining) following an 
ischaemic insult with a more moderate reduction in microglial activation. In another study, 
mice lacking IL -6 were no different in terms of infarct size and neurological function when 
subjected to transient ischaemia. The authors interpreted this observation as IL -6 having no 
influence on ischaemic injury although the cytokine could have an effect on the long -term 
recovery following ischaemia. In the IL -6 knockout animals the levels of expression of the 
other cytokines (IL -1(3 and TNFa) were less suggesting that IL -6 may enhance the 
expression of these cytokines via positive feedback mechanisms. This decreased 
inflammatory response was however not associated with a reduction in ischaemic injury 
(Clark et al., 2000). Experimentation with transgenic animals has been one method used to 
study the cytokine function in the pathophysiology of ischaemia however knock out animals 
have shown that compensatory mechanisms exist and the results should be interpreted with 
caution (Turrin & Plata -Salaman, 2000). Loddick et al. (1998) demonstrated that IL -6 
bioactivity increases following permanent MCA occlusion peaking at 24 hrs and proposed a 
neuroprotective role for the cytokine that has been suggested by others (Beamer et al., 1995; 
Clark et al., 1999). They also demonstrated that the administration of exogenous IL -6 
reduced ischaemic damage (Loddick et al., 1998). Suzuki et al. (2000) speculated that 
activated microglia seen following ischaemia area are a secondary source of IL -6 and may be 
associated with neuroprotection (Suzuki et al., 2000). 
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Experiements to detect the presence of protein in LPS stimulated and ischaemic tissue were 
performed once analysis of cytokine expression at the message level had been established. 
The failure to achieve any results with the Western analysis was disappointing although it is 
well recognised that the detection of cytokines by this method is notoriously difficult 
(Rothwell et al., 1996). A number of different approaches of tissue preparation were used, 
conditions for incubations altered and detection system changed with little success. Again 
time constraints limited the pursuit of this technique. ELISA experiments for the cytokines 
were not used initially because of the inability to distinguish between the pro- and mature 
forms of the proteins, in particular IL-1[3. Recently ELISA assays have been produced that 
do detect the different forms of the protein and are currently being set up for use in the 
laboratory. As mentioned previously analysis of IL -6 by ELISA was not performed because 
at present there are no reagents available. At the time of experimentation the IL-113 reagents 
for the rat isoforms were not available but were being developed. The experiments with the 
available reagents were performed with a view to completing the experiments when the 
improved reagents were obtainable. Legos et al. (2000) showed for the first time that the 
temporal changes in IL-113 protein assessed by ELISA following MCA occlusion were 
consistent with published data on the upregulation of the cytokine's mRNA. They also 
demonstrated that the later larger elevation of IL -1f3 protein at 3 days post- occlusion was 
associated with the influx of inflammatory cells (Legos et al., 2000). 
ELISA experiments were not performed on cultured microglial cells as these studies were 
being undertaken by Mrs Eliane Chirnside, working on a parallel project. Both IL-1[3 and 
TNFa were detected in the ischaemic tissue using the ELISA. LPS was again included as a 
positive control. The increases in the IL -lß protein mirrored the increase in mRNA detected 
by MPCR with detection at 3 hrs and a greater response seen at 24 hrs. In contrast, 
the TNFa 
data was surprising as the MPCR data showed the presence of mRNA 
but no protein was 
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detected at either 3 or 24 hrs. This observation may be explained by inability of the 
compromised cells in the ischaemic tissue to translate the message into protein. Protein 
translation requires ATP which may be limited and intact translation machinery that may be 
damaged following the reduction of blood flow (Sharp et al., 2000; Krause & Tiffany, 1993). 
Differences in IL -113 and TNFa protein translation may be explained by different sensitivites 
of the associated enzymes in the ischaemic environment. There were also discrepancies in 
the data for the permanent monofilament model. Analysis of the mRNA showed an IL -113 
and TNFa response at 24 hrs only whereas IL-113 was detected following permanent 
occlusion at 3 hrs by ELISA and no TNFa was detected at all. 
CONCLUSIONS 
The main conclusion that can be drawn from the observations concerning the cytokine 
expression in this chapter is that while there is a notable response, it has been difficult to 
quantify and assess. The data from the in vivo experiments tend to suggest that cytokines are 
expressed earlier in the transient model and may therefore be an endogenous response 
whereas the later response in the permanent model would fit with the infiltration of 
peripheral inflammatory cells. It has also been demonstrated that the cytokine response to 
LPS is different to that observed following an ischaemic insult. The data shows, not 
unsurprisingly that dead cells (i.e. those in the ischaemic core) do not produce cytokine 
mRNA and that the presence of a message does not necessarily equate with protein 
expression. The microglia do appear to be a source of cytokines following LPS stimulation 
and the natural extension of these experiments would be to examine the cytokine response 
following an anoxic insult. 
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CHAPTER 7 
General discussion & summary 
The inflammatory response to cerebral ischaemia is a complex interaction diverse of 
signalling pathways involving the cells of the brain parenchyma, which occurs in a 
compromised setting for cell survival. The dissection of the components of this response has 
proven challenging but has been approached in a systematic manner in order to establish the 
contribution of various elements of the response to the pathophysiology. The flow diagram 
shows a schematic representation of the thesis rationale (Figure 52). 
Initial experiments established both the rat permanent and transient monofilament model of 
MCA occlusion and compared these two models and the Endothelin -1 model of cerebral 
ischaemia, both in terms of volume of damage and oedema. The data revealed that there 
were no significant differences in either parameter but that the administration of FK506 
showed different neuroprotective efficacy of the compound in the different models. In this 
respect, FK506 had a greater protective effect in the transient monofilament model. 
Experiments that examined increasing times of ischaemia suggested that reperfusion was not 
detrimental to the tissue as no differences were observed in lesion volume. The unequal 
neuroprotective effect of FK506 in transient and permanent model appeared to reflect 
differences in tissue response associated with reperfusion and reperfusion -linked differences 
in the inflammatory response following vessel occlusion. The Endothelin -I model was not 
included in further studies although it is considered to be a permanent occlusion (Sharkey et 
al., 1994). The duration of the ischaemia is uncontrolled and there is a gradual return 
206 
COMPARISON OF ANIMAL MODELS OF 
FOCAL CEREBRAL ISCHAEMIA 
NO DIFFERENCES IN 
VOLUME OF DAMAGE 
FK506 HAS A GREATER EFFECT IN 
THE TRANSIENT MODEL 
DIFFERENCES IN NEUROPROTECTION MAY BE ASSOCIATED WITH 
MODEL - REPERFUSION COMPONENT 
LINK BETWEEN REPERFUSION AND 
INFLAMMATION 
? MECHANISM OF ACTION ? 












CELLS -* MICROGLIA 
RESPOND RAPIDLY TO INSULT 








of blood between 3 and 6 hrs post -occlusion which would further complicate analysis. The 
neuroprotective efficacy of the FK506 in the Et -1 model was however similar to that of the 
transient model suggesting that there is reperfusion in the model or perhaps residual blood 
flow. 
The hypothesis that FK506 affected components of the inflammatory response that is 
intimately associated with reperfusion was pursued. The rapid response of the microglia in 
white matter to an ischaemic event and the sensitvity of this response to FK506 in vivo, 
implicated these cells in the damage process of ischaemia and highlighted them as prime 
targets for therapeutic manipulation. However, when this response was investigated in vivo 
by immunohistochemistry and Western analysis the results were inconclusive. LPS which 
initiates an inflammatory response in the brain, was used as a positive control throughout 
these experiments. The analysis of the microglial response to LPS was conducted in vitro 
both morphologically and by immunohistochemistry with little success and was followed by 
the analysis of genes potentially upregulated by an ischaemic insult. The studies, although 
not conclusive, demonstated that FK506 had an effect on the morphology of the microglia 
and an alternative approach to analysing the activation of the cells was sought. The 
neuroprotective efficacy of doxycycline and its effect on microglial morphology was also 
examined. The compound proved to be neither neuroproective nor alter the microglial 
response to an ischaemic insult which contrasts with exisiting data. 
Expression of the genes of the pro- inflammatory cytokines (IL -1 ß, IL -6 and TNFa) was 
performed using multiplex polymerase chain reaction on the premise that if the genes where 
expressed that the corresponding protein should, in theory, be detectable. Cytokine gene 
expression in microglia was altered by LPS stimulation and established. The technology 
(MPCR) used was then applied to the tissue from animals that had been subjected to both 
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permanent and transient MCA occlusion. The initial aim of simplification of the analysis to 
the gene level was to allow analysis to be conducted in reverse ultimately leading back to the 
in vivo setting. The LPS stimulated expression not only allowed detection and validation of 
the technology used but showed a different response to that seen following ischaemia. 
ELISA experiments for IL -1 ß and TNFa provided information regarding their expression in 
ischaemic tissue. IL -113 was detected at both 3 and 24 hrs post -insult with a greater response 
noted at 24 hrs. This expression could be linked to the infiltration of peripheral immune cells 
such as leukocytes. No TNFa response was detected despite the presence of mRNA. There 
was no difference in expression of the cytokines between models and FK506 administration 
had no effect on expression. 
The conclusions that can be drawn from the work in this thesis suggest that there is a small 
but detectable inflammatory response to focal cerebral ischaemia. The microglial data could 
suggest their involvement in an acute response that may be FK506 sensitive but because the 
experiments are performed at the limits of the technology, it is difficult to give a definitive 
answer. The inflammatory response shown by IL -1 f3 expression at 24 hrs is possibly an 
exogenous response and targeting this may be beneficial but is generally regarded to be 
outwith the therapeutic window for neuroprotection. There are differences in the cellular 
response to reperfusion and this involves components of the inflammatory cascade in the 
different models of focal cerebral ischaemia but the differences do not affect the ultimate fate 
of the cells. It does however provide avenues for therapeutic intervention. In situations where 
reperfusion is established the tissue appeared to be more amenable to neuroprotection by 
FK506 and it is possible that this is associated with the blockade of inflammatory 
mechanisms. 
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Much of the analysis conducted during this thesis could now be done differently with the 
availability of new technology and advances in experimental techniques. New antibodies that 
distinguish the mature and precursor forms of the cytokine proteins are now obtainable, 
equipment that allows quantitative analysis of the gene products removing the element of 
subjective analysis of the experiments and machines that analyse and quantify Western 
analysis gels are now on the market. The work in this thesis has not only investigated the 
role of inflammation, specifically the contribution of the microglia but has established 
models and techniques for studying cerebral ischaemia that have been extended and continue 
to be investigated by others in the laboratory. 
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APPENDICES 
APPENDIX 1 Histology 
PHOSPHATE BUFFERED SALINE (PBS) 
14.5 mM sodium chloride (Fisher) 
11.5 mM disodium hydrogen orthophosphate (anhydrous) (Fisher) 
7.25 mM sodium dihydrogen orthophosphate (anhydrous) (Fisons) 
Dissolved in MilliQ (MO) H2O. pH to 7.4 by addition of NaOH pellets (Fisher). 
4 % PARAFORMALDEHYDE FIX (PFA) 
Dissolve 40 g paraformaldehyde (Fischer) per 1000 ml PBS. Add 2 NaOH pellets. Heat to 
55 -60 °C on stirring hotplate until clear. Cool and pH to 7.4 with HC1. 
PERIODATE- LYSINE -PARAFORMALDEHYDE (PLP) FIX 
Lysine phosphate buffer 0.2 M lysine hydrochloride (Sigma) 
0.1 M disodium hydrogen orthophosphate (Fisher) 
Mixed together 4:1 to get pH 7.4. Doubled the volume with 100 mM phosphate buffer. 
Phosphate buffer 1.48 g.500 ml"' sodium dihydrogen orthophosphate (Fisons) 
5.75 g.500 ml -' disodium hydrogen phosphate (Fisher) 
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4 Paraformaldehyde 8 g.100 ml-' in MQ H2O (Fisher) 
Combined lysine phosphate buffer with paraformaldehyde (3:1) and added 
0.2 g.100 ml-' sodium periodate (BDH Chemicals Ltd, UK). 
GELATIN SUBBED SLIDES 
All slides used for histology were coated with 1 % gelatin (BDH Chemicals Ltd, UK). 5 g of 
gelatin was dissolved in 500 ml MQ H20. Once dissolved 0.5 g chromic potassium sulphate 
(Sigma) was added and the solution filtered. Slides were immersed in the solution for 2 min 
and then dried overnight at 37 °C. 
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APPENDIX 2 Cell Culture 
COMPLETE BASAL MEDIUM EAGLE (BME) 
Basal Medium Eagle (Sigma) 
10 % heat -inactivated foetal calf serum (FCS) (46 -53 °C for 30 min) (GibcoBRL) 
0.5 % glucose (8.3 ml of 30 % stock solution) (Sigma) 
2 mM L- glutamine (Sigma) 
Penicillin -streptomycin (100 U.0.1 mg') (Sigma) 
Heat inactivated FCS, glucose, glutamine and penicillin -streptomycin were added to 500 ml 
Basal Medium Eagles and stored at 4 °C. 
TRYPSIN 
12.5 mg dissolved in 4 ml Hank's Balanced Salt Solution (HBSS; Gibco) and then filtered 
sterilised (Nalgene 0.2 µm syringe filter). 
DNASE 
DNase (10 000 U; Sigma) was dissolved in 3 ml HBSS (Gibco) and filtered sterilised 
( Nalgene 0.2 .tm syringe filter). 1 ml was added to 4 ml trypsin and 2 ml to 8 ml of the 
Complete Basal Medium Eagle. 
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APPENDIX 3 Molecular Biology 
lOx RNA GEL RUNNING BUFFER 
266 mM MOPS (Sigma) 
2.48 g ethylenediamine tetra- acetic acid (EDTA) disodium salt (Fisher) 
2.73 g Sodium acetate (BDH Chemicals) 
Made up to 500 ml with MQ 1120. pH 7.0 with 5 M NaOH (Fisher) and stored at 4 °C 
`LARGE' FORMALDEHYDE AGAROSE GEL ELECTROPHORESIS 
1.5 % AGAROSE IN 1 X RUNNING BUFFER 
2.25 g agarose (Promega) melted in 127.5 ml MQ H2O in the microwave.15 ml 10x RNA gel 
running buffer added and allowed to cool to < 50 °C. 8.1 ml formaldehyde (Sigma) added, 
gel poured and allowed to set. 
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`SMALL' FORMALDEHYDE AGAROSE GEL ELECTROPHORESIS 
1.5 % Agarose in I x Running Buffer 
0.563 g agarose (Promega) melted in 31.9 ml MQ H2O in the microwave. 3.75 ml 10x RNA 
gel running buffer added and allowed to cool to < 50 °C. 2.025 ml formaldehyde (Sigma) 
added, gel poured and allowed to set. 
RNA SAMPLE BUFFER 
100 µ1 10x RNA gel running buffer 
178 .tl formaldehyde (Sigma) 
500 .xl formamide (Promega) 
RNA DYE SOLUTION 
0.1 % Bromophenol Blue (Sigma) 
7.5 % Ficoll (Sigma) 
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MASTER MIX 
For each PCR reaction a master mix including the upstream and downstream primers for the 
gene of interest was made in a final reaction volume of 50 µl. 
1 x PCR buffer (Promega) 
2 mM MgC12 (Promega) 
200 nM dNTPs (deoxyribonucleoside triphosphates, Pharmacia) 
0.5 p.M of upstream and downstream primers (SigmaGenosys) 
2.5U Taq polymerase (Promega) 
MQ H2O 
50X TRIS ACETATE EDTA (TAE) BUFFER 
242 g Tris base (Sigma) 
57.1.ml glacial acetic acid (Fisher) 
100 ml 0.5 M EDTA (Sigma) pH 8 
AGAROSE GEL ELECTROPHORESIS 
0.8 % agarose (Promega) gel for routine electrophoresis and 2 % gel for electrophoresis of 
MPCR products in 1 x TAE (0.4 M Tris acetate; 0.001 M EDTA, Sigma) 
0.8 or 2 g agarose melted with 2 ml 50x TAE and topped up to 100 ml with MQ H2O. 
Allowed to cool to < 50 °C, 3 pi ethidium bromide (EtBr, Sigma; 50 mg.ml -1) 
added, poured 
and allowed to set. 
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MULTIPLEX POLYMERASE CHAIN REACTION (MPCR) MIXTURE 
Reagents supplied with MPCR detailed in Chapter 6. 
30.5 !Al distilled water 
5 id 10x MPCR buffer 
5 µl 10x MPCR primers 
0.5 µl Taq DNA polymerase (Promega) 
5 µl Sample cDNA or 10x control cDNA from kit 
4µl 3.12mMdNTP 
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Nucleotide sequence of interleukin -1 ß (Acc. # E01884). The derived amino acid sequence is 
shown above the nucleotide sequence. Nucleotides are numbered on the left starting from the 
A of the ATG initiation codon. The green boxes denoted the binding sites of the upstream 
and downstream primers for a 522 bp PCR fragment (Delgado -Rizo et al., 1998). 
218 
GGCATAACAGGCTCATCTGGGATCCTCTCCAGTCAGGCTTCCTTGTGCAAGTGTCTGAAGCAGCT 
Met Ala Thr Val Pro Glu Leu Asn Cys Glu Ile Ala Ala Phe Asp Ser Glu 17 
1 ATG GCA ACT GTC CCT GAA CTC AAC TGT GAA ATA GCA GCT TTC GAC AGT GAG 
Glu Asn Asp Leu Phe Phe Glu Ala Asp Arg Pro Gln Lys Ile Lys Asp Cys 34 
66 GAG AAT GAC CTG TTC TTT GAG GCT GAC AGA CCC CAA AAG ATT AAG GAT TGC 
Phe Gln Ala Leu Asp Leu Gly Cys Pro Asp Glu Ser Ile Gln Leu Gln Ile 51 
117 TTC CAA GCC CTT GAC TTG GGC TGT CCA GAT GAG AGC ATC CAG CTT CAA ATC 
Ser Gln Gln His Leu Asp Lys Ser Phe Arg Lys Ala Val Ser Leu Ile Val 68 
168 TCA CAG CAG CAT CTC GAC AAG AGC TTC AGG AAG GCA GTG TCA CTC ATT GTG 
Ala Val Glu Lys Leu Trp Gln Leu Pro Met Ser Cys Pro Trp Ser Phe Gln 85 
219 GCT GTG GAG AAG CTG TGG CAG CTA CCT ATG TCT TGC CCG TGG AGC Ti _ 
Asp Glu Asp Pro Ser Thr Phe Phe Ser Phe Ile Phe Glu Glu Glu Pro Val 102 
270 CC TTC TTT TCC TTC ATC TTT GAA GAA GAG CCC GTC 
Leu Cys Asp Ser Trp Asp Asp Asp Asp Leu Leu Val Cys Asp Val Pro Ile 119 
321 CTC TGT GAC TCG TGG GAT GAT GAC GAC CTG CTA GTG TGT GAT GTT CCC ATT 
Arg Gln Leu His Cys Arg Leu Arg Asp Glu Gin Gln Lys Cys Leu Val Leu 136 
372 AGA CAG CTG CAC TGC AGG CTT CGA GAT GAA CAA CAA AAA TGC CTC GTG CTG 
Ser Asp Pro Cys Glu Leu Lys Ala Leu His Leu Asn Gly Gln Asn Ile Ser 153 
423 TCT GAC CCA TGT GAG CTG AAA GCT CTC CAC CTC AAT GGA CAG AAC ATA AGC 
Gln Gln Val Val Phe Ser Net Ser Phe Val Gln Gly Glu Thr Ser Asn Asp 170 
474 CAA CAA GTG GTA TTC TCC ATG AGC TTT GTA CAA GGA GAG ACA AGC AAC GAC 
Lys Ile Pro Val Ala Leu Gly Leu Lys Gly Lys Asn Leu Tyr Leu Ser Cys 187 
525 AAA ATC CCT GTG GCC TTG GGC CTC AAG GGG AAG AAT CTA TAC CTG TCC TGT 
Val Met Lys Asp Gly Thr Pro Thr Leu Gln Leu Glu Ser Val Asp Pro Lys 204 
576 GTG ATG AAA GAC GGC ACA CCC ACC CTG CAG CTG GAG AGT GTG GAT CCC AAA 
Gln Tyr Pro Lys Lys Lys Met Glu Lys Arg Phe Val Phe Asn Lys Ile Glu 221 
627 CAA TAC CCA AAG AAG AAG ATG GAA AAG CGC TTT GTC TTC AAC AAG ATA GAA 
Val Lys Thr Lys Val Glu Phe Glu Ser Ala Gin Phe Pro Asn Trp Tyr Ile 238 
678 GTC AAG ACC AAA GTG GAG TTT GAG TCT GCA CAG TTC CCC AAC TGG TAC ATC 
Ser Thr Ser Gln Ala Glu His Arg Pro Val Phe Leu Gly Asn Ser Asn Gly 255 
729 AGC ACC TCT CAA GCA GAG CAC AGA CCT GTC TTC CTA 
Arg Asp Ile Val Asp Phe Thr Met Glu Pro Val Se Ser Stop 268 




Nucleotide sequence of interleukin -6 (Acc. # M26744). The derived amino acid sequence is 
shown above the nucleotide sequence. Nucleotides are numbered on the left starting from the 
A of the ATG initiation codon. The red boxes denoted the binding sites of the upstream and 
downstream primers for a 496 bp PCR fragment (Delgado -Rizo et al., 1998). 
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1 AGCTCATTCTGTCTCGAGCCCACCAGGAACGAAAGTCAACTCCATCTGCCCTTCAGGAACAGCT 
Met Lys Phe Leu Ser Ala Arg Asp Phe Gln Pro Val Ala Phe Leu Gly Leu 17 
65 ATG AAG TTT CTC TCC GCA AGA G G GGA CTG 
Met Leu Leu Thr Ala Thr Ala Phe Pro Thr Ser Gln Val Arg Arg Gly Asp 34 
116 ATG TTG TTG ACA GCC ACT GCC TTC CCT ACT TCA CAA GTC CGG AGA GGA GAC 
Phe Thr Glu Asp Thr Thr His Asn Arg Pro Val Tyr Thr Thr Ser Gln Val 51 
167 TTC ACA GAG GAT ACC ACC CAC AAC AGA CCA GTA TAT ACC ACT TCA CAA GTC 
Gly Gly Leu Ile Thr Tyr Val Leu Arg Glu Ile Leu Glu Met Arg Lys Glu 68 
218 GGA GGC TTA ATT ACA TAT GTT CTC AGG GAG ATC TTG GAA ATG AGA AAA GAG 
Leu Cys Asn Gly Asn Ser Asp Cys Met Asn Ser Asp Asp Ala Leu Ser Glu 85 
269 TTG TGC AAT GGC AAT TCT GAT TGT ATG AAC AGC GAT GAT GCA CTG TCA GAA 
Asn Asn Leu Lys Leu Pro Glu Ile Gln Arg Asn Asp Gly Cys Phe Gln Thr 102 
320 AAC AAT CTG AAA CTT CCA GAA ATA CAA AGA AAT GAT GGA TGC TTC CAA ACT 
Gly Tyr Asn Gln Glu Ile Cys Leu Leu Lys Ile Cys Ser Gly Leu Leu Glu 119 
371 GGA TAT AAC CAG GAA ATT TGC CTA TTG AAA ATC TGC TCT GGT CTT CTG GAG 
Phe Arg Phe Tyr Leu Glu Phe Val Lys Asn Asn Leu Gln Asp Asn Lys Lys 136 
422 TTC CGT TTC TAC CTG GAG TTT GTG AAG AAC AAC TTA CAA GAT AAC AAG AAA 
Asp Lys Ala Arg Val Ile Gln Ser Asn Thr Glu Thr Leu Val His Ile Phe 153 
473 GAC AAA GCC AGA GTC ATT CAG AGC AAT ACT GAA ACC CTA GTT CAT ATC TTC 
Lys Gln Glu Ile Lys Asp Ser Tyr Lys Ile Val Leu Pro Thr Pro Thr Ser 170 
524 AAA CAA GAG ATA AAA GAC TCA TAT AAA ATA GTC CTT CCT 
Asn Ala Leu Leu Met Glu Lys Leu Glu Ser Gln Lys Glu Trp Leu Arg Thr 187 
575 CTA ATG GAG AAG TTA GAG TCA CAG AAG GAG TGG CTA AGG ACC 
Lys Thr Ile Gln Leu Ile Leu Lys Ala Leu Glu Glu Phe Leu Lys Val Thr 204 
626 AAG ACC ATC CAA CTC ATC TTG AAA GCA CTT GAA GAA TTT CTA AAG GTC ACT 
Met Arg Ser Thr Arg Gln Thr Stop 211 







Nucleotide sequence of tumour necrosis factor a (Acc. # X66539/S40199). The derived 
amino acid sequence is shown above the nucleotide sequence. Nucleotides are numbered on 
the left starting from the A of the ATG initiation codon. The yellow boxes denoted the 
binding sites of the upstream and downstream primers for a 468 bp PCR fragment 
(Delgado -Rizo et al., 1998). 
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Met Ser Thr Glu Ser Met Ile Arg Asp Val Glu Leu Ala Glu Glu Ala Leu 17 
1 ATG AGC ACA GAA AGC ATG ATC CGA GAT GTG GAA CTG GCA GAG GAG GCG CTC 
Pro Lys Lys Met Gly Gly Leu Gln Asn Ser Arg Arg Cys Leu Cys Leu Ser 34 
52 CCC AAA AAG ATG GGG GGC CTC CAG AAC TCC AGG CGG TGT CTG TGC CTC AGC 
Leu Phe Ser Phe Pro Leu Val Ala Gly Ala Thr Thr Leu Phe Cys Leu Leu 51 
103 CTC TTC TCA TTC CCG CTC GTG GCG GGG GCC ACC ACG CTC TTC TGT CTA CTG 
Asn Phe Gly Val Ile Gly Pro Asn Lys Glu Glu Lys Phe Pro Asn Gly Leu 68 
154 AAC TTC GGG GTG ATC GGT CCC AAC AAG GAG GAG AAG TTC CCA AAT GGG CTC 
Pro Leu Ile Ser Ser Met Ala Gln Thr Leu Thr Leu Arg Ser Ser Ser Gln 85 
205 CCT CTC ATC AGT TCC ATG GCC CAG ACC CTC ACA CTC AGA TCA TCT TCT CAA 
Asn Ser Ser Asp Lys Pro Val Ala His Val Val Ala Asn His Gln Ala Glu 102 
256 AAC TCG AGT GAC AAG CCC GTA GCC CAC GTC GTA GCA AAC CAC CAA GCA GAG 
Glu Gln Leu Glu Trp Leu Ser Gln Arg Ala Asn Ala Leu Leu Ala Asn Gly 119 
307 GAG CAG CTG GAG TGG CTG AGC CAG CGT GCC AAC GCC CTC CTG GCC AAT GGC 
Met Asp Leu Lys Asp Asn Gln Leu Val Val Pro Ala Asp Gly Leu Tyr Leu 136 
358 ATG GAT CTC AAA GAC AAC CAA CTG GTG GTA CCA GCA GAT GGG CTG TAC CTT 
Ile Tyr Ser Gln Val Leu Phe Lys Gly Gln Gly Cys Pro Asp Tyr Val Leu 153 
409 ATC TAC TCC CAG GTT CTC TTC AAG GGA CAA GGC TGC CCC GAC TAT GTG CTC 
Leu Thr His Thr Val Ser Arg Phe Ala Thr Ser Tyr Gln Glu Lys Val Ser 170 
460 CTC ACC CAC ACC GTC AGC CGA TTT GCC ACT TCA TAC CAG GAG AAA GTC AGC 
Leu Leu Ser Ala Ile Lys Ser Pro Cys Pro Lys Asp Thr Pro Glu Gly Ala 187 
511 CTC CTC TCC GCC ATC AAG AGC CCT TGC CCT AAG GAC ACC CCT GAG GGA GCT 
Glu Leu Lys Pro Trp Tyr Glu Pro Met Tyr Leu Gly Gly Val Ser Gln Leu 204 
562 GAG CTC AAG CCC TGG TAT GAG CCC ATG TAC CTG GGA GGA GTC TCC CAG CTG 
Glu Lys Gly Asp Leu Leu Ser Ala Glu Val Asn Leu Pro Lys Tyr Leu Asp 
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613 GAG AAG GGG GAC CTG CTC AGC GCT GAG GTC AAC CTG CICC AAG TAC 
TTA GAC 
Ile Thr Glu Ser Gly Gln Val Tyr Phe Gly Val Ile Ala 
Leu 235 
664 OTC ACG GIAG TCC GGG CAG GTC TAC TTT GGA GTC ATT GCT CTG 
TGA 
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APPENDIX 4 Extraction 
EXTRACTION BUFFER 
10 mM HEPES KOH pH 7.4 (Sigma) 
2 mM MgCIZ (Sigma) 
5 mM EGTA (Sigma) 
0.5 % CHAPS (Sigma) 
50 mM KCI (Sigma) 
Phosphatase inhibitor cocktail - 2.5 mM sodium pyrophosphate, 1 mM glycerophosphate 
1 mM sodium orthovanadate (Sigma) 
10 pg.m1 -1 protease inhibitor cocktail - leupeptin, pepstatin A and aprotinin (Sigma) 
1 mM PMSF (Sigma) 
10 x extraction buffer minus inhibitor cocktails and PMSF was made, aliquotted and stored 




SDS ACRYLAMIDE GELS 
12 %Acrylamide Gel 
Western Blotting 
8 ml 30 % Acrylamide /Bis solution 29:1 (3.3 % C) (BioRad) 
4 ml 1.5 M Tris pH 8.8 (Sigma) 
0.16 ml 10 % SDS (Sigma) 
16 µl TEMED (Sigma) 
120 µl 10 % ammonium persulphate (Sigma) 
3.7 m1 MQ H2O 
4 % Acrylamide Stacking Gel 
1.3 ml 30 % Acrylamide/Bis solution 29:1 (3.3 % C) (BioRad) 
1.25 ml 1 M Tris pH 6.8 (Sigma) 
0.1 ml 10 % SDS (Sigma) 
0.2 10 µl TEMED (Sigma) 
75 µ1 10 % ammonium persulphate (Sigma) 
7.3 m1 MQ H2O 
For both 12 % and 4 % gels stock solutions for acrylamide, Tris and SDS were made and 
stored at 4 °C. To pour the gels the appropriate volume of TEMED and freshly made 
ammonium persulphate was added. Gels were poured between Hoefer glass plates 
(Pharmacia) plates with 10/15 well comb. 
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SAMPLE BUFFER 
2 ml Glycerol (Sigma) 
2 ml 10 % SDS (Sigma) 
0.25 mg Bromophenol Blue (Sigma) 
2.5 ml stacking gel buffer (6.06 g Tris in 100 ml, 4 ml 10 % SDS pH 6.8) 
0.5 ml ß- mercaptoethanol (Sigma) 
STOCK SOLUTIONS OF RECOMBINANT CYTOKINE STANDARDS 
Interleukin -1/3 (R & D Systems, Lot Q202904) 
10 mg supplied was reconstituted in 0.5 ml sterile PBS containing 1.5 mg.ml "' BSA (0.15 %) 
to give 20 .ig.ml -' stock solution. Aliquotted and stored at -70 °C 
Interleukin -6 (R & D Systems, Lot ANW01905C) 
10 mg supplied in 144 µl 45 % CH3CN, 0.1 % TFA and 50 µg BSA per 1 µg of cytokine at 
final concentration of 0.0694 µg.ml"'. Aliquotted and stored at -70 °C. 
Tumour Necrosis Factor a (R & D Systems, Lot AGM019051C) 
10 mg supplied was reconstituted in 0.5 ml sterile PBS containing 1.5 mg.ml -' BSA (0.15 %) 
to give 20 µg.ml -' stock solution. Aliquotted and stored at -70 °C 
CYTOKINE ANTIBODIES 
Anti - Interleukin -113 (R & D Systems, Lot YR39041) 
Anti- Interleukin-6 (R & D Systems, Lot BCZ028102) 
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Anti -Tumour Necrosis Factor a (R & D Systems, Lot XI028121) 
All cytokine antibodies were reconstituted in sterile PBS to give 0.1 mg.ml"' solution, 
aliquotted and stored at -70 °C. 
TRIS /GLYCINE BUFFER (10X) 
0.25 mM Tris (Sigma) 
1.92 M Glycine (Sigma) 
RUNNING BUFFER 
1 x Tris /glycine buffer 
0.1 % SDS (Sigma) 
TRANSFER BUFFER 
1 x Tris /glycine buffer 
20 % methanol (Fisher) 
TRIS BUFFERED SALINE -TWEEN 20 (TBST) pH 7.4 
50 mM Tris (Sigma) 
0.5 M NaC1 (Sigma) 
0.5 % Tween 20 (Sigma) 
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SILVER STAINING OF POLYACRYLAMIDE GELS 
Gels were initially fixed in 100 ml of 10 % ethanol (v /v) and 0.5 % (v /v) glacial acetic acid 
for 10 min and then stained in 11.2 mM AgNO3 for 10 min. Gels were washed in MQ H2O 
and protein bands developed by addition of 0.75 M NaOH containing 
0.25 % formaldehyde. The reaction was stopped after 10 min when the bands were clearly 
visible by the addition of 1 % glacial acid. 
Coomasie sensitivity: 0.1 -1 µg 
Silver staining sensitivity: 1 -10 ng 
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APPENDIX 6 ELISA 
All reagents and samples were brought to room temperature before use. 
IL-1(3 (RLBOO) 
Assay Diluent RD 1 -21 
Calibrator Diluent RD5Y 
IL-1f3 Standard: Reconstituted with Calibrator Diluent to produce a 2000 pg.ml-' stock 
solution from which a series of six 2 -fold dilutions were made to establish a standard curve. 
TNFa (RTA00) 
Assay Diluent RD 1-41 
Calibrator Diluent RD5 -17 
TNFa Standard: Reconstituted with Calibrator Diluent to produce a 800 pg.m1 "' stock 
solution from which a series of six 2 -fold dilutions were made to establish a standard curve. 
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APPENDIX 7 Exclusion Criteria 
An animal will be considered to be integral to the study at the origin of the procedure. 
Exclusion from the study will occur if the animal fulfils any of the following criteria: 
a) Death 
i) During or post surgery. 
ii) Animal terminated by researcher /other due to falling outwith 
project severity limits. 
iii) Animal terminated due to unseen circumstances unrelated to the 
study that may bias the result (details to be provided). 
b) Surgical misses 
i) No damage (clear miss determined by histology). 
ii) Where no cortical damage is observed and striatal damage is 
restricted to <_ 2 of the 9 template regions and < 10 mm3 and Evans 
Blue staining confirms incorrect placement of the monofilament. 
c) Standard deviations 
d) Other 
i) Animals will be excluded from the study if upon termination of the 
study the value of the total volume of damage of an individual 
animal is > 2 standard deviations from the mean total of the whole 
group. 
i) Any contralateral damage. 
230 
ii) Reperfusion established > ± 10 min from designated occlusion time. 
iii) Drug/vehicle not administered by appropriate route. 
iv) Drug /vehicle administered in inappropriate solution. 
v) Haematoma/ blood clots observed on brain surface or in blood 
vessels (i.e. Circle of Willis). 
vi) Weight loss > 33 % of pre- operation weight. 
The entire study will be excluded if the animal exclusion rate is > 40 %. 
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APPENDIX 8 Computerised digital morplrometry 
Templates were modified from `The Rat Brain in Stereotaxic Co- ordinates', Paxinos & 
Watson (1986) (Paxinos & Watson, 1986). The 9 templates were chosen to cover the area of 
a characteristic MCA occlusion damage from +4.2 to -7.8 from Bregma ( +4.2, +2.2, +1.2, 
+0.2, -0.8, -3.8, -5.8, -7.8) with easily recognisable anatomical landmarks. The levels were 
roughly based on those already in use by other investigators who demonstrated accurate 
assessment of the volume of damage with 8 levels without a loss of accuracy (Osborne et al., 
1987). This method of calculating the volume of damage also accounts for distortion or 
shrinkage that may occur following perfusion fixation and oedema associated with the 
lesion. 
Stained sections were examined by light microscopy and the damage annotated onto the 
templates in pencil initially and then coloured dark blue. The templates were digitised using 
the MCID M5+ image analyser (version 4.00 Rev 1.5) and the total area of damage 
computed for 82 regions of the rat brain (37.7 pixels.mm' on the horizontal and 36.6 
pixels.mm' on the vertical). Values obtained were transposed into an Excel workbook and 
the volume of damage calculated using the trapezoid rule (Chapter 2). This model has been 
reported to give consistently accurate results when calculating the volume of objects with 
unequal distances between sampled sections. A number of other methodologies (rectangular 
estimation, Cavalieri's rule, Simpson's rule, parabolic estimation) were also compared in the 
process of establishing the validity of the trapezoid rule for calculation of the volume 
damage (Rosen & Harry, 1990). Damage calculated was grouped into cortex, striatum and 
mid -line (all non -cortical and non- striatal regions) regions. Data was graphed using 
SigmaPlot 5.0 and analysed statistically using SigmaStat 2.03. 
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VALIDATION 
A number of experiments were performed to validate the use of the computerised digital 
morphometry to quantify the volume of damage. The initial experiment compared observer 
variation (John Sharkey and Jennifer McCarter). The second experiment compared the 
volume of damage scored on the new templates with that calculated by the `cut and weigh' 
method previously used in the laboratory. There was no significant difference between the 
two people scoring in terms of volume or distribution of damage (correlation coefficient = 
0.95; n = 17). Comparison of the new and old methods revealed that was no difference in the 
volume of damage calculated by the two methods (p > 0.05). The new MCID method was 
however more practical and reproducible and quicker and allows efficient handling of the 
data generated thus speeding up the time taken to fully analyse a series of experiments. 
Page 234 Description of the 82 regions of the 9 rat stereotaxic templates used for 
computerised digital morphometry analysis. 
Page 235 Sample of the stereotaxic templates used to score ischaemic damage. 
Page 236 Rat stereotaxic templates showing division of the regions into cortex, 
striatum and mid -line. 
Page 237 Sample of the Excel worksheet used to calculate volume of damage from the 
raw data. 
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RAT BRAIN REGIONS 
BREGMA +4.2 
1. Medial, ventral & ventrolateral orbital cortex; 
cingulate cortex areas I & 3 
2. Frontal cortex area 2 
3. Agranular insular cortex 
4. Lateral orbital cortex 
5. Anterior olfactory nuclei 
BREGMA +2.2 
6. Frontal cortex area 2 
7. Frontal cortex area 1 & 3 
8. Parietal cortex area 1 
9. Agranular insular cortex; ventrolateral & 
lateral orbital cortex; claustrum 
10. Piriform cortex 
11. Basal forebrain 
12. Accumbens nucleus 
13. Caudate putamen 
14. Cingulate cortex areas 1 & 3, infralimbic 
cortex, dorsal peduncular cortex, tenia tecta 
BREGMA +1.2 
15. Cingulate cortex areas 1 & 2 
16. Frontal cortex area 2 
17. Frontal cortex area 1; forelimb area of cortex 
18. Parietal cortex area 1 
19. Agranular, dysgranular & granular insular 
cortex; claustrum 
20. Piriform cortex 
21. Septum; basal forebrain 
22. Accumbens nucleus 
23. Caudate putamen 
BREGMA +0.2 
24. Cingulate cortex areas 1 & 2 
25. Frontal cortex area 2 
26. Frontal cortex area 1; forelimb area of cortex 
27. Parietal cortex area 1 & 2 
28. Agranular, dysgranular & granular insular 
cortex; claustrum 
29. Piriform cortex; dorsal endopiriform cortex 
30. Lateral septum; basal forebrain 
31. Caudate putamen 
32. Medial septum 
BREGMA -0.8 
33. Cingulate cortex areas 1 & 2 
34. Frontal cortex area 2 
35. Frontal cortex area I; forelimb & hindlimb 
area of cortex 
36. Parietal cortex area 1 & 2 
37. Agranular & granular insular cortex; 
claustrum 
38. Piriform cortex 
39. Anterior hypothalamic arca 
40. Globus pallidus 
41. Caudate putamen 
BREGMA -1.8 
42. Retrospenial cortex 
43. Frontal cortex area 2 
44. Frontal cortex area 1; hindlimb area of cortex 
45. Parietal cortex area I & 2 
46. Perirhinal cortex 
47. Piriform cortex 
48. Hypothalamic nuclei & amygdaloid nuclei 
49. Thalamic nuclei 
50. Globus pallidus 
51. Caudate putamen 
BREGMA -3.8 
52. Retrospenial cortex 
53. Occipital cortex 
54. Parietal cortex area 1 & 2 
55. Temporal cortex 
56. Perirhinal cortex 
57. Piriform cortex 
58. Amygdaloid nuclei 
59. Caudate putamen 
60. Cerebral peduncle 
61. Hypothalamic nuclei 
62. Thalamic nuclei 
63. Hippocampus 
64. Hanbenula nucleus 
BREGMA -5.8 
Retrospenial cortex 
66. Occipital cortex 
67. Temporal cortex 
68. Perirhinal cortex 
69. Entorhinal cortex 
70. Hippocampus & amygdaloid nuclei 
71. Deep mesencephalic nuclie 
72. Substantia nigra 
73. Central gray 
BREGMA -7.8 
74. Retrospenial cortex 
75. Occipital cortex 
76. Temporal cortex 
77. Perirhinal cortex 
78. Entorhinal cortex 
79. Tegmental nuclei 
80. Central grey 
81. Raphe nuclei 
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